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ABSTRACT OF DISSERTATION 
 
 
MITOCHONDRIAL TRANSPLANTATION AFTER SPINAL CORD 
INJURY:  EFFECTS ON TISSUE BIOENERGETICS AND FUNCTIONAL 
NEUROPROTECTION 
Contusion spinal cord injury (SCI) results in devastating life-long debilitation 
in which there are currently no effective treatments. The primary injury site 
presents a complex environment marked by subsequent secondary 
pathophysiological cascades involving excessive reactive oxygen and nitrogen 
species (ROS/RNS) production, glutamate-induced excitotoxicity, calcium 
dysregulation, and delayed neuronal apoptosis. Many of these cascades involve 
mitochondrial dysfunction, thus a single mitochondrial-centric therapy that targets 
a variety of these factors could be far reaching in its potential benefits after SCI. 
As such, this dissertation examines whether transplantation of exogenous 
mitochondria after SCI can attenuate secondary injury cascades to decrease the 
spread and severity of the injury.  
Our first experiment tested the dose-dependent effects of mitochondrial 
transplantation on the ability to maintain acute overall bioenergetics after SCI. We 
compared transplantation of mitochondria originating from two different sources- 
cultured PC12 cells or rat soleus leg muscle. 24 hours after injury, State III oxygen 
consumption rates were maintained to over 80% of sham levels when 100ug of 
mitochondria was transplanted, regardless of the origin of the mitochondria. 
Complex I enzyme activity assays corroborated our findings that the 100ug dosage 
gave optimal benefits compared to vehicle injection. 
We also analyzed the rostral-caudal distribution and cell-type colocalization 
of transplanted transgenically-labeled tGFP mitochondria after SCI. There were 
greater volumes and rostral-caudal spread of tGFP mitochondria at the 24 hour 
time point compared to 7 days post injection. tGFP mitochondria had the greatest 
propensity to colocalize with macrophages and pericytes. Colocalization was 
evident in endothelial cells, oligodendrocytes and astrocytes, though no such co-
labeling was present in neurons. Further, colocalization of tGFP was always 
greater at the 24 hour time compared to 48 hour or 7days post injection time points. 
These data indicate that there is a cell-type difference in incorporation potential of 
exogenous mitochondria which changes over time. 
 
Finally, we tested the effects of mitochondrial transplantation on long term 
functional recovery. Animals were injected with either vehicle, 100ug cell-derived 
mitochondria, or 100ug muscle-derived mitochondria immediately after contusion 
SCI. Functional analyses including BBB overground locomotor scale and von Frey 
mechanical sensitivity tests did not show any differences between treatment 
groups. Likewise, there were no differences in tissue sparing when mitochondria 
were transplanted compared to vehicle injections, though there were higher 
neuronal cell counts in tGFP mitochondria injected groups caudal of the injury site.  
These studies present the potential of mitochondrial transplantation for 
therapeutic intervention after SCI. While our acute measures do not correspond 
into long term recovery, we show that at 24 hours transplanted mitochondria do 
have an effect on bioenergetics and that they are taken into host cells. We believe 
that further investigation into caveats and technical refinement is necessary at this 
time to translate the evident acute bioenergetic recovery into long term functional 
recovery. 
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CHAPTER 1 
INTRODUCTION AND HYPOTHESIS   
 
1. Introduction to Mitochondria 
Mitochondria are located in the cell cytoplasm and often referred to as the 
powerhouse of the cell, as they produce most of the cell’s energy in the form of 
adenosine triphosphate (ATP). However, they are also referred to as the nuclear 
power plant of the cell as they can efficiently make ATP while simultaneously 
producing a small but manageable amount of destructive oxidative agents known 
as reactive oxygen species (ROS). When mitochondria are damaged they can 
become extremely reactive and damaging to themselves and surrounding 
mitochondria, unleashing numerous pathways that can lead to both apoptosis 
and necrosis. Therefore, a delicate balance must be maintained for these 
organelles to function at optimal efficiency without devastating consequences.  
 
1.1.1 Mitochondrial DNA 
It is theorized that mitochondria were once bacteria that became engulfed 
by a cell and utilized for its respiratory capabilities. Evidence of this theory lies in 
the fact that mitochondria have two lipid membranes and their own circular 
mitochondrial DNA (mtDNA) (Nass & Nass 1963), which allows them to make 
their own proteins (Mc et al 1958). As evolution progressed, cells became more 
dependent on mitochondria for their energy supply, even integrating the coding 
for key mitochondrial proteins within the nuclear DNA. mtDNA only encodes for 
13 mitochondrial proteins and needs the cell’s nuclear DNA to provide the rest of 
the mitochondrial proteins.   
mtDNA replication and transcription occurs in the S and G2 phases of the 
cell cycle (Pica-Mattoccia & Attardi 1971, Pica-Mattoccia & Attardi 1972), but 
mitochondrial protein synthesis doubles during interphase and remains relatively 
constant during the cell cycle (England & Attardi 1974).  
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Mitochondria have a distinct DNA polymerase separate from that of nuclear DNA 
(Ch'ih & Kalf 1969, Meyer & Simpson 1970). mtDNA lacks exons and histones, 
which protect nuclear DNA by creating a tighter structural formation. Because of 
this and their proximity to the electron transport chain (ETC) which is prone to 
release oxidative molecules, mtDNA undergo mutations at a higher rate than 
nuclear DNA (Brown et al 1979).  
Mitochondria are inherited maternally (Hutchison et al 1974), meaning that 
each offspring will have mtDNA identical to their mother’s with no input from the 
father’s mtDNA, making it possible to track familial lineage using the maternal 
mitochondria. This also implicates maternal inheritance of mtDNA mutations and 
disorders. It has been suggested that there are no recombinant abilities in 
mtDNA; when creating mouse x rat somatic cell hybrids and rat cytoplasmic 
hybrids, Hayashi et al (1985) found that there was no mtDNA recombination even 
when chloramphenicol (CAP) resistant mtDNA was incorporated into a CAP-
sensitive cell. The cell remained resistant to CAP, but the mtDNA was 
unchanged. The group theorized that since mtDNA is inherited completely 
maternally, there is no necessity for recombination of mtDNA, and thus it has lost 
the ability to do so (Hayashi et al 1985). However, the amount of mutated mtDNA 
in an egg can vary, known as heteroplasmy (Lightowlers et al 1997), resulting in 
differing phenotypes creating inheritance patterns that may not be obvious.  
Interestingly, mitochondrial replacement has been attempted in fertilization 
techniques to replace defective mtDNA with healthy mtDNA from a donor (Cohen 
et al 1998, Cohen et al 1997). Mouse models demonstrating the synchronous 
transfer of cytoplasts from a donor oocyte to a recipient oocyte which led to the 
development of a healthy zygote (Levron et al 1996) furthered the research 
efforts of human ooplasmic donation. Clinical studies testing injection of a small 
portion of cytoplasm which includes mRNA, protein, and mitochondria from a 
healthy donor oocyte into a compromised oocyte with subsequent fertilization 
and implantation resulted in successful pregnancy (Cohen et al 1998, Cohen et 
al 1997). The developing embryo thus contained nuclear DNA from the mother 
and father, along with mtDNA from the donor egg. While cytoplasmic transfer 
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therapy resulted in successful births, it was banned in the United States in 2001 
for ethical reasons; however the practice is still being performed legally in other 
countries (Ishii 2014). A similar therapy aimed at avoiding mtDNA mutation 
inheritance by providing three biological parents uses a nuclear transfer 
technique- a mother and father providing the nuclear DNA, and a separate donor 
for the mtDNA (Reardon 2016). The nucleus is removed from the mother’s egg 
(containing unhealthy mitochondria) and implanted into a donor egg (containing 
healthy mitochondria) in which the nucleus and genetic material has been 
removed. The resulting egg contains donor mitochondria (with mtDNA) and 
cytoplasm, and the mother’s nucleus (with nuclear DNA). The egg is then 
fertilized with the father’s sperm and an embryo develops with three distinct 
genetic parents. This therapy has been shown in non-human primates to 
circumvent the genetic inheritance of mitochondrial disease when the mother’s 
mitochondria carry DNA mutations (Tachibana et al 2009).   
 
1.1.2 Oxidative Phosphorylation  
Mitochondria provide for most of the cell’s energy needs in the form of 
ATP (Figure 1.1A-1). In the process of oxidative phosphorylation mitochondria 
use substrates produced by the Kreb’s cycle in the mitochondrial matrix, namely 
reduced nicotinamide adenine dinucleotide (NADH) and flavin adenine 
dinucleotide (FADH), to power the electron transport system (ETS) located in the 
inner mitochondrial membrane (IMM). NADH donates an electron to complex I of 
ETC, an exchange that results in hydrogen atoms being pumped against a 
concentration gradient from the matrix into the intermembrane space. The 
electron then passes across the other complexes of the ETC in a series of 
oxidation/reduction reactions, each time releasing energy and pumping hydrogen 
from the matrix to the intermembrane space (for comprehensive review see 
Nicholls & Ferguson 2013). This creates a membrane potential (between 140 
and 180 mV) across the inner mitochondrial membrane, which is used by 
complex V to form ATP from adenosine diphosphate (ADP) with simultaneous 
passage of hydrogen back into the mitochondrial matrix (Reid et al 1966). When 
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the electron reaches complex IV, it is released back into the matrix where it joins 
with oxygen. The oxygen is held at complex IV until enough electrons are present 
to allow it to form two water molecules. During oxidative phosphorylation, some 
ROS are created but are in small amounts that can be counteracted by 
endogenous antioxidant mechanisms within the mitochondria (see Cheeseman & 
Slater 1993, Droge 2002). 
 
 
Figure 1.1. Schematic depiction of how mitochondrial transplantation after 
injury may promote cell survival. A. During normal cellular function, 
mitochondria sequester and store calcium in their matrix and produce ATP (1) 
while NMDA receptors remain closed (2). B. After traumatic injury, the cell is 
subjected to glutamate excitotoxicity mediated by activated NMDA receptors (3) 
which allow massive calcium influx into cells (4) and subsequent uptake into 
mitochondria. This causes a loss of membrane potential across the inner 
mitochondrial membrane leading to MPTP formation and subsequent swelling of 
mitochondria (5). Consequent bursting of the outer mitochondrial membrane then 
releases calcium, ROS, and apoptotic factors (6). ROS damages membrane 
lipids, mtDNA, electron transport chain proteins, and nuclear DNA (7), which 
leads to death of adjacent mitochondria (8). C. After healthy mitochondria, 
depicted in green, are transplanted into damaged cells they can increase 
antioxidants to combat ROS release (9) and provide new sources of mtDNA (10). 
Further, these mitochondria increase ATP production (11) and overall calcium 
buffering capacity (12) in the compromised cells. 
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1.1.3 Endogenous Antioxidant Systems 
During oxidative phosphorylation, electron flow leads to a small amount of 
ROS production, namely in the form of superoxide radicals. Electrons released 
from the ETC can reduce oxygen molecules to superoxides (O2-). Manganese 
superoxide dismutase (MnSOD) localized within the mitochondria (Weisiger & 
Fridovich 1973) can oxidize superoxides into less reactive hydrogen peroxide 
(McCord & Fridovich 1969). Hydrogen peroxide, however, can undergo the 
Fenton reaction, creating hydroxyl radicals (OH-) that can damage lipids, 
proteins, and nucleic acids (Winterbourn 1995). Alternatively, glutathione 
peroxidase can convert hydrogen peroxide into water and is present in the 
intermembrane space of mitochondria (Arai et al 1999). Damage to mitochondria 
can be countered by an increase of the endogenous antioxidant systems 
activities. For example, complex I deficiencies increase the expression of 
MnSOD which turns superoxide into hydrogen peroxide in cultured fibroblasts 
(Pitkanen & Robinson 1996).   
 
1.1.4 Calcium Buffering  
The mitochondrial matrix holds a negative charge of around -240mV, (see 
Michelakis 2008) allowing the mitochondria to actively sequester positively 
charged calcium ions into their matrix (Figure 1.1A-1). This is important as 
calcium is involved in various intracellular signaling pathways. Under normal 
conditions, concentration of cytoplasmic calcium is 0.1µM and extracellular 
calcium concentration is 1mM, favoring calcium movement into the cytoplasm 
(see Bianchi et al 2004). The IMM has a potential of -180mV, favoring calcium 
influx into the matrix through the calcium uniporter (Bygrave & Ash 1977), with 
equilibrium being reached when the calcium concentration within the 
mitochondrial matrix reaches 106 higher than the cytosol (Bianchi et al 2004).  
Once inside the matrix, energy is required to export calcium back out of the 
matrix to overcome the electrochemical force driving calcium influx. It is found 
that the energy released from ATP hydrolysis (34.1kJ/mol) is sufficient to allow 
movement of 1 mol of calcium  (33kJ) across the inner mitochondrial membrane 
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and into the intermembrane space (Bianchi et al 2004). Importantly, calcium is 
required for the activation of different metabolic enzymes such as pyruvate 
dehydrogenase, α-ketoglutaratedehydrogenase, and isocitrate dehydrogenase. 
Calcium influx into the mitochondrial matrix leads to increased metabolism 
through interaction with these metabolic enzymes, increasing ATP production for 
the cell (Jouaville et al 1999).  
 
1.1.5 Mitochondrial Fusion and Fission 
It is not uncommon to see mitochondria depicted in textbooks as small, 
bean-shaped organelles. To the contrary, mitochondrion are very dynamic 
organelles that constantly undergo fusion and fission, creating an ever-changing 
network contained within the cytoplasm. In healthy cells, these fusion/fission 
events are well-balanced for the turnover of mitochondria and serves multiple 
purposes pertaining to the health of both the mitochondria and the cell. Fusion 
can allow for segregation of damaged areas of the mitochondria with subsequent 
fission and mitophagy (a mitochondrial specific form of autophagy) of this 
section, serving to maintain a healthy membrane potential of the remaining 
mitochondria (Twig et al 2008a). This group also found that loss of membrane 
potential decreased the probability for the mitochondrion to undergo fusion, 
which could be a protective mechanism keeping damaged mitochondria from 
joining and affecting the mitochondrial network. Depolarized mitochondria are 
then targeted for autophagy (Priault et al 2005). Mitochondria will undergo 
increased levels of fission before apoptosis (Suen et al 2008). Stressed or 
starved mitochondria can undergo a process known as hyperfusion, in which the 
mitochondria produce higher amounts of ATP (Tondera et al 2009). Fused 
mitochondria can share their components such as metabolites, proteins and 
mtDNA, known as complementation (Arimura et al 2004, Chen et al 2005). 
Fusion of mitochondria containing mutated mtDNA with mitochondria containing 
healthy mtDNA could allow a cell to overcome the effects of having mutant 
mtDNA (Nakada et al 2001). Each of these mechanisms is adapted for 
maintaining the healthiest possible mitochondrial network for the cell.  
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1.1.6 Mitochondria Act as a Death Switch  
Cell death is a physiologically important and normal occurrence that is 
used to keep an organism in homeostasis. Without cell death, there would be no 
opportunities for newer, healthier cells to take over vital functions of the tissue. 
However, excessive cell death can be detrimental. An early feature of cellular 
apoptosis is disruption of the ETS. Mitochondrial function is necessary for cells to 
undergo apoptosis, as this form of controlled cellular death requires energy (see 
Kroemer et al 1998). Cytochrome c, a protein in the electron transport chain, can 
act as a signal for apoptosis; when released into the cytosol it can bind to 
activating factor-1 causing formation of an apoptosome complex that then 
activates caspases necessary to signal the induction of apoptosis (see Riedl & 
Salvesen 2007). A consequence of damaged ETS is a drop in ATP production; in 
cases of extreme ATP depletion the cell undergoes necrosis which is typically 
detrimental to nearby cells (Ankarcrona et al 1995, Eguchi et al 1997). Acute 
insult in vitro using high concentrations of N-methyl-D-aspartate (NMDA) or free 
radicals result in necrosis, but the apoptotic pathway is favored when less 
concentrated NMDA and free radicals are present. Further, NMDA-induced cell 
death can be prevented with the use of NMDA receptor antagonists, but not 
when free radicals are simultaneously present (Bonfoco et al 1995).  
 
1.1.7 Mitochondrial Dysfunction 
There is an important stability necessary for mitochondria to optimally 
carry out their biological functions essential to cell survival. Damage to 
mitochondria can be exponentially devastating as they not only fail to provide 
these vital biological functions, but they can be extremely hazardous and 
damaging to nearby mitochondria and cells. Mitochondrial dysfunction is 
implicated in many disease states such as Parkinson’s Disease (Mizuno et al 
1989, Winklhofer & Haass 2010), Alzheimer’s Disease (Swerdlow & Khan 2004), 
muscular dystrophy (Onopiuk et al 2009), macular degeneration (Burdon 1995), 
and ageing-related neurodegeneration (Lin & Beal 2006). Importantly, 
mitochondria dysfunction is also involved in pathologies seen after many 
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traumatic insults including cardiac infarctions (Braunwald & Kloner 1985, Ide et al 
2001), stroke (Bolanos et al 2009, Krajewski et al 1999, Sims & Muyderman 
2010), traumatic brain injury (Aygok et al 2008, Singh et al 2006, Xiong et al 
1997), and spinal cord injury (Huang et al 2012, Sullivan et al 2007).  
Our lab, in collaboration with others, have shown there is substantial 
mitochondrial dysfunction after traumatic spinal cord injury (SCI). Studies have 
shown that mitochondrial ETC functions are compromised and there is increased  
mitochondrial oxidative stress as soon as 6 hours after injury (Jin et al 2004, 
McEwen et al 2007, Patel et al 2010, Patel et al 2009b, Sullivan et al 2007). 
Mitochondrial respiration is significantly decreased as early as 6 hours post 
injury, with further progressive decline in respiration over 24 hours post injury 
(Sullivan et al 2007). This group also showed significant increases in markers of 
oxidation at 24 hours post injury. A different group studying a rat model of spinal 
contusion injury found that glutathione, an endogenous antioxidant, and ATP 
levels were significantly decreased as early as 2 hours after injury and that this 
decrease continued to progress over 24 hours post injury (Jia et al 2016). 
Interestingly, this group also reported mitochondrial fusion increases immediately 
after injury, followed by a turn to mitochondrial fission corresponding to 
decreased ATP and glutathione and increased apoptosis signaling cytochrome c 
and caspase 3 release. There is evidence that mitochondrial function drastically 
changes after SCI, thus the next sections will explore the pathophysiology 
following SCI with emphasis on the role that dysfunctional mitochondria play.  
 
1.2 Introduction to Spinal Cord Injury 
Spinal cord injury is a devastating condition with life-long consequences 
and there are currently no effective treatments for reversing the pathophysiology 
after injury. In the United States there are approximately 17,000 new cases of 
SCI each year (Center 2016). There are different types of SCI such as 
transection, ischemia, and penetration, though a contusion type of injury is most 
common, where there is a physical compression and bruising of the spinal cord 
by the bones of the spinal column. Injury progression following the initial 
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mechanical insult can be separated into two phases commonly referred to as the 
primary injury and the secondary injury (Norenberg et al 2004). The immediate 
time point after injury is the primary injury phase and represents the physical 
destruction and necrosis of tissue (Baptiste & Fehlings 2006, Dumont et al 2001). 
Even at this early time point, glutamate excitotoxicity and microglial activation are 
present (Donnelly & Popovich 2008, Wrathall et al 1996). Additionally, vascular 
hemorrhaging and vasospasms occur resulting in ischemia of the spinal cord 
(Ducker & Assenmacher 1969). The pathophysiological events at this immediate 
time point is important, though typically not clinically accessible for treatment 
interventions. Accordingly, many current treatments aim to address the 
secondary injury phase. 
 
1.2.1 Secondary Pathophysiological Cascades Following SCI 
The secondary injury phase contributes to the spread and severity of 
tissue damage over time. The progression of the secondary injury phase has 
been further separated into different sub-phases (Rowland et al 2008). The 
immediate phase comprises the first 2 hours after injury. The acute phase 
follows; it is separated into the early acute phase which is 2-48 hours after injury, 
and the subacute phase which is 2 days to 2 weeks after injury. The early acute 
phase includes free radical production, delayed cellular apoptosis, excitotoxicity, 
calcium dysregulation, axonal degeneration, ischemia, and inflammation 
(Cuzzocrea et al 2001, Faden et al 1988, Fiskum 2000, Lewen et al 2000, Tator 
& Fehlings 1991). The subsequent intermediate phase is 2 weeks to 6 months 
post-injury, and the chronic phase begins at 6 after injury. The average time it 
takes to diagnose a patient after injury is 3.2 hours, which makes the early acute 
secondary injury phase the earliest clinically feasible target for therapeutic 
intervention (Bracken et al 1997).  
 
1.2.1.1 Ionic Dysregulation and Excitotoxicity  
Ionic imbalance and excitatory molecule release are prevalent 
manifestations in the secondary injury phase after SCI that potentiate further 
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damage (Agrawal & Fehlings 1996, Allen 1914, Hall et al 1989, Young & Koreh 
1986). Glutamate is an excitatory neurotransmitter that can be neurotoxic in the 
brain during occurrences of overwhelming exposure (Olney & Sharpe 1969). 
After SCI, glutamate is released from damaged cells and binds to NMDA and α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors located 
on the membrane of nearby cells (Figure 1.1A-2). This causes channel opening 
and unregulated influx of excessive sodium and calcium into cells, known as 
excitotoxicity (Hume et al 1991, Lucas & Newhouse 1957, MacDermott et al 
1986, Manev et al 1989, Olney 1969, Tator 1991) (Figure 1.1B-3,4). 
Calcium ionic dysregulation can cause disruptions in cellular signaling 
processes, mitochondrial function, and increase initiation of apoptotic pathways 
and neuronal death (Choi 1988, Senter & Venes 1978, Tymianski & Tator 1996). 
Importantly, mitochondria can sequester large amounts of positively charged 
calcium ions within their negatively charged matrix. In cases of extreme 
intracellular calcium concentrations, increased calcium sequestration in the 
mitochondrial matrix results in a loss of membrane potential across the IMM as 
the matrix becomes more positively charged (Rottenberg & Scarpa 1974). 
Loss of membrane potential then results in decreased calcium buffering 
capacity with subsequent calcium dysregulation within the cell such as activation 
of calpains and phospholipases that induce the release of apoptosis inducing 
factor (AIF) from mitochondria (Polster et al 2005), downstream release of 
cytochrome c, and formation of the mitochondrial membrane permeability 
transition pore (MPTP) (Krajewska et al 2004). Formation of the MPTP (Figure 
1.1B-5) is a phenomenon in which a mega channel forms allowing water, ions, 
and molecules up to 1500 Daltons to move freely across the inner mitochondrial 
membrane (Hunter & Haworth 1979, Hunter et al 1976). Upon MPTP formation 
water will follow its osmotic gradient and pass into the highly concentrated matrix 
causing swelling of the mitochondria and bursting of the outer mitochondrial 
membrane (Figure 1.1B-6), consequently releasing ROS, reactive nitrogen 
species (RNS), calcium, and cytochrome c into the cell. Cyclophilin D is a 
component of the MPTP that interacts with mitochondrial amyloid-beta protein in 
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Alzheimer’s disease (Du et al 2008). This group showed that an Alzheimer’s 
mouse model deficient in cyclophilin D had increased mitochondrial Ca2+ 
buffering capacity and memory and spatial learning scores compared to mice 
with cyclophilin D. Using a small molecule inhibitor that binds to cyclophilin D 
such as C-9 decreases the detrimental effects of Aβ and calcium-induced MPTP 
opening (Valasani et al 2016, Valasani et al 2014), further indicating MPTP as a 
therapeutic target for neuronal disease states. 
In addition to causing potential mitochondrial swelling and MPTP, NMDA 
receptor activation and calcium influx also leads to activation of nitric oxide 
synthase, resulting in production of nitric oxide, a powerful oxidant (Dawson et al 
1991). Overstimulation of NMDA receptors can also result in ROS production 
including the formation of superoxide radicals (Lafon-Cazal et al 1993). 
Superoxide radicals react with nitric oxide to form peroxynitrite (Beckman et al 
1990), an oxidant which reacts with lipid membranes, proteins, and DNA and 
may further cause release of calcium by mitochondria which can be inhibited by 
cyclosporin A (Packer & Murphy 1994).  
Increased glutamate levels in the presence of extracellular calcium in vitro 
causes neuronal degeneration (Choi 1985) that can be inhibited by using NMDA 
antagonists (Choi 1988). Thus, blockade of excitatory NMDA or AMPA receptors 
has been a therapeutic target for neuroprotection with promising results (Agrawal 
& Fehlings 1996, Gill & Lodge 1997, Hall & Braughler 1982, Young & Koreh 
1986).  
 
1.2.1.2 Free Radical Release 
Free radical production is an important implication after traumatic injury to 
central nervous system tissue. ROS/RNS are released, oxidizing nearby 
proteins, lipids, DNA and mtDNA, propagating subsequent reactive species 
production and increasing the spread of damage (Hall & Braughler 1993). 
Neurons in the spinal cord are especially vulnerable to oxidative damage. They 
have a relatively high concentration of polyunsaturated fatty acids in their lipid 
membrane that contain double bonds easily broken by ROS. Resident microglia 
12 
 
can increase ROS production when activated, and neurons have relatively little 
endogenous antioxidant mechanisms (for review of CNS tissue vulnerability to 
ROS, see Friedman 2011). ROS and RNS release from mitochondria may further 
damage nearby proteins and lipids in the mitochondrial membranes, as well as 
mtDNA (Figure 1.1B-7). When mitochondria undergo oxidative damage they 
release higher amounts of ROS, and when the ROS overload becomes too much 
for the endogenous antioxidant systems to handle, these mitochondria will also 
undergo MPTP. This illustrates how one damaged mitochondria can cause a 
domino effect resulting in widespread mitochondrial damage within the cell until a 
threshold is passed to signal the cell to undergo apoptosis or necrosis (Figure 
1.1B-8).  
Xu et al (2005) used a superoxide dismutase (SOD1) overexpressing 
transgenic mouse model of compression spinal cord injury to investigate ROS-
mediated motor neuron death (Xu et al 2005). They found that there was less 
ROS production and motor neuron cell death in animals overexpressing SOD1 
compared to wild type animals. The use of antioxidants such as tirilazad 
mesylate (Hall 1995) and methylprednisolone have been tested to counter the 
detrimental effects of reactive species after nervous system trauma (Hall & 
Braughler 1982, Hall et al 1989, Saunders et al 1987). Clinical trials were 
performed using methylprednisolone after contusion SCI (Bracken et al 1985, 
Bracken et al 1997). Importantly, this study found that timing of treatment is 
crucial, with benefits after treatment more profound with shorter times between 
injury and treatment. Initial results were promising, though these studies have 
come under scrutiny for possible side effects leading to controversy and the 
discontinued clinical use of methylprednisolone.  
 
1.2.1.3 Inflammatory Response 
After injury there are remarkable and complex inflammatory responses 
that can contribute to the escalation of secondary pathophysiology (Blight 1985, 
Blight 1992, Carlson et al 1998, Fehlings & Nguyen 2010, Fleming et al 2006). 
The immediate inflammatory response after injury includes neutrophil invasion 
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and resident microglial activation. Breakdown of the blood brain barrier, coupled 
with invasion of peripheral immune cells and cytokine activation, causes intricate 
inflammatory responses in the injured tissue that are both injury-severity and 
time-dependent (Popovich et al 1996). There is controversy as to the benefits vs 
detriments afforded by the inflammatory response after SCI. Macrophages can 
have multiple phenotypes depending on the injury environment and signaling 
cues. For instance, M1 macrophages produce cytokines and ROS that augment 
inflammation of the injury site. Inflammation can cause demyelination (Cammer 
et al 1978, Selmaj & Raine 1988, Wisniewski & Bloom 1975), inhibit axonal 
growth (Berry & Riches 1974), release ROS/RNS (Griot et al 1989, Merrill et al 
1993), release cytokines and increase the progression of injury and cell death 
(Means & Anderson 1983). Blocking macrophage migration to the injury site 
helps alleviate some of the secondary injury pathophysiology and improve 
functional recovery after SCI (Popovich et al 1999). Additionally, 
immunosuppressants have been used to fight the inflammatory response as a 
therapeutic treatment after SCI (Bethea et al 1999, Blight 1994, Taoka et al 
1997). However, it needs to be noted that the inflammatory response does serve 
a purpose in tissue healing. M2 phenotype macrophages have anti-inflammatory 
actions and promote wound healing- for review on macrophage subtypes (see 
Murray & Wynn 2011). For instance, macrophages can create a permissive 
environment for neuronal regeneration in a model of optic nerve injury (David et 
al 1990, Hirschberg et al 1994, Perry et al 1987). Therefore, it is important to 
understand the complexity of the inflammatory response so that targets can be 
specifically identified based on the therapeutic goals to counter inflammation but 
encourage healing.  
It is apparent that mitochondria are of bacterial in origin, as evident by 
common morphological properties including circular DNA, double membranes 
including cardiolipin, lack of histones, and the ability to form N-formyl peptides.  
Because these properties are also recognized by the body’s immune system as 
bacterial and thus non-self, or something to be eradicated, the mitochondria can 
stimulate an immune response similar to that induced by a bacterial infection 
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(Lotze et al 2007). Damage-associated molecular patterns (DAMPs) are located 
on the cell surface, secreted into the extracellular matrix, or produced as a 
byproduct of degradation (Garg et al 2010). Pattern recognition receptors are 
expressed on dendritic cells and macrophages that recognize DAMPs and cause 
upregulation of proinflammatory cytokine production (Krysko et al 2011, 
Rubartelli & Lotze 2007). Some DAMPs associated with mitochondria include 
mtDNA (Collins et al 2004, Zhang et al 2010b), N-formylmethionyl proteins (Carp 
1982), Cytochrome c, ATP (Ghiringhelli et al 2009, Iyer et al 2009), cardiolipin 
(Sorice et al 2004), carbamoyl phosphate synthase (Struck et al 2005), and ROS 
(Kazama et al 2008). ATP released from cells into the extracellular matrix acts to 
recruit monocytes and neutrophils in a model of human neutrophil chemotaxis in 
vitro (Chen et al 2006, Elliott et al 2009) as well as activation of inflammasomes 
(Schroder & Tschopp 2010). In cases of severe tissue trauma, cellular necrosis 
can release massive quantities of mitochondrial particles, including mtDNA, 
which have been found to activate neutrophils and create an immune response in 
a rat model of trauma/hemorrhagic shock (Zhang et al 2010a, Zhang et al 
2010b). Thus, the presence of mitochondria or mitochondrial-derived particles in 
the extracellular matrix after traumatic tissue damage such as SCI can increase 
immune and inflammatory responses including macrophage infiltration.  
 
1.2.1.4 Vasculature Changes 
Primary injury causes direct mechanical damage to the spinal cord 
vasculature and subsequent disruption of blood flow within the cord leading to 
progressive tissue loss (Wolman 1965) which is followed by later reperfusion of 
the vessels (Senter & Venes 1978). Hemorrhaging after injury can cause 
prolonged pressure on the spinal cord and cell death (Allen 1914). Damage to 
vessels results in a breakdown of the blood spinal cord barrier, allowing for 
unrestricted access of small molecules to the central nervous system (CNS) 
tissue. There is some disagreement on the length of time between SCI and the 
reestablishment of the blood spinal cord barrier, which may be due to the 
different methods of measuring permeability (Matsushita et al 2015). 
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Reestablishment of the blood spinal cord barrier in a rat model of SCI has been 
reported as early as 14 days post injury (Noble & Wrathall 1989), though it has 
been reported that the blood spinal cord barrier is still compromised up 28 days 
(Popovich et al 1996) or 56 days post injury (Cohen et al 2009). Microvascular 
damage is thought to exacerbate the secondary injury cascades, and could be a 
target for early treatment after SCI (Tator 1991, Tator & Fehlings 1991). Gray 
matter has higher metabolic needs than white matter and is more vulnerable to 
damage induced by hypoxia and ischemia (Dumont 2001). Ischemia with 
subsequent reperfusion injury has been shown to increase the production of free 
radicals such as ROS from complex I of mitochondria (Tompkins et al 2006), and 
oxidation of lipids and proteins that compromises the integrity of membranes, 
DNA, and enzymes among other cellular components including mitochondria 
(Cuzzocrea et al 2001).  
 
1.3 Therapeutic Methods of Targeting Mitochondrial Dysfunction after SCI 
As described in the previous section (Chapter 1.2), many of the 
secondary pathophysiological cascades following SCI are closely associated with 
mitochondrial dysfunction, making these organelles a popular therapeutic target. 
Accordingly, different treatments for restoring or maintaining mitochondrial 
function following neurotrauma such as uncoupling agents, antioxidant addition, 
and biofuel addition have been tested, with varying degrees of effectiveness.   
 
1.3.1 Mild Uncoupling 
Drugs that uncouple the mitochondrial ETS have been investigated for 
their potential benefits in retaining mitochondrial function after different models of 
traumatic nervous tissue damage in vivo (Jin et al 2004, Patel et al 2009b, 
Rodriguez-Jimnez et al 2012, Sullivan et al 2004). Using drugs to mildly uncouple 
the ETC from complex V allows hydrogen atoms to diffuse freely from the 
intermembrane space back into the matrix  (see Skulachev 1998). This allows for 
maximal transport of electrons through the ETC, without conversion of ADP to 
ATP. When the uncoupling is mild, there can be a buildup and maintenance of 
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membrane potential across the IMM. This maintenance of membrane potential is 
beneficial in that the mitochondria are less likely to go through MPTP. Using mild 
uncoupling proteins (UCP2 and UCP3) has been shown to reduce ROS 
production and may be beneficial in treating neurodegenerative diseases (see 
Brand & Esteves 2005). One group found addition of the uncoupler 2,4-
dinitrophenol resulted in neuroprotection in a rat model of quinolinic acid- induced 
Huntington’s disease (Maragos et al 2003). Importantly, intraperitoneal injection 
of 2,4-dinitrophenol was found to maintain mitochondrial bioenergetics and 
reduce oxidative markers to sham levels when given 15 or 30 min after contusion 
SCI (Patel et al 2009b).  
 
1.3.2 Antioxidants  
The use of antioxidants to supplement the endogenous mitochondrial 
antioxidant systems have been used to combat free radicals such as ROS and 
RNS (see Bains & Hall 2012, Smith et al 2008). Reactive species can attack and 
damage mitochondrial electron transport complexes and mtDNA, further 
increasing mitochondrial dysfunction. Administration of antioxidants or precursors 
to antioxidants has been shown to have beneficial effects for Parkinson’s disease 
(Jin et al 2014) and traumatic brain injury (Hall et al 2010). Intraperitoneal 
injections of N-acetylcysteine amide, a precursor to glutathione, in a rat model of 
SCI significanlty maintained both mitochondrial respiration and hindlimb 
functional recovery compared to vehicle (Patel et al 2014). Dietary administration 
of the antioxidant resveratrol has been shown to increase mitochondrial 
antioxidant enzyme activity (MnSOD) in mouse brains (Robb et al 2008) and 
reduce oxidative stress in cultured coronary endothelial cells (Ungvari et al 
2009). Tempol treatment is shown to decrease oxidative stress and mitochondrial 
dysfunction while increasing cell survival and ATP production in a mouse model 
of nephrotoxicity (Ahmed et al 2014), and partially restore mitochondrial 
respiration in a model of rat SCI (Xiong & Hall 2009). Intraperitoneal injections of 
tempol maintained nonsynaptic, but not synaptic, mitochondrial bioenergetics 
when administered 15 minutes after contusion SCI, and reduced peroxynitrite-
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derived 3-nitrotyrosine and protein oxidation (Patel et al 2009b). Further, modified 
antioxidants can be specifically delivered to mitochondria for optimal 
effectiveness (see Sheu et al 2006). 
 
1.3.3 Substrate Addition 
Substrates that feed into the ETC have also been utilized as mitochondrial 
therapy. Increasing the amount of substrates such as NADH, acetyl-CoA, and 
succinate can increase mitochondrial bioenergetics. The subsequent increase in 
ATP production not only provides more energy to the cell, but helps to maintain a 
healthy membrane potential across the IMM (for review see Pettegrew et al 
2000). Biofuels such as pyruvate and beta-hydroxybutyrate have been found to 
restore mitochondrial respiration when delivered to cultured neurons after 
glucose deprivation (Laird et al 2013). Other alternative substrates that can be 
used by mitochondria for respiration, such as acetyl-L-carnitine, have beneficial 
effects in clinical trials for Alzheimer’s and Parkinson’s disease (Carta & Calvani 
1991, Puca et al 1990), and it lowers oxidative damage and restores 
mitochondrial function in rat models of aging (Liu et al 2002, Petruzzella et al 
1992). Not only did acetyl-L-carnitine significantly restore mitochondrial 
bioenergetics compared to vehicle, it also provided significant hindlimb functional 
recovery and tissue sparing in a rat model of severe SCI (Patel et al 2012, Patel 
et al 2010).  
 
1.4 Mitochondrial Transplantation 
A burgeoning approach used in mitochondrial medicine (Armstrong 2007, 
Luft 1994) is transplanting mitochondria from a healthy, exogenous source into 
damaged tissues in the effort to rescue cells or tissues from death. Various 
models of mitochondrial transplantation have been investigated, each with their 
own caveats and insights, which is discussed in Chapter 2. Many of the 
‘mitochondrial medicines’ that have been explored, such as antioxidants and 
alternative substrates (biofuels), have a short therapeutic time window in which to 
treat damaged mitochondria before the oxidative and energy depletion damage 
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becomes overwhelming. Importantly, they cannot replace mitochondria that are 
already lost. With transplantation methods to replace damaged mitochondria it 
may be possible to decrease ROS production within the cell (Figure 1.1C-9), 
provide a new pool of exogenous mtDNA damaged from oxidative processes 
(Figure 1.1C-10), increase energy production (Figure 1.1C-11), and increase 
calcium buffering capacity (Figure 1.1C-12). By providing new mitochondria to 
the cell it will retain enough energy-producing capacity for survival, thus allowing 
damaged mitochondria to undergo mitophagy, a form of mitochondria-specific 
targeted autophagy (see Ding & Yin 2012), to maintain sufficient energy 
production sources for self-repair. The prospect of replacing damaged and 
dysfunctional mitochondria with healthy exogenous mitochondria has already 
been attempted with promising results, though no such intervention has been 
attempted in models of spinal cord injury.  
 
1.5 Hypothesis of Dissertation 
As described above, contusion SCI is a complex and phasic event that 
results in permanent damage. Mitochondria are implicated in many aspects of 
the pathophysiological progression, and are therefore a therapeutic target after 
injury. Pioneering work in our lab characterizing mitochondrial dysfunction after 
SCI led to the discovery that preservation of mitochondrial function correlates 
with tissue sparing and better long-term hindlimb recovery after injury (Patel et al 
2012, Patel et al 2014). As such, our lab has been actively investigating other 
methodologies of mitochondrial therapeutics. Early publications describing 
successful mitochondrial transplantation in models of cardiac tissue ex vivo or 
lung tissue injury in vivo (Islam et al 2012, McCully et al 2009) caught our 
attention as an exciting and novel therapeutic strategy. With the existing 
experience in our lab of performing microglial cell transplantation into the spinal 
cord after injury (Rabchevsky & Streit 1997) and extensive knowledge of 
mitochondrial bioenergetics after SCI, it was a logical step forward to branch out 
into the field of mitochondrial transplantation.   
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While the published mitochondrial transplantation approaches showed 
promise in alleviating tissue damage and mitochondrial dysfunction in different 
organ systems and pathologies such as cardiac infarction and lung damage, no 
studies have investigated the potential benefits of supplementing healthy 
mitochondria into the injured spinal cord. As such, the hypothesis of this 
dissertation is isolated mitochondria can be successfully transplanted into injured 
spinal cord tissue and increase overall host mitochondrial bioenergetics and cell 
survival, resulting in tissue sparing and improved functional recovery. To test our 
hypothesis, we first characterized and optimized techniques for isolating 
transgenically-labeled mitochondria from cultured cells for transplantation 
(Chapter 4). We then performed experiments to find the optimal dosage of 
mitochondria transplantation to maximally restore cellular bioenergetics following 
acute contusion SCI (Chapter 5.3.1). Next, we characterized both time and cell-
type dependent incorporation of tGFP-labeled mitochondria after injury (Chapter 
5.3.2). Finally, we assessed tissue sparing and functional recovery benefits 
afforded by mitochondrial transplantation (Chapter 5.3.3).  
 
 
 
 
Note: 
Portions of this chapter were adapted and reprinted by permission from 
Elsevier: Jenna L. Gollihue and Alexander G. Rabchevsky. (2017) Prospects for 
Therapeutic Mitochondrial Transplantation. Mitochondrion. 2017 May 19 DOI: 
10.1016/j.mito.2017.05.007 
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CHAPTER 2 
History of Mitochondrial Transplantation 
 
2.1 Methods of Transplantation 
While mitochondrial replacement therapy has been proven successful in 
embryonic genetic therapies (see Chapter 1.1.1), there is a dire need to develop 
complementary approaches for treating adults who suffer from mtDNA defects 
and mitochondrial dysfunctions. The transplantation of mitochondria isolated from 
one source into different recipient cells has been successful in various models 
and multiple studies have shown incorporation of exogenous mitochondria via 
direct injection, co-incubation, and cell-mediated transfer, both in vitro and in 
vivo. This chapter investigates the techniques used for transplantation of 
mitochondria into a host cell/tissue, methods used to verify successful transfer, 
and the benefits that transplantation has afforded various models of 
mitochondrial dysfunction.  
 
2.1.1 In vitro Transplantation 
As early as 1982, the possibility of isolated mitochondrial transplantation 
into mouse adrenal and embryonal carcinoma cell cultures was shown (Clark & 
Shay 1982). Chloramphenicol- and efrapeptin-resistant mitochondria were 
isolated from mammalian cells and co-incubated with cells lacking resistance to 
the mitochondrial-targeting antibiotics. The isolated mitochondria labeled with 
rhodamine 123 were not only endocytosed by the cells as visualized by 
fluorescence microscopy, but they also conferred resistance indicating 
successful incorporation of the exogenous mitochondria. This resistance was 
present in 12 passages of the cells as the mtDNA was retained. Damaging the 
resistant mitochondria with UV light before co-incubation rendered them 
incapable of conferring resistance to co-incubated cells. Moreover, resistance 
could not be conferred between species (mouse into human), introducing a 
caveat in mitochondrial transplantations- that various cell types may have 
different propensities to take up mitochondria originating from different sources.  
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Another group that capitalized on conferred resistance via mitochondria 
transplantation showed that direct injection of isolated mitochondria into cultured 
cells is a viable technique for replacing endogenous mtDNA (King & Attardi 
1988). Using ethidium bromide, mtDNA was reduced in 143B human 
osteosarcoma cells to 3% of control levels. Mitochondria were then isolated from 
chloramphenicol-resistant CAP23 cells and microinjected into mtDNA-depleted 
143B cells. Subsequent addition of chloramphenicol to the recipient cells failed to 
kill them, indicating successful incorporation of CAP23 mitochondria. Further, the 
cells contained CAP23 mtDNA at five weeks after injection while the nuclear 
DNA was only that of 143B cells, indicating the transfer of only mtDNA.   
Direct microinjection of isolated mitochondria into cultured cells was 
thought to be impractical based on the size of mitochondria compared to the 
gauge of injection needles (Yang & Koob 2012), despite that previous studies 
used needles with tip diameter of 1 um or less (King & Attardi 1988). To 
counteract this, mitochondria were first injected into oocytes to allow larger 
diameter needles to be used and then a mitocytoplast containing the cell 
membrane, cytoplasm, and the previously injected mitochondria was taken from 
the oocyte (Yang & Koob 2012). This mitocytoplast could then be fused with 
recipient lung carcinoma LL2/rho0 cells that are devoid of mtDNA so that 
mitochondria were then transferred into the recipient cell cytoplasm. An important 
finding in this study revealed that when a cell is in the presence of two different 
species of mtDNA, recipient cells will favor the survival of syngeneic mtDNA, 
similar to the findings of Clark and Shay (1982).  
Others have explored direct injection techniques in which mitochondria 
were isolated from rabbit heart tissue and injected into regions of ischemic rabbit 
hearts ex vivo shortly before reperfusion (McCully et al 2009). Autologous 
mitochondria were directly injected into heart tissue following 29 minutes of 
ischemia, which resulted in decreased infarct size of the post-ischemic tissue. 
Injections of frozen, non-functional mitochondria into heart tissue showed that 
functional, respiratory competent mitochondria were necessary to decrease 
ischemic infarct size and maintain function of cardiac tissues.  
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In addition to direct transfer approaches into host cells, the possibility of 
mitochondrial transfer by co-incubation has been investigated. Co-incubation of 
cultured cells with isolated mitochondria results in successful incorporation of the 
exogenous mitochondria into host cells, often those that had undergone some 
sort of insult. Xenogenic transfer of mitochondria was evident when isolated 
mitochondria were co-incubated with cells in vitro, resulting in the successful 
incorporation of exogenous mitochondria (Katrangi et al 2007). It was shown that 
healthy murine mitochondria were taken into compromised human mesenchymal 
stem cells, resulting in their restored respiratory capabilities. The group 
demonstrated transfer by fluorescently labeling and tracking isolated 
mitochondria, measuring respiration changes in the cells after transfer, and 
detecting exogenously-derived mtDNA using polymerase chain reaction (PCR) 
techniques. These results contrast those found by Clark and Shay (1982) in 
which mitochondria originating from one species were found not to transfer via 
co-incubation into host cells of a different species.  
Others have studied transfer of isolated mitochondria conjugated to a cell-
penetrating peptide, Pep-1 (Chang et al 2013b). Pep-1 causes translocation of its 
cargo in an endosomal-independent manner and has been used to deliver small 
peptides and DNA sequences, but never entire organelles (for review see Morris 
et al 2008). Using mitochondrial specific fluorescent dyes, Chang et al (2013) 
reported that transplantation of mitochondria into recipient cells was found only 
when mitochondria were conjugated with Pep-1. Conjugated mitochondria-Pep-1 
were isolated and co-incubated either with cells derived from myoclonic epilepsy 
with ragged-red fibers (MERRF) syndrome that had mutated mtDNA hindering 
mitochondrial protein synthesis or with cells lacking mtDNA. The exogenous 
mitochondria-Pep-1 co-localized with host mitochondria and resulted in the 
recovery of mitochondrial membrane potential in cells, increased oxygen 
consumption, increased ATP production, and decreased lactate production, all 
indicating a switch from anaerobic to aerobic respiration. This is in contrast to 
previous reports (Clark & Shay 1982, Katrangi et al 2007) that showed isolated 
mitochondria could be taken up by host cells in vitro without Pep-1.   
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In cell-to-cell transfer paradigms, it has been shown that co-culturing 
human lung epithelial cells containing damaged and/or depleted mitochondria 
with healthy adult human bone marrow stem cells results in donation of healthy 
stem cell mitochondria and rescue of epithelial cells that contained functional 
mitochondria, as indicated by increased ATP production and translation of 
mitochondrial protein COXII (Spees et al 2006). Microscopy showed that the 
bone marrow stem cells made cytoplasmic projections towards the epithelial 
cells, shuttling mitochondria through the extensions between connected cells. In 
contrast to other studies, this group showed no evidence of isolated 
mitochondrial transfer into cells using co-incubation methods- when comparing 
transplantation of isolated mitochondria versus cell-to-cell transplantation, 
transfer was only attained in a cell-cell fashion, suggesting that movement of 
exogenous mitochondria into host cells is an active process.  
Nanotube formation between cells was reported through which organelles, 
including mitochondria, were exchanged from one cell to another when co-
culturing human bone marrow mesenchymal stem cells with rat embryonic 
cardiac myocytes (Plotnikov et al 2008). After co-culturing for 24 hours, the cells 
formed nanotube connections and Tetramethylrhodamine Ethyl Ester (TMRE)-
labeled mitochondria were visualized within the nanotubes; TMRE is a 
membrane potential-dependent mitochondrial dye. Further, the propensity of 
each cell type to form tunneling nanotubes was higher when co-cultured with the 
xenogenic cell type compared to a syngeneic cell type. By using calcein-AM, a 
cell membrane permeant dye, the group was able to demonstrate the movement 
of cytoplasmic contents in both directions between cultured cells using scanning 
confocal microscopy, indicating that cytoplasm from both cardiomyocytes and 
human mesenchymal stem cells was shared. It was also shown that physically 
disrupting tunneling nanotube formation with gentle shaking inhibited this sharing 
of cytosolic contents. Using MitoTracker Red and MitoTracker Green FM dyes, 
each specific for one cell type, they visualized mitochondrial transfer between the 
co-cultured cells. There was no detectable transfer at 3 hours but was evident 
after 24 hours of co-culturing. Interestingly, mitochondria movement was 
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apparent from the mesenchymal stem cells to the cardiomyocytes, but there was 
no reciprocal movement and no co-localization of the MitoTracker markers, 
indicating that mitochondria originating from the two different sources did not 
undergo fusion at 24 hours. 
Another group found that co-culturing of rat cardiomyoblasts that had 
undergone oxygen glucose deprivation (OGD) with healthy mouse mesenchymal 
stem cells resulted in the formation of 200-500 nm diameter nanotubes between 
cells after 2 hours, and that after 24 hours these nanotubes contained the 
membrane potential-dependent dye MitoTracker Red (Cselenyak et al 2010). 
This indicated the presence of functionally competent mitochondria, although the 
directionality of movement was not obvious using time-lapse confocal 
microscopy. Importantly, such co-culturing significantly rescued the 
cardiomyoblasts from OGD.  
Others have reported the formation of tunneling nanotubes in cultured 
cells that underwent ultraviolet radiation stress (Wang & Gerdes 2015). They 
showed that PC-12 cells in the beginning stages of apoptosis formed nanotubes 
that reached out to healthy, unstressed cells and that when UV-stressed cells 
were co-cultured with healthy cells there was reduced cell death compared to co-
culturing with UV-stressed cells. EdU (5-ethynyl-2’-deoxyuridine)-labeled mtDNA 
could be detected in the stressed cells, indicating transfer had occurred into the 
damaged cells. They further found that mtDNA-deficient PC-12 cells lacking 
electron transport function could not rescue UV-stressed cells whereas PC-12 
cells with functional mitochondria did.  
It is important to note that the reported successful transfer of mitochondria 
from one cell type to another appears to be most prevalent when transfer 
occurred from a healthy cell to a cell with dysfunctional and/or depleted 
mitochondria. While there are many caveats when considering donor vs recipient 
cell types in the propensity to take up mitochondria, there appear to be 
mechanisms that allow damaged cells to receive mitochondria more readily than 
healthy cells. For example, Cho et. al. (2012) found that cell-to-cell mitochondrial 
transfer occurred via partial cell fusion, but only when the receiving cell had 
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dysfunctional mitochondria. The group showed that co-culturing of human 
mesenchymal stem cells with both human osteosarcoma 143B cells lacking 
mtDNA and cells with severe R6G toxin-induced mitochondrial dysfunction 
resulted in the transfer of mitochondria accompanied by their increased ATP and 
oxygen consumption. However, transfer was not evident when recipient cells had 
mtDNA mutations, leading the group to conclude that mitochondrial transfer 
occurs only when mitochondrial function is severely hindered or absent (Cho et al 
2012).  
 
2.1.2 In vivo Transplantation 
Phylogenetic mapping and mitochondrial transplantation methods have 
been performed in a number of animal models in vivo. Interestingly, a study 
investigating the phylogeny of different canine species with canine transmissible 
venereal tumor (CTVT) by sequencing their mitochondrial genome (Rebbeck et 
al 2011) revealed an unexpectedly high polymorphism rate in the CTVT samples 
thought to be caused by transfer of mitochondria from the dogs into the 
cancerous tumor cells. The group theorized that host (dog) mitochondria may be 
healthier than that of the CTVT cells, encouraging transfer of mitochondria and 
subsequent increase in CTVT metabolic health. This theory reflects an 
endogenous mechanism of mitochondrial transfer in vivo, from one cell to 
another.  
The McCully group who studied direct injection of mitochondria ex vivo 
(McCully et al 2009) also reported successful mitochondrial transplantation in 
vivo using a direct injection technique (Masuzawa et al 2013). Autologous 
transplantation of isolated mitochondria directly into ischemic rabbit hearts 
immediately before reperfusion resulted in increased mechanical function as 
soon as 10 minutes after injection, in addition to significantly higher ATP content 
at 2 days post injection. Further, they showed via confocal microscopy that 
cardiomyocytes can take in exogenous mitochondria as early as 2 hours after 
transplantation and do not illicit an immune response. The group recently 
compared direct injection mitochondrial transplantation to a more clinically 
26 
 
relevant, less invasive vascular perfusion delivery method (Cowan et al 2016). 
Rabbit hearts underwent focal ischemia for 30 minutes in situ followed by 
reperfusion and delivery of mitochondria isolated from adult human cardiac 
fibroblasts. Mitochondria were delivered either by direct injection into the 
ischemic heart tissue or they were perfused through the coronary artery. They 
noted that a large amount of mitochondria were found in the interstitial spaces, 
but some mitochondria were co-localized within cardiomyocytes. Vascular 
delivery of mitochondria resulted in a larger dispersal area, while direct injection 
resulted in a higher concentration in smaller regions of tissue. Importantly, this 
study showed that both direct injection and vascular delivery of mitochondria 
afforded functional protection in measures of muscle contractility and decreased 
infarct size after ischemia-reperfusion injury. The group then aimed to show 
these results in a larger, more clinically relevant animal model. Kaza et al (2016) 
studied the autologous transplant of mitochondria isolated from the pectoralis 
major muscle into a porcine model of ischemia reperfusion (Kaza et al 2016).  
Regional ischemia injury was performed, blocking blood flow for 24 min, after 
which isolated mitochondria were given to the heart, with reperfusion of the heart 
following immediately after mitochondrial delivery. The animals then survived for 
4 weeks. Results from this study are important as they show that there was no 
increase in inflammatory or immune reactivity when mitochondria were delivered. 
There was also significantly larger infarct size in vehicle injected animals 
compared to mitochondria treated animals. Further, injected mitochondria were 
still present at the 4 week time point.  
In addition to direct injections in vivo, cell-to-cell transfer of mitochondria 
has also been reported in vivo. One study instilled mouse bone marrow derived 
stromal cells (mBMSC) into acutely injured mouse lungs which resulted in 
connexin pore-dependent attachment of the mBMSC to the injured lung 
epithelium (Islam et al 2012). This attachment was followed by nanotube 
formation and delivery of mitochondria-containing vesicles into the injured tissue, 
leading to increased ATP production and cell survival after injury. The group 
determined that connexin pore and gap junction channel formation was 
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necessary for such transfer since blocking connexin pore formation inhibited gap 
junction channel formation, which was then found to inhibit cytosolic mixing 
between the two cells. When dynamin, a GTPase responsible for endocytosis in 
the eukaryotic cell, was inhibited mitochondrial delivery was blocked leading the 
group to posit endocytosis to be the mechanism responsible for mitochondrial 
transfer. Again, it is important to note that the mitochondria were transferred to 
damaged cells or tissues.  
Recent compelling studies have shown that endogenous mitochondrial 
transfer occurs between resident astrocytes and neurons after stroke injury 
(Hayakawa et al 2016). The investigators stimulated astrocytes in vitro to release 
mitochondria by upregulating the CD38 protein, and found that the addition of 
these astrocyte-derived mitochondria in a model of neuronal cell injury in vitro 
was successful in increasing neuronal ATP production and cell survival, and that 
these mitochondria were incorporated into the neuronal cells. They further 
studied this in vivo by directly injecting astrocyte-derived mitochondria into the 
injury site 3 days after inducing cerebral ischemia in mice and found these 
mitochondria were taken into neurons. The endogenous transfer of mitochondria 
was seen in these transgenic mice with labeled astrocytic mitochondria that were 
found within neurons 24 hours after ischemic stroke, and cell survival signals 
such as phosphorylated AKT were increased after this transfer (Hayakawa et al 
2016).  
Direct injection of isolated mitochondria has been explored in a 6-OHDA 
rat model of Parkinson’s Disease (PD) (Chang et al 2013a). Transgenically-
labeled GFP-mitochondria were conjugated to Pep-1, a cell penetrating peptide, 
and injected in a dose dependent manner into the medial forebrain bundle. The 
group found that GFP labeled mitochondria were evident at 12 weeks post 
injection using fluorescent microscopy, however, they did not detect foreign 
mtDNA at these time points. Importantly, they also noted mitochondrial 
aggregation at the highest dosage used (2.1µg) compared to the lowest dosage 
(0.525 µg), which was less aggregated and more extensively dispersed. They 
hypothesized that the aggregation at higher concentrations led to decreased 
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penetration of mitochondria into host tissues; this is supported by their findings 
which delineate the lower dosage treatments as having higher efficacy for 
different outcome measures of recovery including cell survival and behavior. Both 
the low and middle dosage group (1.05µg) resulted in significantly higher cell 
body numbers in the substantia nigra compared to vehicle injected animals. 
Additionally, these two lower dosage groups gave significantly higher 
mitochondrial complex I, III, and V activity compared to vehicle. Functional 
recovery was analyzed using apomorphine-induced rotation assessment and 
showed conjugated mitochondria/Pep-1 injection at the two lower dosages 
improved rotational scores closer to baseline compared to vehicle injected 
animals.  
In a later study, the same group utilized xenogenic transfer in PD rats 
(Chang et al 2016). When mitochondria with or without Pep-1 conjugation were 
injected into the medial forebrain bundle, oxidation of substantia nigra cell DNA 
was decreased compared to vehicle injection. They simultaneously performed 
allogeneic transplantation using transgenically-labeled GFP mitochondria 
isolated from PC-12 cells. 3 months after transplantation, locomotion comparing 
distance, speed, and amount of movement were analyzed for each animal. After 
onset of PD by using 6-OHDA, there is significantly decreased locomotor activity. 
Locomotor scores of 6-OHDA animals were significantly increased when 
transplanting either allogeneic or xenogenic mitochondria, but only when 
conjugated with Pep-1; there was not such locomotor recovery when non- Pep-1 
conjugated mitochondria were injected. Interestingly, locomotor scores were 
higher in the allogeneic Pep-1/mitochondria group compared to the xenogenic 
Pep-1/mitochondria group, suggesting there may be differences when using 
mitochondria from sources that are unlike the recipient strain or species. Pep-1 
conjugated mitochondrial transplant also resulted in significantly increased 
neuronal survival and tyrosine hydroxylase immunoreactivity, and increased 
amount of complex I compared to vehicle injection. Importantly, GFP 
immunofluorescence was apparent in the substantia nigra dopaminergic neurons 
3 months after Pep-1 conjugated GFP-mitochondria administration. It should also 
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be noted that 6-OHDA injury increased inflammatory cytokines such as IL-1a, IL-
1b, IL-10, IL-5, and IL-18, and that Pep-1 conjugated mitochondrial delivery 
significantly decreased these levels.  
 
2.2 Tracking Exogenous Mitochondria after Transplantation 
Various methods have been utilized to verify that exogenous mitochondria 
are successfully transplanted into host cells. One common procedure is to 
transplant exogenous mitochondria of one species animal into a host cell of a 
different species, followed by PCR on the host cell mtDNA showing that the 
exogenous mtDNA is present (Islam et al 2012, Kitani et al 2014b, Yang & Koob 
2012). PCR is also performed to show transfer of mtDNA into cells lacking 
mtDNA (Spees et al 2006) or transfer of mitochondria containing a specific 
sequence for chloramphenicol resistance (King & Attardi 1988). Alternatively, 
species-specific mitochondrial antibodies are used to detect exogenous 
mitochondria (Masuzawa et al 2013). Mitochondria can be fluorescently labeled 
pre-injection to visualize after uptake into the host cells by either transfection 
methods (Chang et al 2013b, Islam et al 2012, Kitani et al 2014b, Spees et al 
2006, Wang & Gerdes 2015, Yang & Koob 2012), using mitochondrial-specific 
dyes such as MitoTrackers or rhodamine derivatives  (Chang et al 2013b, Clark 
& Shay 1982, Cselenyak et al 2010, Katrangi et al 2007, Masuzawa et al 2013, 
McCully et al 2009, Plotnikov et al 2008), or transgenic mice in which a subset of 
mitochondria are fluorescently labeled (Hayakawa et al 2016). Another method 
labels mitochondria using pHrodo Red, a pH-sensitive label that indicates proton 
levels. Using this, increased fluorescence of cardiomyocytes in vitro could be 
measured, indicating mitochondrial internalization that could be quantified as a 
number of mitochondria per nucleus (Pacak et al 2015).  
 
2.3 Mitochondria Transplantation Increases Health of Host Cells and 
Tissues 
Many different outcome measures are being used to show that 
transplanted mitochondria have beneficial effects on host tissues. Energy 
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production, mitochondrial protein translation, and enzyme activities have all been 
reported to be increased after transplantation. One group found a three-fold 
increase in ATP levels and a decrease in lactate levels in cells rescued by cell-to-
cell mitochondrial transfer, indicating that the host cells with depleted mtDNA 
were able to switch from anaerobic respiration to aerobic respiration after 
receiving mitochondria (Spees et al 2006). Further, the host cells that contained 
extensive mtDNA damage could again translate mitochondrial proteins, namely 
COXII, after incorporating exogenous mitochondria. Others showed that 
mitochondrial transplantation into damaged lung epithelia resulted in increased 
ATP production approaching control levels, not only in the cells that received 
exogenous mitochondria, but also in juxtaposition alveoli (Islam et al 2012). The 
increase in ATP to normal levels rescued functional surfactant excretion by the 
alveolar cells. Increased cellular ATP content and oxygen consumption rates 
were also reported after exogenous mitochondria internalization into either 
cultured cardiomyocytes or HeLa cells lacking mtDNA, and PCR confirmed 
replacement with exogenous mtDNA in the cells (Pacak et al 2015).  
Mitochondrial function and ROS production have also been used to 
assess the benefits of mitochondrial transplantation. For instance, flow cytometry 
and the fluorescent dyes rhodamine 123 and JCI have been used to determine 
changes in mitochondrial membrane potential in culture using MERRF cells 
(Chang et al 2013b). They also measured oxygen consumption rates as well as 
ATP levels, cell viability, amount of fusion and fission proteins, caspase-3/-7 
activity, mtDNA copy number, mitochondrial mass, and mitochondrial calcium 
uptake. ATP production has also been assessed using fluorometric analyses. 
TBARS (thiobarbituric acid-reactive substances) has been used to show 
differences in oxidative damage and TdT-mediated dUTP nick-end labeling 
(TUNEL) assays have been used to investigate apoptosis (McCully et al 2009). 
This latter group also employed Mito-Tracker Orange CMTMRos label to show 
that labeled mitochondria maintained a viable membrane potential and their 
oxygen consumption rates showed that they were respiration competent.   
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2.4 Mechanisms for Mitochondrial Incorporation 
Cell-to-cell fusion has been disputed as a necessary mechanism of 
mitochondrial transfer. When co-culturing human mesenchymal stem cells with 
human alveolar epithelial cells lacking mitochondrial DNA, transfer of 
mitochondrial but not nuclear DNA was reported (Spees et al 2006). Further, the 
addition of platelets or isolated mitochondria to cultured cells lacking mtDNA did 
not result in mtDNA transfer, indicating the incorporation of exogenous 
mitochondria is not a passive process. In fact, the mesenchymal cells made 
cytoplasmic extensions towards alveolar cells lacking mtDNA, after which the 
depleted cells began dividing after being rescued by mitochondrial transfer. It 
was not shown whether mitochondrial transfer was achieved through nanotube 
formation or budding of mitochondria-filled vesicles from the donor cells. 
However, other groups have demonstrated that co-incubation of cells with 
purified isolated mitochondria results in the uptake of exogenous mitochondria 
into cells (Clark & Shay 1982, Katrangi et al 2007). This indicates an uncertainty 
as to whether mitochondria can be passively endocytosed in cell culture. There 
may be a difference among cell types in the ability to incorporate exogenous 
materials, as was demonstrated in an earlier study examining incorporation of 
nuclear DNA among different cell types (Wigler et al 1980). Clark and Shay 
(1982) similarly showed that different cell lines had a different propensity to 
uptake co-incubated isolated mitochondria, suggesting that mitochondria are 
taken up by recipient cells via different endocytic properties according to 
phenotype.   
Islam et al (2012) reported that physical docking of mBMSC to injured lung 
epithelial cells was necessary for transfer of mitochondria to alveolar cells.  
mBMSC attachment to injured cells occurred at areas of high CX43 connexin 
concentration on lung epithelial cells, and specifically blocking CX43 hindered 
binding and transfer of cytosolic contents from mBMSC to epithelial cells. In vitro, 
mBMSC formed nanotubes with epithelial cells and released microvesicles 
containing DsRed-labeled mitochondria. They concluded that gap junctional 
channels are necessary for attachment, while microvesicles and nanotubes are 
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needed for the movement of mitochondria. Inhibition of dynamin blocked 
mitochondrial transfer, implicating that endocytosis is responsible for the 
engulfment of mBMSC microvesicles (Islam et al 2012). Koyanagi et al examined 
intercellular connections and whether large structures, including organelles such 
as mitochondria, could be transferred between cells (Koyanagi et al 2005). They 
found that when human endothelial progenitor cells were co-cultured with 
cardiomyocytes containing MitoTracker-labeled mitochondria, time lapse imaging 
showed formation of transient nanotubular structures and the progression of 
labeled structures moving from the cardiomyocytes to the endothelial progenitor 
cells. Interestingly, the reverse transport was not evident: when endothelial 
progenitor cell mitochondria were labeled with MitoTracker there was not 
transport to the unlabeled cardiomyocytes, indicating there may be cell-type 
differences that are important to consider for mitochondria transfer. Wang et al 
showed that tunneling nanotubes can be formed in vitro, providing a pathway for 
mitochondrial transfer (Wang & Gerdes 2015). PC-12 cells stressed by UV 
created tunneling nanotubes with a larger diameter and containing microtubules 
that attached to control, unstressed cells. Fluorescence microscopy detected 
tagged mitochondria located within nanotubes connecting stressed and control 
cells, but no presence of mitochondria in nanotubes connecting only control, 
unstressed cells. Live cell imaging techniques allowed tracking of mitochondria 
from the control cell, through the nanotubes, and into the stressed cells. When 
tunneling nanotube formation was inhibited using cytochalasin B, an F-actin 
depolymerizing agent, they found a higher incidence of cell death with the UV 
stressed/unstressed co-culture suggesting that nanotube formation was 
necessary for the rescue effect. They also showed positive co-localization of 
MitoTracker Red-labeled mitochondria with immunostained microtubules located 
within the nanotubes. They further transgenically labeled mitochondria with 
DsRed2-mito in the control cells to quantify their transfer into stressed cells. 
Using cytochalasin B to inhibit the nanotubes decreased the amount of Dsred2-
mito in the stressed cells. 
33 
 
A comparative study was performed by the McCully group to determine 
the mechanism of mitochondrial internalization in vitro (Pacak et al 2015). 
Chemicals were utilized to inhibit different internalization mechanisms, such as 
cytochalasin D to block actin polymerization, methyl-β-cyclodextrin to block 
caveola-dependent-clathrin-dependent endocytosis, nocodazole to block 
tunneling nanotubes, and 5-(N-Ethyl-N-isopropyl) amiloride to block macro-
pinocytosis. The only chemical that changed mitochondrial internalization was 
cytochalasin D, indicating that actin polymerization is involved in mitochondrial 
uptake into the cardiomyocyte cells, though it was not evident how the 
mitochondria left the endosomes once they were internalized. The other 
chemicals had no beneficial effects suggesting that clathrin-dependent 
endocytosis, tunneling nanotubes, and macro-pinocytosis are not involved. This 
is in accordance with their previous report that mitochondria were not co-
localized with lysosomes, caveolae or autophagosomes upon internalization 
(Masuzawa et al 2013). In contrast, others utilized fluorescent live imaging to 
track movement of transgenically-labeled DsRed mitochondria into mesenchymal 
cells and reported that macropinocytosis is necessary for mitochondrial 
internalization in vitro (Kitani et al 2014b). It should be noted that various 
dosages of 5-(N-Ethyl-N-isopropyl) amiloride were used in attempts to block 
macro-pinocytosis in the different cell types used in each study. Recently, 
mitochondrial incorporation in neurons was theorized to be integrin-mediated, 
though the authors stated further investigation was necessary (Hayakawa et al 
2016).  
 
2.5 Summary 
Chapter 1 discussed in detail the intricacies of mitochondrial involvement 
with the secondary pathophysiological cascades after SCI. Their involvement has 
made mitochondria a logical target for therapeutic intervention in the acute 
stages of SCI. Currently, a multitude of treatments are being tested that aim to 
maintain or increase the integrity of mitochondrial health following injury, though 
replacement therapies have yet to be investigated. Chapter 2 investigated the 
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history of mitochondrial transplantation, including the most recent in vivo studies. 
Though these novel in vivo studies are few in number and use other types of 
injury models, we believe the transplantation paradigm is translatable into our 
SCI injury models. As we are the first lab to perform such a transplantation after 
SCI, we had to carefully and methodically choose and characterize multiple 
procedures to best test our hypotheses, which are delineated in the following 
chapters.  
 
 
 
Note: 
Portions of this chapter were adapted and reprinted by permission from 
Elsevier: Jenna L. Gollihue and Alexander G. Rabchevsky. (2017) Prospects for 
Therapeutic Mitochondrial Transplantation. Mitochondrion. 2017 May 19 DOI: 
10.1016/j.mito.2017.05.007 
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CHAPTER 3 
Validation and Optimization of Experimental Models  
 
There are multiple injury models, analytical techniques, and outcome 
measures that could be used to test our hypotheses. We used historical data 
from our lab and from other research fields to validate our experimental 
techniques. There are caveats to consider for each technique, and while these 
were our first-choice methods, alternatives were considered as discussed in the 
future directions section (see Chapter 6.3).  
 
3.1 Contusion Injury and Behavioral Assessments 
The SCI model used in our experiments was a severe contusion injury 
(250 kDyn) at the L1/L2 spinal level using the force-controlled infinite horizon 
impactor (Scheff et al 2003), and assessment of hindlimb functional recovery was 
performed using the Basso, Beattie, Bresnahan (BBB) scale. Our experiments 
were designed to determine if mitochondrial transplantation could afford 
functional recovery after severe SCI. We hypothesized that functional recovery 
would be maintained through increased cell survival including gray matter 
neurons surrounding the injury site. Therefore, we considered a spinal injury level 
and behavioral analysis that would elucidate functional recovery based on gray 
matter sparing. 
The BBB open field locomotor scale was developed using a rat model of 
contusion SCI using the OSU impactor or NYU impactor at the T7-9 level to 
grade different levels of hindlimb functional recovery (Basso et al 1995). The 
group also later showed that recovery of hindlimb locomotor function after a 
complete thoracic transection SCI is dependent upon descending tracts and that 
at least 10% sparing of the ventral white matter is necessary for weight bearing 
steps (Basso et al 1996). Others similarly found that in the absence of gray 
matter loss, a majority of ventral white matter loss is necessary to detect 
functional deficits in an ethidium bromide demyelinating injury in adult rats (Loy et 
al 2002). Therefore, using the BBB to measure recovery of function after a 
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thoracic SCI is a primary measure of white matter sparing of descending spinal 
tracts. Recovery of BBB scores after an L1/L2 level injury, however, is a measure 
of gray matter sparing; this was demonstrated when a specifically gray matter 
injury utilizing spinal injections of kainic acid at T9 did not result in decreased 
BBB scores, but a gray matter lesion at the L1/L2 level resulted in lasting 
functional deficits without disrupting descending white matter pathways 
(Magnuson et al 1999). The Magnuson group later discovered that functional 
deficits as measured by the BBB were dependent upon loss of intermediate gray 
matter interneurons at this level, and not ventral motor neurons of the lumbar 
enlargement (Hadi et al 2000). This indicates that the behavioral recovery relied 
upon the sparing of the central pattern generator (CPG) interneurons in the 
intermediate gray matter that are located in lamina VII and X of the L1/L2 spinal 
level and are responsible for the rhythmic pattern of hindlimb stepping (Grillner 
1975, Kjaerulff & Kiehn 1996). Investigators found that a moderate-severe 
contusion injury at the L2 spinal level resulted in significantly depleted locomotor 
function that correlates to gray matter tissue sparing, injury level, and injury 
severity (Magnuson et al 2005). They also found that the amount of spared white 
matter at this level of injury did not correlate to the functional deficit, further 
demonstrating gray matter loss was responsible for the low BBB scores. As our 
mitochondrial transplantation experiments are hypothesized to be 
neuroprotective, we chose the L1/L2 injury model to measure functional recovery 
using the BBB scoring system that was sensitive to gray matter sparing. 
Further, the BBB scale is a 0-21 point scale that can be split into different 
segments analyzing 1) joint movements, 2) stepping and coordination, and 3) 
fine details of paw movements such as toe clearance and balance. Historically 
we have found that after a 250kDyne L1/L2 injury we can expect a plateau of 
functional recovery at a score around 7 indicating extensive joint movements with 
no hindlimb weight bearing or stepping (Patel et al 2012). Increases in recovery 
by mitochondrial transplantation may increase the scores to the walking and 
patterned stepping scores. Restoration of function via the CPGs will result in 
more differences in the upper two thirds of the BBB scale, giving greater 
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separation of animals that are stepping. Attempts to modify the scale for post hoc 
analysis have been published, placing more emphasis on certain parts of the 
scale that are more translational, or making the scale more ordinal by decreasing 
emphasis on scores that are rarely assigned (Ferguson et al 2004). We reported 
these post hoc analyses in addition to our BBB testing to further differentiate 
recovery between treatment groups (Chapter 5.3.3).  
 
3.2 Cultured Cells as the Source of Transplanted Mitochondria 
From very early stages of our experiments, a major goal was to 
demonstrate that transplanted mitochondria can be successfully incorporated into 
host cells in vivo. For this purpose, we chose to transgenically label mitochondria 
in cell culture, allowing us to tag the mitochondria indelibly before their 
transplantation to track them in situ. PC-12-Adh cells were chosen as the cell line 
to be transfected with the pTurboGFP-mito vector. PC-12 cells originate from the 
adrenal gland of a Rattus norvegicus pheochromocytoma tumor and are 
neuronal-like in their development. Further, we chose to transplant mitochondria 
between like species based on studies that showed mitochondrial transplantation 
in vitro was more efficient when the same species of donor mitochondria were 
used (Clark & Shay 1982, Yang & Koob 2012). For instance, they showed that 
isolated murine mitochondria were more apt to be incorporated into cultured 
murine cells, but were not able to incorporate into human cells. 
 
3.3 Stable Selection and Purification of tGFP PC-12 Cells 
When first performing these experiments, we used a pTurbo-GFP-mito 
vector (evrogen cat # FP517 Farmingdale, NY) that contains a neomycin-
resistant cassette to transform naïve PC-12 cells. We performed a G418 dose 
response selection curve, and determined that 400 µg/mL was necessary to kill 
PC-12 cells that do not have a neomycin resistance cassette. While under 
constant selection, individual turbo green fluorescent protein (tGFP) positive cells 
colonies were manually picked from the plates to grow in separate dishes, a 
technique commonly performed to give a pool of stably transfected cells. 
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However, we soon noticed that the transfection rate was not 100%, and the cells 
that were tGFP+ had varying degrees of fluorescence. We then decided to 
change the antibiotic resistant cassette of the vector to puromycin instead of 
neomycin and repeat our selection process in the hopes that we could obtain a 
colony with high tGFP expression rates.  
To create our vector, the coding sequence for tGFP and the mitochondrial 
targeting sequence was removed from the original pTurbo-GFP-mito vector and 
inserted into a pIRESpuro3 vector (for details see 4.2.1). The resulting plasmid 
contained the mitochondrial targeting sequence, tGFP coding sequence, and 
puromycin resistance sequence. PC-12 cells were transfected with the resultant 
DNA and the cells were propagated under puromycin selection (concentration for 
selection curve determined to be 3µg/mL puromycin), first very sparsely. 
Fluorescent microscopy was used to verify tGFP+ cell colonies, which were then 
physically selected and re-plated as described. The result was a colony of cells 
that had close to 100% tGFP-expression at high levels that did not seem to 
disappear with generations further removed from initial transfection. However, it 
is important to note that these cells grew more slowly than unlabeled PC-12 cells, 
and they had overall lower respiration rates (see Chapter 4.3.4). Regardless, the 
tGFP mitochondria had an indelible marker that is critical for tracking purposes. 
Because we are genetically altering cells and possibly affecting the function of 
mitochondria destined for transplantation, we had to first characterize the 
differences between our labeled mitochondria and unlabeled mitochondria. For 
this, we delved into a series of experiments, which is discussed in detail in 
Chapter 4.  
 
3.4 Muscle Tissue as the Source of Donated Mitochondria  
While tGFP-labeled mitochondria are optimal for visualization after 
transplantation, they respire much more slowly and may have inherently lower 
metabolic requirements compared to mitochondria isolated from naïve spinal 
cord tissue. Historically, state III oxygen consumption rates (OCR) of spinal cord 
mitochondria isolated from naïve SD rats is typically close to 600 pmol 
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oxygen/min (Patel et al 2014). Typical state III OCR of cell-derived mitochondria 
labeled with tGFP is closer to 300 pmol oxygen/min (see Chapter 4.3.4). As 
such, we chose to also evaluate the transplantation of mitochondria that had a 
higher metabolic potential more similar to mitochondria residing in the spinal 
cord. We therefore tested muscle mitochondria that were isolated from naïve 
Sprague Dawley rats, and transplanted into a different rat that had received SCI.  
While this transplantation is syngeneic, and not autologous, it does serve the 
purpose of transplanting high respiration-competent mitochondria into the spinal 
cord. In the future, muscle mitochondria transplantation may be clinically 
relevant- after a patient undergoes a SCI, it may be possible to isolate one’s own 
mitochondria from a muscle biopsy providing for an autologous transplantation. 
 
3.5 Injection Sites 
Our mitochondrial injections were performed in the injury penumbra 
surrounding the primary contusion injury site. The primary injury site is necrotic, 
while the penumbra contains at-risk tissue that may be salvaged by mitochondrial 
transplantation therapy (see Chapter 1.2). The heterogeneous cell types of the 
spinal cord are all susceptible to oxidative damage and mitochondrial 
compromise after SCI, and we hypothesized that mitochondria would be able to 
incorporate into a variety of cell types in the spinal cord. Affording 
neuroprotection was a main goal of these experiments, regardless if this is 
possible directly through transplantation of mitochondria into neurons or indirectly 
through mitochondrial incorporation into various cell types in the injury penumbra 
making the environment more favorable for cell survival. Therefore, our injections 
were made into the medial lateral gray matter near the white matter interface so 
that injected mitochondria had the opportunity to incorporate into various cell 
types that are typically found in both the white and gray matter. This also places 
the injection bolus near lamina VII/X which includes the CPG interneurons critical 
for patterned locomotor stepping (Figure 3.1).  
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Figure 3.1.  Location of mitochondria injections into the injured spinal cord. 
A. Laminectomy was made at thoracic level T12, exposing the L1/L2 spinal level. 
A 250 kDyne injury was performed, followed within 30 minutes by mitochondrial 
injections (green). Four injections were made into the injury penumbra, 
surrounding the injury site at the L1/L2 spinal level. B. Injections were targeted to 
the medio-lateral gray matter. This allowed for the dispersion of exogenous 
mitochondria into nearby white matter as well as gray matter.  Importantly, this 
placed tGFP mitochondria in close proximity of CPG interneurons (boxed area), 
which are located within Lamina VII (yellow) and Lamina X (purple). 
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3.6 Using the Seahorse Flux Analyzer for Respiration Measurements 
Function of the mitochondrial electron transport system has been 
examined using substrates and inhibitors to manipulate different complexes of 
the ETC and measuring the subsequent oxygen consumption rates. This has 
historically been done using the popular Clarke-type oxytherm electrode, though 
a relatively new method that uses the same concept is the Seahorse Flux 
Analyzer XFe 24. We chose to use the Seahorse for our OCR analysis of 
mitochondria for its ease of use and higher throughput of samples.  
The Seahorse Flux Analyzer XFe 24 is an automated system that was 
initially developed to assay cultured cells, but techniques were developed to use 
this device to measure OCR of isolated mitochondria with as little as 5 µg 
mitochondria protein per well necessary for analysis (Rogers et al 2011). They 
noted that the optimal concentration of mitochondria to assay is that which will 
give an increased and sustained OCR with addition of ADP, with a significant 
decrease after the addition of oligomycin. We have optimized our concentration 
of isolated mitochondria to be 5- 7.5 µg per well. This allows us to easily run each 
sample in triplicate, with leftover mitochondria that can be frozen and used for 
other assays. The oxytherm, on the other hand, requires a relatively large 
amount of protein per sample, about 80 µg/ sample run.  
The time required for a sample run is much lower for the automated 
Seahorse (about 30 minutes for one plate containing 7 samples in technical 
triplicate) compared to the oxytherm (15-20 minutes per sample). After the 
process of mitochondrial isolation, samples are left on ice until they can be 
analyzed. The order of sample analysis using the oxytherm may influence 
results, with those run later having been isolated and on ice for much longer, 
possibly compromising the mitochondria compared to those run first in order.   
One benefit that the oxytherm offers is that you can watch and manipulate 
the trace in real time. For instance, if you have a bad reading in the oxytherm, 
you can immediately re-start the trace if you have enough sample. There have 
been mechanical failures in which the seahorse plate got stuck in the reader, or 
had bad baseline readings ruining all the samples for the day. While there is a 
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surplus of sample, the plates need to be incubated overnight- so that you do not 
have a replacement plate if needed. Attempting to prepare for the worst and 
incubating an extra plate for each experiment can get very costly, as plates and 
substrates are expensive.  
State V.1 should be the maximal respiration rate after addition of the ETC 
uncoupler protonophore, carbonilcyanide p-trifluoromethoxyphenylhydrazone 
(FCCP). However, while this is always the case in the oxytherm, it is not always 
the case with the seahorse. On multiple experimental days, the seahorse tended 
to give lower state V.1 readings compared to state III. One of the theories is that 
FCCP is interacting with the plastic of the seahorse plate, so that it is not fully 
interacting with the mitochondria (Sauerbeck et al 2011). While we assume that 
this interaction is similar in each plate, we have seen plates with very high 
maximal V.1 rates, and other plates with the same experimental groups have 
state V.1 lower than state III. This is an important caveat to consider, and for this 
reason we emphasize state III OCR results when analyzing our results.  
 
3.7 Removing Contamination from Culture-Derived Mitochondria  
Many different iterations of mitochondria isolations were performed to 
increase the yield and health of mitochondria isolated from cell culture. 
Modifications were made from our usual protocol of mitochondrial isolation from 
spinal cord tissue, including addition of drill press homogenizations and three 
rounds of nitrogen bombing (detailed isolation protocol in Chapter 4.2.2). In our 
first mitochondrial transplantation studies, we had difficulty pulling the 100 µg 
(33.3 µg/µL) dosage into injection needles. We could successfully pull 50 µg 
(16.6 µg/µL) dosage into the needle- though this still often proved to be difficult 
with clogging that resulted in bubble formation in the needle. We knew that the 
clogging issue was specific to cell culture-derived mitochondria, as preliminary 
feasibility studies used 200 µg (66.6 µg/uL) of spinal cord-derived mitochondria 
without problems. At this point we assumed that 50 µg was the highest feasible 
concentration using cell-derived mitochondria, and carried out initial experiments 
using this dosage including acute bioenergetics and long term behavioral and 
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histological studies. Preliminary studies indicated that 50 µg tGFP mitochondria 
injection/cord resulted in significantly maintained state III OCR (Figure 3.2). 
 
 
Figure 3.2. Mitochondrial respiration following SCI and tGFP mitochondrial 
transplant. tGFP-labeled mitochondria were isolated and injected immediately 
after L1/L2 spinal cord injury. 24 hours later, mitochondria were isolated and 
analyzed for mitochondrial respiration. State III OCR was maintained with 50 µg 
tGFP mitochondrial transplantation. Bars are means ± SEM. *p<0.05 vs Sham 
Laminectomy; #p<0.05 vs Vehicle; + p<0.05 vs contusion only. (one-way ANOVA 
for each state, Tukey’s multiple comparison). N= 4-5/group in triplicate. 
 
During long term transplantation studies, we noted a conspicuous layer of 
white film on isolated culture-derived mitochondria after ficoll purification steps.  
Gentle removal of this layer, followed by an additional resuspension and 
centrifugation step resulted in mitochondria that could be pulled into the needle at 
a dosage of 150 µg (or 50 µg/µL). At this time, it is not known what comprised the 
non-mitochondrial fraction that was removed, though all subsequent studies 
utilized these extra purification steps.  
 
3.8 Conclusions 
Using historical data and preliminary studies, we determined the optimal 
parameters to use for our injury and injections, as well as important outcome 
measures that were used in the ensuing experiments. As these techniques are 
being used in a novel paradigm of transplantation, they come with their specific 
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set of caveats that are discussed further in Chapter 6. The studies described in 
the subsequent chapters provide a foundation for mitochondrial transplantation 
after SCI, while possible refinements in future studies can continually modify and 
enhance our mitochondrial transplantation paradigm. 
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CHAPTER 4 
 Optimization of Mitochondrial Isolation Techniques for 
Intraspinal Transplantation Procedures 
 
4.1 Introduction 
Mitochondria are widely referred to as the powerhouse of the cell. They 
sustain life by providing the cell with energy in the form of ATP via a process 
known as oxidative phosphorylation, and are crucial regulators of calcium 
buffering and apoptosis (Nunnari & Suomalainen 2012). Since mitochondria are 
vital to maintain normal cellular functions, their dysfunction can have widespread 
and devastating effects. Mitochondrial dysfunction has long been associated with 
neuronal trauma and ischemia/reperfusion damage to central nervous system 
tissues (Azbill et al 1997, Fiskum 2000, Sullivan et al 2005, Visavadiya et al 
2015). Promising pharmacotherapies have been developed to target 
mitochondrial dysfunction using antioxidants (Bains & Hall 2012, Gilgun-Sherki et 
al 2002, Jin et al 2014, Patel et al 2014, Smith et al 2008), ETS uncouplers 
(Cunha et al 2011, Jin et al 2004, Patel et al 2009b, Rodriguez-Jimnez et al 
2012, Sullivan et al 2004), and alternative biofuels (Patel et al 2010, Petruzzella 
et al 1992) to feed into the electron transport system. In the burgeoning field of 
organelle transplantation, a novel paradigm has emerged to transplant 
exogenous, well-coupled mitochondria to replace those that are nonfunctional. 
As evidenced with earlier experiments, not only can this approach supplement 
the original pool of mitochondria with more endogenous antioxidant systems and 
improve energy producing capabilities, but it can also replace those mitochondria 
that are too damaged to function (Chang et al 2016, Hayakawa et al 2016, Islam 
et al 2012, Katrangi et al 2007, Masuzawa et al 2013, Pacak et al 2015). 
Mitochondrial transplantation has been shown to have beneficial effects in 
different injury models in vitro using co-incubation methods (Chang et al 2013b, 
Clark & Shay 1982, Elliott et al 2012, Katrangi et al 2007), direct injection 
techniques (King & Attardi 1988) or co-cultured cell delivery approaches 
(Cselenyak et al 2010, Plotnikov et al 2008, Spees et al 2006, Wang & Gerdes 
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2015, Yang & Koob 2012); as well as in vivo using direct injections (Masuzawa et 
al 2013) or cell-to-cell transfer (Islam et al 2012). In the emerging field of 
mitochondrial medicine (for reviews see Armstrong 2007, Luft 1994), 
mitochondrial transplantation has a unique set of caveats that require careful 
consideration. Multiple labs have shown that exogenous mitochondria can be 
integrated into host cells (Chang et al 2013b, Clark & Shay 1982, Cselenyak et al 
2010, Islam et al 2012, Katrangi et al 2007, Kitani et al 2014a, Masuzawa et al 
2013, Pacak et al 2015, Spees et al 2006). Relevant to the current study, 
verification of mitochondrial incorporation into host tissues has been performed 
using various techniques including quantifying transplanted mitochondrial DNA 
(Islam et al 2012, Spees et al 2006, Yang & Koob 2012) or visualizing 
mitochondria with transgenic labeling or post-isolation fluorescence tagging 
(Chang et al 2013b, Clark & Shay 1982, Kitani et al 2014a, Lin et al 2013, 
Masuzawa et al 2013, McCully et al 2009, Plotnikov et al 2008). More recently, it 
has been reported that mitochondrial particles are transferred from astrocytes 
into nearby damaged neurons after ischemic stroke in mice, resulting in 
neuroprotection (Hayakawa et al 2016). This group also showed that injecting 
isolated mitochondria particles labeled with MitoTracker Red CMXRos into the 
mouse brain allows for tracking of mitochondria in the CNS in situ.  
Using fluorescent mitochondrial labels does not come without its caveats. 
Different mitochondrial dyes have been utilized when tracking mitochondria in 
vitro (Chang et al 2013b, McCully et al 2009, Plotnikov et al 2008). Transgenic 
labeling of mitochondria in vitro provides a stable alternative to labeling with more 
photosensitive MitoTracker dyes (Rizzuto et al 1996, Shitara et al 2001). While 
MitoTracker Green FM is a dye whose fluorescence intensity is altered with 
changing membrane potentials (Keij et al 2000), it is reported that the 
MitoTracker dyes can inhibit mitochondrial respiration (Buckman et al 2001). The 
latter group reported that upon mitochondrial damage, such as uncoupling using 
FCCP, MitoTracker dyes were released into the cell cytoplasm, indicating that 
these dyes are not irreversibly bound to the mitochondria. MitoTracker Green FM 
is reported to be cytotoxic in Hela cells even at low concentrations of 250 nM 
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(Han et al 2013), and MitoTracker Red CMXRos is toxic to human 143B 
osteosarcoma cells (Minamikawa et al 1999). CMXRos is a photosensitizer that 
causes chemical damage when subjected to laser scanning, such as used in 
confocal imaging.  
To address the fidelity of using fluorescent trackers to label exogenous 
mitochondria, we investigated the use of transgenically-labeled mitochondria 
isolated from cell culture compared to traditionally labeled MitoTracker 
mitochondria to ascertain which could provide a non-toxic, indelible tag that 
allows for long-term visualization of transplanted mitochondria in vitro. Our 
results showed that the tGFP label did not dissociate from isolated transgenic 
mitochondria, but the MitoTracker Green FM label detached from mitochondria. 
We then used time-lapse confocal imaging to reveal the incorporation of 
exogenous tGFP mitochondria into PC-12 cells after brief co-incubation. After we 
established optimal isolation protocols to obtain well-coupled and easily 
identifiable mitochondria for characterizing transplantation into cell cultures, we 
addressed technical hurdles for transplanting mitochondria in vivo. 
Immunohistochemical evidence shows that these transgenically-labeled 
mitochondria can be injected into the spinal cord with host cellular uptake within 
24 hours post injection. In summary, we show successful transplantation of 
exogenous, transgenically labeled mitochondria both into PC-12 cells in vitro and 
within various host cells in the rat spinal cord in situ. These experiments 
delineate a superior method of using transgenic cell lines for the purpose of 
isolating well coupled mitochondria that have a permanent fluorescent label that 
allows real time tracking of transplanted mitochondria. This lays the foundation to 
apply these techniques of mitochondrial transplantation after SCI to discern cell 
type incorporation and the effects on overall bioenergetics and tissue sparing.  
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4.2 Materials and Methods 
4.2.1 Transgenic Labeling of PC-12 Cells 
The section of the plasmid vector pTurbo-GFP-mito (evrogen cat # FP517 
Farmingdale, NY) containing the sequence coding for both tGFP and the 
mitochondrial targeting sequence was removed and inserted into a pIRESpuro3 
vector. Briefly, the restriction enzymes NheI-HF and NotI-HF were used to digest 
both vectors.  NheI cuts the pTurbo-GFP-mito vector at the 591 position, and 
NotI cuts at the 1406 position. Within these cuts are the mitochondrial targeting 
sequence and the turbo-GFP coding sequence. This insert was then gel purified 
and ligated with the PIRESpuro3 vector using a rapid DNA ligation kit (Roche). 
The resulting plasmid contained CMV promoter, the mitochondrial targeting 
sequence, tGFP coding sequence, and puromycin resistance sequence. 
OneShotStbl3 E. coli (Invitrogen cat no C7373-03 Carlsbad, CA) were then 
transformed with the resulting plasmid. Briefly, the plasmid was diluted to 1ng/µL 
and used according to manufacturer protocol for E. coli transformation. One 
colony from the resulting plate was then selected for plasmid DNA purification 
using a Miniprep kit (Qiagen 27106 Valencia, CA) according to manufacturer’s 
protocol.  PC-12 Adh (ATCC CRL-1721.1 Manassas, VA) cells used in these 
experiments were grown at 37°C with 95% air, 5% CO2 in complete growth 
media consisting of F-12K Medium (ATCC cat # 30-2004 Manassas, VA) with 
2.5% fetal bovine serum (Atlanta Biologicals # S1111OH, Atlanta, GA), 15% 
horse serum (Gibco # 26050-070), and 1.1% penicillin streptomycin (Corning # 
30-002-CI, Tewksbury, MA). Cells were passaged every 3-4 days. Transfection 
was carried out using LipoJet In Vitro DNA and siRNA Transfection kit (SignaGen 
Laboratories Rockville, MD) according to manufacturer’s protocol for transfecting 
adherent cells. At 24 hours after transfection, selective media (3 µg/mL 
puromycin in complete media) was applied to the cells. Cells were stably 
transfected by continual growth in selective media for the remainder of the 
studies. 
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4.2.2 Mitochondrial Isolation from Cell Culture 
Isolation of mitochondria from cell culture was carried out by using 
techniques for isolating mitochondria from spinal cords (Patel et al 2014), with 
modifications for removing PC-12 Adh cells from culture plates and 
homogenization with additional nitrogen bomb steps to ensure cellular disruption. 
Briefly, cells were removed from 15cm culture plates at 95% confluence by 
trypsinization (0.25% Trypsin EDTA) or manual cell scraping, as described for 
experiments comparing cell removal techniques. Cells were concentrated by 
centrifugation at 500 x g for 5 min at 4°C and resuspended in 2 mL isolation 
buffer (215 mM mannitol, 75 mM sucrose, 0.1% BSA, 20 mM HEPES, pH 
adjusted to 7.2 with KOH) containing 1 mM ethylene glycol tetraacetic acid 
(EGTA). The solution was centrifuged at 1.8 rcf for 3min, 4°C. The resulting pellet 
was then resuspended and mechanically homogenized using a drill press with 10 
gentle passes of the pestle into and out of the solution. The cells were then 
nitrogen bombed at 1500 psi, 10 min, 4°C to further release mitochondria from 
cells and increase yield. Mechanical homogenization was then repeated before 
the solution was again centrifuged at 1.8 rcf, 3 min, 4°C. The supernatant 
containing mitochondria was removed and saved in an Eppendorf tube to be 
combined at later step. To further increase mitochondrial yield, the pellet was 
resuspended in isolation buffer, and mechanical homogenization and nitrogen 
bombing steps were repeated. The solution was again centrifuged at 1.8 rcf, 3 
min, 4°C, after which the supernatant containing mitochondria was saved and the 
pellet was again resuspended and underwent mechanical homogenization, 
nitrogen bombing, and centrifugation at 1.8rcf for 3min, 4°C. Finally, the 3 
resulting supernatant portions that had been saved from previous steps were 
centrifuged at 13,000 rcf for 10 min at 4°C, and the pellets were then 
resuspended in isolation buffer, combined into one sample, and purified using 
ficoll gradient (7.5%/10%) centrifugation at 32,000 rpm for 30 min, 4°C. After 
centrifugation, mitochondria remain in a pellet at the bottom of the tube. 
Importantly, we found that there is an inconspicuous layer of non-mitochondrial 
particles lying on top of the pellet that must be aspirated gently prior to removing 
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the rest of the supernatant. The purified mitochondrial pellet was resuspended 
600µL isolation buffer without EGTA and centrifuged at 10,000 rcf, 10 min, 4°C 
resulting in the final pellet which was then resuspended in 20 µL isolation buffer 
without EGTA. 2 µL of this was used in the Pierce BCA protein assay kit (Thermo 
Scientific cat# 23227 Rockford, IL) with the Biotek Synergy HT plate reader 
(Winooski, VT) measuring absorbance at 560 nm to determine mitochondrial 
protein concentration.  
 
4.2.3 MitoTracker Green Labeling and Filter Testing 
Mitochondria were isolated from naïve, unlabeled PC-12 Adh cell cultures 
(see previous section 4.2.2). After centrifugation at 10,000 rcf, 10min, 4°C, the 
mitochondria were labeled with MitoTracker Green FM (MTG, Invitrogen cat# 
M7514) according to manufacturer’s protocol. Briefly, mitochondria were 
incubated with 1 uM MTG for 5 min at room temperature, covered from light. The 
solution was centrifuged at 10,000 rcf, 10 min, 4°C to wash any remaining 
unbound MTG. The mitochondrial pellet was then resuspended in isolation buffer 
with EGTA, drawn into a 1mL syringe, slowly passed through a 0.2 µm pore 
Nalgene filter (Thermo Scientific cat # 723-2520) placed at the end of the 
syringe, and then seeded onto 35 mm plates containing unlabeled PC-12 Adh 
cells. The cells were placed in a 37°C incubator for 1 hour, after which they were 
imaged using a Nikon confocal microscope (see 4.2.7). In tandem, a filter test 
was performed on isolated tGFP mitochondria, which were drawn into a separate 
syringe, passed through a filter and seeded onto naïve cells for imaging.  
 
4.2.4 Transmission Electron Microscopy 
For transmission electron microscopy (TEM), tGFP-labeled mitochondria 
were isolated as described above. After 10,000 rcf centrifugation, the 
mitochondrial pellet was fixed in 3% glutaraldehyde in sodium cacodylate buffer 
overnight at 4°C. The pellet was then rinsed in 0.2M sodium cacodylate buffer 3 
times for 5 minutes each at 4°C. The pellet was then placed in 2% osmium 
tetroxide for 1 hour at 4°C, followed by washing in distilled water 5 times for 5 
51 
 
min each at 4°C. The pellet was then placed in 2% uranyl acetate overnight at 
4°C. The sample was rinsed in distilled water 5 times for 5 min each at room 
temperature, followed by sequential ethyl alcohol dehydrations in 30, 50, 70, and 
90% ethyl alcohol (EtOH) for 10 min each at room temperature. This was 
followed by three washes in 100% EtOH for 15 min each wash at room 
temperature. The pellet was then washed in resin (23.1% ERL 4221 (3,4-
Epoxycyclohexylmethyl-3’,4’-epoxycyclohexane carboxylate) Electron 
Microscopy Sciences Hatfield PA), 18.5% DER (Diglycidyl ether of polypropylene 
glycol, Electron Microscopy Sciences Hatfield PA), 57.7% NSA (Nonenyl succinic 
anhydride, Electron Microscopy Sciences Hatfield PA), 0.69% DMAE 
(Dimethylaminoethanol, Electron Microscopy Sciences Hatfield PA) 3 times, each 
for 1 hour at room temperature with gentle spinning. The pellet was then cut into 
smaller sections, placed in fresh resin in molded blocks, and incubated at 60°F 
for 48 hours. Blocks were then trimmed and cut at 90 nm thickness using Ultracut 
UCT (Leica Microsystems, Buffalo Grove IL). Sections were placed onto copper 
grids and allowed to dry at room temp, covered to protect from dust 
accumulation, overnight. The mounted grids were then processed using lead 
citrate. Briefly, each grid was placed on top of a drop of 0.5% aqueous lead 
citrate at room temperature in a petri dish containing sodium hydroxide pellets to 
absorb carbon dioxide. Grids were left on the droplet for 3 minutes, then moved 
to a new droplet of distilled water, in turn “washing” the grid. The grid was moved 
to a fresh droplet of water every 5 min, for a total of 5 washes then dabbed with a 
Kimwipe to remove the excess water and allowed to dry. Grids were then imaged 
at 60kV on a Philips TECNAI 12 BT transmission electron microscope. Captured 
images represent the inner portion of the mitochondria pellet.  
 
4.2.5 Assaying Respiration of Isolated Mitochondria 
Mitochondria, whether labeled or not, were assayed for OCR immediately 
after isolation using the Seahorse Bioscience XFe Flux Analyzer as described 
previously (Sauerbeck et al 2011, Patel et al 2014). Briefly, isolated mitochondria 
were applied into cell plate cartridges that were then centrifuged to concentrate 
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mitochondria to the bottom of each well. Then, automatically 5mM pyruvate/ 2.5 
mM malate/ 1mM ADP, 1µg/uL oligomycin, 3 µM FCCP, and 100nM 
rotenone/10mM succinate were sequentially added to each well. Oxygen levels 
were measured after each substrate/inhibitor addition over time to obtain OCR in 
each instance of manipulating different complexes of the electron transport 
system.  
 
4.2.6 Co-incubation of PC-12 Cells with Transgenically-Labeled tGFP 
Mitochondria 
Transgenically-labeled tGFP mitochondria were isolated from cell culture 
and then applied to confluent naïve (unlabeled) PC-12 Adh cells. tGFP 
mitochondria were isolated as described above (section 4.2.2) and diluted to 
desired concentrations using complete media at 37°C. Naïve PC-12 cells were 
plated 24 hours prior in 35mm dishes (MatTek corp. Part no. P35GC-1.5-14-C 
Ashland, MA) with glass coverslip bottoms for imaging purposes. The media on 
naïve PC-12 cells was replaced with mitochondrial-supplemented media at 
concentrations of 5, 10, or 20 µg per 2mL of media, which was left on the cells for 
1 or 2 hours dependent on the experimental design at 37°C on a gently rocking 
platform. The mitochondria-enriched media was then aspirated and the cells 
were rinsed once, followed by replacement with fresh complete media at 37°C 
and imaging.   
 
4.2.7 Imaging of PC-12 Adh Cells After Mitochondrial Transplantation 
Cells were evaluated using a confocal Nikon Ti-e inverted microscope 
(Nikon Instruments Melville NY) for high magnification and live imaging purposes 
or an American Microscopy Group (AMG) Evos fluorescent microscope for low 
magnification images to verify transfection efficiency of tGFP. For live imaging, 
the cell plates were placed in an incubation chamber situated above an inverted 
laser, set to 5% CO2 and 37°C. Cells were imaged using wavelengths for tGFP 
using excitation laser 488-20 nm (Nikon) or using the green fluorescent protein 
(GFP) filter cube (EVOS).  
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4.2.8 Quantification of tGFP Transplantation in vitro 
tGFP-labeled mitochondria at three different dosages (5 µg, 10 µg or 20 
µg) were applied to and incubated with unlabeled PC-12 Adh cells (Passage 31, 
80% confluent in 35 mm dish) for 2 hours before washing and imaging (section 
4.2.7). In each of 3 separate experimental runs performed on separate days, 
each dosage was applied to 3 different culture dishes, and 4 random non-
overlapping fields of view in each dish were captured using Nikon confocal 
microscopy representing the region of interest (ROI). These images were taken 
on live, non-fixed cells. After capturing the ROI, the image was thresholded 
above background fluorescence, and quantification of the number of green 
fluorescent objects was calculated using Nikon NIS software (Nikon Instruments).   
 
4.2.9 Microinjection of tGFP Mitochondria in vivo  
Adult female Sprague Dawley rats (250g, Harlan, n=13) underwent a T12 
laminectomy to expose the L1/L2 spinal level (Patel et al 2012). Isolated tGFP 
mitochondria were injected into the mediolateral gray matter at 4 circumferential 
sites of the spinal cord separated by 2mM in the rostral caudal direction using a 
glass micropipette needle (World Precision Instruments, Sarasota, FL cat no. 
4878) pulled and beveled to a 20-30 µm inner diameter pore opening. One cohort 
of naïve animals was used to determine tGFP co-localization with other 
mitochondrial markers (n=2). Each injection site consisted of 750 nL of 12.5µg 
tGFP mitochondria suspended in vehicle (isolation buffer with 5mM pyruvate, 2.5 
mM malate and 10mM succinate); hence a total of 50µg tGFP mitochondria in 
3µL vehicle was injected per cord. Animals survived 24 hours after injections and 
then spinal cords were processed for histological assessment. A separate cohort 
of animals was used to determine cell-type co-localization after SCI (n=11). Each 
injection site consisted of 750 nL of either vehicle (n=3) (isolation buffer with 
5mM pyruvate, 2.5 mM malate and 10mM succinate) or 25µg tGFP mitochondria 
(n=8) suspended in vehicle; hence a total of 100µg tGFP mitochondria in 3µL 
vehicle was injected per cord. Animals survived 24 (n=6) or 48 (n=5) hours after 
injections and then spinal cords were processed for histological assessments.  
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4.2.10 Immunohistochemistry and Image Analysis 
At 24 hours after injections animals were overdosed with 0.2 mL Fatal-
Plus solution (Vortech Pharma Ltd., Dearborn, MI) followed by transcardial 
perfusion first with 0.1M phosphate buffered saline (PBS), then 4% 
paraformaldehyde in PBS. A 1.5cm segment of spinal cord centered on theL1/L2 
injection sites was dissected, cryoprotected in 20% sucrose/PBS, embedded in 
gum tragacanth, cryopreserved, and serially cryosectioned coronally at 25µM, 
keeping every section as we have reported (Patel et al 2010, Rabchevsky et al 
2002). Antibodies used for fluorescent imaging and co-localization comparisons 
included rabbit anti-tGFP (0.13µg/mL, Evrogen # Ab513), mouse anti-COXIV 
(2µL/mL, Cell Signal #11967), mouse anti-TOMM20 (5µg/mL, abcam # 
ab56783), mouse anti-RECA1 (5µg/mL, abcam # ab9774), mouse anti-Ox42 
(5µg/mL, abcam # ab78457), goat anti-rabbit 488 (4µg/mL, Invitrogen # A11008), 
goat anti-mouse Biotin (7.5µg/mL, Vector # BA-9200), and Streptavidin Texas 
red (3.3µg/mL, Vector # SA-5006). Images were obtained using Nikon Eclipse Ti 
Confocal microscope and NIS elements software (Nikon Instruments).   
 
4.2.11 Statistical Analyses 
Mander’s overlap analyses were carried out using NIS software (Nikon 
Instruments), in which the percentage of overlap between pixels which were both 
TRITC + and FITC + was calculated within the injection site ROI in tissue 
sections. Changes in OCR and respiratory control ratio (RCR) were analyzed 
using a one-way analysis of variance (ANOVA) for each respiration state. For 
passage OCR comparisons, we first found no differences within the groups of the 
passage OCR using one-way ANOVA. Because there were no differences, the 
passages were combined to do a broad comparison between treatment groups.  
The treatment groups (naïve vs tGFP) were then compared using Student’s T 
test. Dose-response incorporation studies in vitro were analyzed using a one-way 
ANOVA with Tukey’s multiple comparisons. All analyses were performed using 
Graphpad Prism 6 (Graphpad Software, Inc., La Jolla, CA). Significance was set 
to p < 0.05.  
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4.3 Results 
4.3.1 Transgenic Labeling with pTurboGFP-mito Vector 
The pTurboGFP-mito vector encodes tGFP as a fusion protein with the 
mitochondrial targeting sequence of subunit VIII of cytochrome c oxidase 
complex. When transfected into PC-12 cells, this plasmid targets  the protein to 
the inner mitochondrial membrane (Matz et al 1999, Rizzuto et al 1995, Rizzuto 
et al 1989). By exploiting the puromycin resistance cassette of the vector, 
puromycin was used to select for and amplify cells that expressed tGFP (Figure 
4.1). 
 
Figure 4.1. tGFP transfected PC-12 Adh cells.  Representative images show 
PC-12 cells expressing tGFP fluorescent protein under A. bright-field or B. Green 
Fluorescent Protein filters. Cells were under constant selection using puromycin 
(passage 19).  High transfection efficiency is evident, though it should be noted 
that there are varying degrees of signal intensity. C. High magnification of a tGFP 
transfected cell showing perinuclear mitochondrial networks throughout the 
cytoplasm.  A and B taken on AMG scope, scale bar = 50µM. Image C taken on 
Nikon confocal Ti-e microscope, 488nm excitation laser, scale bar= 10µM. 
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4.3.2 Transmission Electron Microscopy 
The morphological features of tGFP-labeled mitochondria under TEM 
showed typical healthy structures such as prominent cristae and intact outer and 
inner mitochondrial membranes (Figure 4.2), as we have reported (Patel et al 
2009a). Verifying the structural integrity of the labeled mitochondria to be 
transplanted is important, but to ensure that isolated tGFP mitochondria were 
functioning properly we assessed their respiration rates to confirm the integrity of 
the electron transport system; notably in comparison to mitochondria labeled with 
a fluorescent dye. 
 
Figure 4.2. TEM images of tGFP mitochondria. TEM shows that the tGFP-
labeled mitochondria have dense cristae (yellow arrows) and intact membranes 
(white arrows), indicative of healthy mitochondria. B. is a higher magnification of 
boxed insert shown in A. Scale bars = 1 um (A), 200 nm (B). 
 
4.3.3 Comparing Fidelity of Mitochondrial Labels 
There are concerns about both the fidelity of MTG to irreversibly label 
targeted mitochondria and the potential to affect the function of isolated 
mitochondria (Buckman et al 2001). To compare the fidelity of the MTG label 
versus the transgenic tGFP label, we performed an experiment in which labeled, 
isolated mitochondria were gently pushed through a 0.2 µM filter which does not 
allow the mitochondria (0.4 – 1 µM) to pass through, but does allow for unbound 
MTG or tGFP to pass through. We found that while the filtered MTG/mitochondria 
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solution resulted in positive green fluorescence labeling of naive cells (Figure 
4.3A), there was no fluorescent labeling with the filtered tGFP/mitochondria 
solution (Figure 4.3B). This indicates that using MTG in mitochondria 
transplantation experiments may render ambiguous results since the dye can 
label endogenous mitochondria as well. Therefore, transgenic labeling of 
mitochondria in cultured cells affords an alternative method of labeling 
mitochondria in an indelible manner.  
 
 
Figure 4.3. MTG label dissociates from mitochondria, leading to non-
specific labeling. A. MTG labeling (green) of PC-12 cells after MTG 
mitochondria solution passage through 0.02 um filter. B. Absence of tGFP 
fluorescence after passing the tGFP mitochondria solution through 0.02um filter, 
indicating no leakage of the label. Scale bars= 50µM. 
 
4.3.4 Testing Respiration of Isolated, Transgenically-Labeled Mitochondria 
Prior to comparing transgenic versus MTG labeling of mitochondria on 
bioenergetic integrity, we tested transgenically labeled tGFP mitochondria for 
functionality to ensure the integrity of the electron transport chain. Isolated 
mitochondria were assayed using the Seahorse Bioscience Flux Analyzer to 
determine the OCR and RCR, as described in section 4.2.5. Mitochondrial 
respiration rates at the different states gives insight into the function of different 
complexes of the mitochondrial electron transport system. The following methods 
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are published in our lab (Patel et al., 2014). For further reference, Brand and 
Nicholls have published a review of mitochondrial assessment techniques and 
theories (Brand & Nicholls 2011). Briefly- addition of pyruvate, malate, and ADP 
creates movement of electrons through the electron transport system, creating 
ATP and consuming oxygen in the process. OCR at this point is referred to as 
state III respiration- it includes the flow of electrons through the electron transport 
chain from complex I through complex IV, including coupling to the ATP synthase 
complex to give a complete picture of the electron transport system integrity. This 
is a measurement of oxygen consumption that corresponds to ATP production. 
Oligomycin is then added, resulting in state IV respiration- where the ATP 
synthase complex is inhibited so that any oxygen consumption is caused by 
leakage of electrons from the electron transport chain. Subsequent addition of 
FCCP, a protonophore, causes collapse of the membrane potential across the 
inner mitochondrial membrane, and uncouples the ATP synthase complex from 
the electron transport chain. Referred to as state V.1 respiration, proton pumping 
across the membrane is at a maximal rate, and is reflected by a high rate of 
oxygen consumption. Final addition of rotenone (a complex I inhibitor) and 
succinate (feeding electrons into complex II) elicits state V.2 respiration. Oxygen 
consumption in this state is caused by electrons entering the electron transport 
chain through complex II. The ratio of state III divided by state IV respiration 
gives the RCR- a ratiometric measurement that is indicative of mitochondrial 
integrity as it incorporates respiration from both the entirety of the electron 
transport chain as well as leakage of electrons. For example, respiratory 
competent mitochondria with low leakage will have a high OCR after pyruvate, 
malate, and ADP addition, but a very low OCR following addition of oligomycin, 
thus resulting in a higher RCR value. 
We first compared mitochondria isolated from cells at various passage 
numbers to ensure that there were no alterations in mitochondrial functionality 
with age or cell passage numbers. Simultaneously, respiration rates of tGFP-
labeled mitochondria were also compared to respiration rates of naïve, unlabeled 
PC-12 mitochondria (Figure 4.4). 
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Figure 4.4.  OCR of isolated tGFP-labeled mitochondria or naïve non-
labeled mitochondria at different passage generations.  One-way ANOVA 
was performed for each state of respiration within treatment groups. With no 
significant differences among passage number OCR values using a one-way 
ANOVA, the groups were collapsed (indicated by the horizontal bars) and 
compared using Student’s T tests to determine overall group effects. RCR were 
analyzed using a one-way ANOVA for each cell group, with Tukey’s multiple 
comparisons. Bars are means ± SEM. *p<0.0001 tGFP vs Naïve; #p<0.05 vs 
tGFP P19. n= 3/group performed in triplicate.  
 
There were no passage-dependent differences in respiration rates within 
cell lines, indicating that the passage generation of the cells did not significantly 
affect respiration; though there was a trend for decreased state III and V.1 OCR 
with increased passages of the tGFP mitochondria group. Therefore, group 
passage OCR values were collapsed to compare differences between naïve and 
tGFP mitochondria at each state. Results showed significant differences in 
respiration when comparing tGFP to naive groups (State III- P < 0.0001; State 
V.1- P <0.0001) (Figure 4.4), indicating that tGFP mitochondria respire at lower 
rates than naïve mitochondria, perhaps producing less ATP. Additionally, there 
were significant differences in RCR values [F (2, 6) = 8.388, P=0.0183]; post hoc 
analyses showed tGFP mitochondria from lower passage numbers had 
significantly higher RCR values. While this is important to note, it is not yet 
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known what optimal respiration rates are for mitochondria to be transplanted 
since ATP production may be different among cell types. Therefore, in 
subsequent experiments we utilized tGFP mitochondria from low passage 
numbers.  
Respiration rates of tGFP-labeled mitochondria were then compared to 
MTG-labeled mitochondria. Results show that regardless of the label, there were 
no significant differences in OCR at any state (State III- [F (2, 6) = 3.652, P= 
0.0917]; State IV- [F (2, 6) = 3.098, P= 0.1190]; State V.1- [F (2, 6) = 2.010, P= 
0.2147]; State V.2- [F (2, 6) = 1.277, P= 0.3450]), or RCR values among groups 
[F (2, 6) = 0.1853, P= 0.8355] (Figure 4.5). The electron transport system does 
not appear hindered by either the MTG or tGFP label as the RCR for each group 
was above 5. While tGFP mitochondria were found again to respire at overall 
lower rates, they remained well-coupled. It should be noted that, per 
manufacturer’s protocol, MTG is reconstituted in Dimethyl sulfoxide (DMSO) to a 
final concentration of 1% DMSO in solution, which may have effects on the lipid 
membrane of mitochondria causing partial mitochondrial ETS uncoupling and 
increased OCR.  
 
Figure 4.5. tGFP vs MTG mitochondrial respiration. Mitochondria were 
isolated from either transgenic tGFP PC-12 cells or naïve PC-12 cells that were 
then labeled using MTG, then assayed for respiration using the Seahorse Flux 
Analyzer. Bars are means ± SEM. (One-way ANOVA for each state) n=3/group, 
performed in triplicate.  
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After isolating well-coupled transgenically-labeled mitochondria from cell 
culture, we optimized techniques for increasing both bioenergetics and 
mitochondrial yield. In order to perform in vivo transplantation experiments, a 
sufficient yield of respiratory-competent mitochondria is needed to elicit 
responses following their supplementation. Using isolation methods with or 
without ficoll, we have found that we can obtain a higher yield of crude 
mitochondria versus purified mitochondria. However, when the health of cell 
culture-derived mitochondria in the crude vs purified fractions was tested, we 
found that purified mitochondria give much higher respiration rates (data not 
shown). Our initial use of trypsin as a means to permeabilize the cell membranes 
and release mitochondria resulted in a higher yield of mitochondria. Importantly, 
however, we found in preliminary studies that intraspinal transplantation of 
mitochondria isolated with trypsin caused tissue damage due to residual trypsin 
remaining in the pellet (data not shown), even after washing and centrifugation. 
Therefore, while the isolated mitochondria appear well-coupled, trace amounts of 
trypsin in the suspension can be detrimental to tissues in vivo. Therefore, 
subsequent studies using mitochondria derived from cell culture were isolated 
using manual scraping with the ficoll purification step.  
During in vivo transplantation experiments, isolated mitochondria may be 
exposed to room temperature (RT) for up to 30 minutes while in the 
microinjection needle. An experiment was performed on tGFP mitochondria to 
test the effects of temperature and substrate supplementation on respiration 
(Figure 4.6). The mitochondria were resuspended in isolation buffer and either 
left at RT or on ice for 30 minutes, and either with or without substrate 
supplementation (5mM pyruvate/malate and 10mM succinate). 
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Figure 4.6. Mitochondrial respiration changes with temperature and 
substrate addition. Mitochondrial respiration was highest when left on ice, with 
state III and V.1 decreasing significantly at RT. Addition of substrates (subs) at 
RT helped maintain state III respiration. Bars are means ± SEM. *p<0.05 vs Ice; 
#p<0.05 vs Ice + subs (One-way ANOVA for each state, Tukey’s multiple 
comparison) n=3/group in triplicate.  
 
Mitochondria that were kept on ice in centrifuge tubes had higher 
respiration rates compared to mitochondria left at RT. State III OCR changed 
significantly [F (3, 8) = 7.407, P= 0.0107] and post hoc analysis revealed 
significantly decreased OCR in samples that were left at room temperature 
without substrates compared to those on ice, with or without substrates. Addition 
of 5mM pyruvate malate and 10mM succinate substrates to mitochondria held at 
RT partially restored state III OCR towards the respiration of mitochondria held 
on ice. This indicates that substrate addition helps to maintain mitochondrial 
bioenergetics in our injection paradigm. 
  State V.1 respiration was significantly different among groups [F (3, 8) = 
22.79, P= 0.0003]; post hoc analyses showed lower respiration in all samples 
compared to the naive sample on ice. There were no differences in State IV [F 
(3, 8) = 2.561, P= 0.1279], State V.2 [F (3, 8) = 2.059, P= 0.1842], or RCR [F (3, 
8) = 0.5777, P= 0.6458] among the groups.  
 
63 
 
4.3.5 tGFP Mitochondrial Transplantation in vitro 
We tested whether isolated transgenically-labeled tGFP mitochondria 
could be incorporated into PC-12 cells by co-incubation. The tGFP mitochondria 
were isolated from cell culture and 10µg was mixed with 2mL fresh complete 
media and added to 35 mm culture dishes that were 80% confluent with naïve 
PC-12 cells. After one hour, cells were live-imaged and showed positive tGFP 
labeling within somas (Figure 4.7).  
 
Figure 4.7. Transplanted tGFP mitochondria are taken into naïve PC-12 Adh 
cells. After 10 µg tGFP mitochondria were incubated with unlabeled PC-12 cells 
for one hour, live-imaging showed positive tGFP labeling within soma. The 
bottom panel shows the X plane, and the right panel shows the Y plane. Cross 
hairs indicate one instance of punctate tGFP mitochondria within a cell. Image 
was taken using Nikon Ti confocal microscope. Scale bar = 25 µm.  
 
We next applied increasing concentrations of tGFP mitochondria to naïve 
PC-12 cells. After two hours of co-incubation, the cells were washed of any 
remaining extracellular mitochondria and live-imaged (Figure 4.8A). Upon 
visualization, there appeared to be much more instances of tGFP labeling in the 
higher dosage groups, with no labeling in the control group (Figure 4.8A). These 
differences in fluorescence were compared to assess the dose-dependent 
incorporation of tGFP mitochondria. Images of the ROIs (Figure 4.8B) were 
captured and thresholded to a non-transplanted plate to remove non-specific 
background fluorescence for quantification. Our results showed that there was a 
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significant dose-dependent difference between different groups [F (3, 8) = 5.430, 
P= 0.0248]; post-hoc analysis showed a significantly higher amount of tGFP 
immunofluorescence within PC-12 Adh cells administered 20µg tGFP 
mitochondria compared to naive with decreasing amounts of fluorescence in the 
lower dosage groups (Figure 4.8C).   
 
Figure 4.8. tGFP mitochondria are taken up by PC-12 Adh cells in a dose-
dependent manner. A. Representative DIC/FITC images of individual ROI in cell 
cultures from each dosage showing varying amounts of tGFP mitochondria within 
cells. B. Schematic depiction of four random non-overlapping ROIs chosen per 
plate analyzed for each dosage, replicated in three plates. C. Quantification of 
ROI densities of tGFP for each dosage administered showed that the 20µg 
transplant group had the highest number of mitochondria taken up. Bars are 
means ± SEM. *p <0.05 vs control group using one-way ANOVA with Tukey’s 
multiple comparisons. n=3/dosage performed in triplicate, scale bar = 50µM, 
applies to all images. 
 
To further confirm that mitochondria were successfully incorporated into 
cultured cells, time-lapse experiments were performed. After 10 µg of isolated 
tGFP-labeled mitochondria were incubated with naïve PC-12 cells for 2 hours as 
described earlier, the cells were imaged over a 12 hour period during which 
positive intracellular tGFP fluorescence was evident (Figure 4.9). Remarkably, 
cells could be seen replicating during this time, segregating transplanted 
mitochondria between daughter cells. 
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Figure 4.9. Movement of exogenous tGFP mitochondria within PC-12 cells. 
After 10 µg tGFP mitochondria was added to naïve PC-12 cells and incubated at 
37°C on a gently rolling platform for 2 hours, they were washed off and replaced 
with complete media before time lapse images were taken over a 12-hour period.  
Images represent beginning of imaging A separated by 100 minutes for each 
time frame (B-F). Mitochondria can be visualized moving within cells (yellow 
arrow). As a cell divides (white asterisk on mother cell in A and B, then on each 
daughter cell in C-F, with division occurring at white line in C), transplanted 
mitochondria can be seen throughout the division process, and are retained in 
the daughter cells (white arrow). Images were taken using Nikon Ti confocal 
microscope. Scale bar = 20µM. 
 
4.3.6 In vivo Transplantation 
Using the optimal isolation methods, mitochondrial transplantation was 
performed in vivo to determine if transgenically-labeled, cell culture-derived 
exogenous mitochondria can be incorporated into living spinal cord tissues. tGFP 
mitochondria were isolated and injected into the medial lateral gray matter of the 
rat spinal cord at the L1/L2 spinal level. 24 hours after transplantation animals 
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were euthanized and spinal cords processed for histology. An anti-tGFP antibody 
was used in tandem with antibodies specific to mitochondrial proteins to 
determine cell type co-localization (Figure 4.10).  
 
 
Figure 4.10. tGFP labeled mitochondria injected into the spinal cord co-
localize with mitochondrial markers. tGFP mitochondria were isolated from 
PC-12 cells and injected into the rat spinal cord. Antibodies against tGFP and the 
inner (A) (COXIV) and outer (B) (TOMM20) mitochondrial membranes show that 
the injected green fluorescence is intact mitochondria. Images taken on Nikon Ti 
confocal microscope. White boxes indicate region of injection and co-localization 
analyses. Scale bar= 100µM.  
 
COXIV antibody targets the inner mitochondrial membrane, while 
TOMM20 antibody targets the outer mitochondrial membrane. When visualized 
with tGFP which also localizes to the inner membrane, COX IV co-localization 
indicates that the tGFP signal is indeed mitochondria. Further, the exogenous 
mitochondria appear intact as the tGFP tag localizes to the inner membrane and 
TOMM20 labels the outer membrane; positive co-localization indicates grafted 
mitochondria with both inner and outer membranes intact (Figure 4.10). When 
quantifying the co-localization of the tGFP positive and Texas Red positive pixels 
in the injection region (indicated by white boxes), the Mander’s overlap value for 
tGFP and COXIV was 0.843 and for tGFP and TOMM20 was 0.855. This 
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indicates that within the region of injection, the tGFP mitochondria are co-
localized with mitochondrial markers.  
Cell type co-localization was evident within macrophages and endothelial 
cells at both 24 and 48 hours after injection (Figure 4.11). Positive signal overlap 
(yellow) of green (tGFP) signal within cell membranes (red) indicate co-
localization.  Exogenous tGFP mitochondria were found to be within both 
microglia/macrophages and endothelial cells of the spinal cord at both 24 and 48 
hours after injection (Figure 4.11). There may be a cell-specific mode for 
mitochondrial incorporation. For example, there is much evidence of punctate 
tGFP+ signal within the cell membrane of macrophages (Fig. 4.11 A and B), 
though it is not known if the mitochondria underwent phagocytosis or whether 
they were passively incorporated into the cytoplasm. Additionally, tGFP 
mitochondria were found within endothelial cells at both time points (Fig. 4.11 C 
and D). There was positive tGFP signal directly associated with the membranes 
of some endothelial cells that appeared perinuclear, which may indicate the 
mitochondria are being taken into perivascular pericytes (Figure 4.11 C, tGFP+ 
signal closely associated with endothelial membrane). Further studies will utilize 
markers for pericytes to determine if exogenous mitochondria are being taken 
into these cells, and we will comprehensively characterize cell-type incorporation 
over time. 
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Figure 4.11.  Exogenous tGFP mitochondria are incorporated into different 
cell types in situ.  tGFP mitochondria were injected into the naïve spinal cord.  
Representative z-stack images were taken from spinal cords at the 24 (A, C) or 
48 hour (B,D) time points after injection. OX42 = microglia/macrophages, RECA 
= endothelial cells. Scale bars = 10µM. Images were taken with Nikon Ti confocal 
microscope.  
 
4.4 Discussion 
The results of our feasibility study demonstrate that transgenically-labeled 
tGFP mitochondria are a viable option for visually tracking transplanted 
mitochondria both in vitro and in situ. It is possible to label the inner mitochondrial 
membrane of cultured cells with tGFP with high transfection efficiency and 
isolated mitochondria have intact inner and outer mitochondrial membranes, as 
well as dense cristae as seen in TEM images. We also found that 
supplementation of isolated mitochondria with pyruvate malate and succinate is 
beneficial for maintaining state III respiration at room temperature for prolonged 
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periods of time often required for transplantation procedures in vivo. Further, we 
demonstrate that the transgenic tGFP label is an indelible marker of transplanted 
mitochondria, and contrary to previous studies (Katrangi et al 2007), we found 
that MTG did not stay irreversibly bound to exogenous mitochondria; this may 
result in host labeling and inaccurate conclusions of successful transplantation.  
Others have also found MTG fluorescence intensity to be at least partially 
dependent upon membrane potential (Keij et al 2000).  
The bioenergetics of mitochondria isolated from cultured cells did not 
change across multiple passages, but there was an overall decreased respiration 
rate of transgenically-labeled mitochondria when compared to unlabeled 
mitochondria. This may be partially contributed to the stable transfection attained 
by puromycin selection. While the transgenic cells have a puromycin resistance 
sequence, they grew more slowly than naive cells at the same passage numbers.  
We noted that the cell doubling time for unlabeled cells is about 24 hours, 
whereas the doubling time for transgenic cells was closer to 72 hours. We did not 
note any higher levels of die-off or cell death while the transgenic cells were 
under selection. At lower cell passage generations, the isolated mitochondria 
remained well-coupled with comparable RCR to naïve mitochondria. In contrast, 
MTG-labeled mitochondria showed higher respiration than tGFP-labeled 
mitochondria, although this increase was not significant. Importantly, naïve, 
MTG-labeled and tGFP-labeled mitochondria had healthy RCRs indicating that 
the electron transport chain is well coupled to the ATP synthase complex. 
Differences in respiration of MTG labeled mitochondria vs naive unlabeled 
mitochondria has been documented (Buckman et al 2001), where it was 
concluded that MTG alters ETC activity such as uncoupling the ETC from ATP 
synthesis.  
Use of transgenically-labeled mitochondria opens the possibilities for cell 
type co-localization/double labeling and tracking experiments to evaluate 
incorporation of exogenous mitochondria distinguishable from host cells. 
Transgenic labeling of mitochondria in vitro can supply a pool of stably 
transfected mitochondria that affords the opportunity to visualize the movement 
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and integration of exogenous mitochondria within host cells and/or tissues. This 
can be especially important in future studies to determine the fusion and fission 
properties of exogenous mitochondria in the context of their successful 
integration into the host mitochondrial networks after transplantation. Further, this 
labeling strategy could be useful for visualizing mitochondria in paradigms of 
transplantation after cytotoxic insult to cultured cells to determine beneficial 
effects afforded by mitochondrial supplementation.  
Upon co-incubation of tGFP mitochondria with naïve PC-12 cells, we 
showed that exogenous mitochondria were taken into cells within hours and 
could be seen moving within cells. This reflects previous reports that 
supplemented mitochondria, labeled in various manners, are taken into cultured 
cells upon co-incubation (Chang et al 2013a, Clark & Shay 1982, Katrangi et al 
2007, Kitani et al 2014b). Our results showed concentration-dependent tGFP 
mitochondria incorporation into naïve cells, and time lapse imaging over 12 hours 
after co-incubation showed tGFP mitochondria moving within cells. We also 
performed in vivo transplantation to test incorporation in spinal cord tissues in 
situ. Co-labeling of TOMM20 and COXIV showed that the tGFP+ signals 
represent exogenous mitochondria, and subsequent immunohistochemistry 
indicated that transplanted tGFP mitochondria were co-localized predominantly 
with both microglia/macrophages and endothelial cells. Further analyses are 
quantifying the incorporation propensity into these cells, as well as other cell 
types of the spinal cord including neurons, oligodendrocytes, and astrocytes.  
Mitochondrial uptake into cells similar to our results has been reported, but it is 
yet unknown what the mechanism of incorporation is- whether the process is 
passive or active, as multiple studies have found evidence for different 
mechanisms not always supporting each other. For instance, some have shown 
that different cell lines are more likely than others to incorporate exogenous 
mitochondria upon co-incubation, which was theorized to be due to differential 
endocytic properties of cell types (Clark & Shay 1982). Others have shown 
xenogenic transfer of exogenous mitochondria in culture upon co-incubation 
(Katrangi et al 2007). It has been posited alternatively that mitochondria cannot 
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be taken into recipient cells via passive endocytosis (Pacak et al 2015). This 
group utilized chemicals to block different methods of internalization and found 
that only cytochalasin D, which blocks actin polymerization, inhibited 
mitochondrial uptake. They also blocked clathrin-dependent endocytosis, 
tunneling nanotubes, and macropinocytosis, but found none of these inhibited 
mitochondrial uptake. However, others reports that macropinocytosis is 
necessary for mitochondrial internalization utilizing the same blocker of 
macropinocytosis the Pacak study used (Kitani et al 2014b). Different cell types 
were used in the two studies, which may support the findings of Clark and Shay 
(1982) that cell types can behave differently. While these studies all support that 
exogenous mitochondria can be taken into host cells in culture, there is not yet 
consensus on mechanisms by which this happens.  
In summary, by using transgenic mitochondrial labeling and time-lapse 
imaging, it is possible to visualize mitochondrial uptake into cells in real time in 
vitro, allowing further investigation into the exact mechanisms of incorporation. 
Importantly, we present data showing that transgenic labeling is indelible without 
affecting mitochondrial integrity so that they may be effectively tracked and 
visualized after transplantation in both cultured cells and tissues in situ. We found 
the transgenic tGFP tag 1) permanently labels mitochondria with no evidence of 
dissociation, 2) does not affect mitochondrial integrity, and 3) is easily identified 
using both fluorescent microscopy alone or with enhanced antibody labeling. Our 
transgenically-labelled mitochondria did have lower overall respiration rates 
compared to unlabeled mitochondria, which is a caveat that must be considered 
for future transplantation experiments. Depending upon the purpose of the 
experiment, there is a caveat that using tGFP mitochondria may respire more 
slowly, but they have a reliable marker for visualization.  
Our next set of experiments utilized these isolation protocols for 
transplantation of exogenous mitochondria into the injured spinal cord to 
determine the effects mitochondria transplantation have on tissues in vivo where 
there is a complex environment including different cell types, potential immune 
responses, as well as further technical hurdles to consider.  
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Note: 
Portions of this chapter were adapted and reprinted by permission from 
Elsevier: Gollihue J.L., Patel S.P., Mashburn C., Eldahan K.C., Sullivan P.G. and 
Rabchevsky A.G. (2017) Optimization of mitochondrial isolation techniques for 
intraspinal transplantation procedures. Journal of Neuroscience Methods 
Epub 2017 May 23 DOI: 10.1016/j.jneumeth.2017.05.023 
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CHAPTER 5 
Mitochondrial Transplantation in vivo: Bioenergetics, Incorporation, and 
Functional Recovery  
 
5.1 Introduction 
Contusion spinal cord injury can result in lifelong debilitation and has a 
profound impact on day to day activities of individuals living with SCI. In the event 
of an injury, the primary injury site comprises necrotic tissue that can cause 
secondary injury cascades, including glutamate excitotoxicity, decreased ATP 
production, increased lipid and protein oxidation, and resulting apoptosis and 
necrosis (see Chapter 1.2 for details). It is widely accepted that mitochondrial 
dysfunction is intimately related to detrimental secondary pathophysiology 
resulting from SCI. Similar to SCI, mitochondrial dysfunction has been found to 
be pivotal to disease and injury progression in other injury models including 
traumatic brain injury, cardiac ischemia, stroke, Parkinson’s disease, and 
Alzheimer’s disease (Aygok et al 2008, Bolanos et al 2009, Ide et al 2001, 
Krajewski et al 1999, Lin & Beal 2006, McCully et al 2009, Mizuno et al 1989, 
Sullivan et al 2007, Swerdlow & Khan 2004, Winklhofer & Haass 2010, Xiong et 
al 1997).  
As such, mitochondrial medicine is a developing field of therapeutics 
aimed at improving mitochondrial health and function for a variety of 
physiological disease and injury states. Several groups have shown that using 
different methods of targeting mitochondria dysfunction results in 
neuroprotection, tissue sparing, and functional recovery. Antioxidants are used to 
decrease ROS and RNS damage caused by dysfunctional mitochondria in 
models of nephrotoxicity, TBI, SCI, PD, neurodegeneration, and oxidative stress 
(Ahmed et al 2014, Bains & Hall 2012, Hall et al 2010, Jin et al 2014, Patel et al 
2014, Robb et al 2008, Sheu et al 2006, Smith et al 2008, Ungvari et al 2009, 
Xiong & Hall 2009). Mild uncoupling of the ETS resulting in increased ATP 
production has also been shown to be a potential therapy for mitochondrial 
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dysfunction  after SCI, quinolinic acid neurological injury, and models of 
neurological insult in vitro (Brand & Esteves 2005, Jin et al 2004, Maragos et al 
2003, Patel et al 2009b, Rodriguez-Jimnez et al 2012, Sullivan et al 2004). 
Mitochondrial substrate precursors such as acetyl L-carnitine (ALC) and N-
acetylcysteine amide (NACA) have been used to improve mitochondrial function 
after TBI, SCI, age-related cognitive function, and PD (Carta & Calvani 1991, 
Laird et al 2013, Liu et al 2002, Patel et al 2012, Patel et al 2010, Petruzzella et 
al 1992, Puca et al 1990).  All of these therapies attempt to increase functional 
neuroprotection by intervening in mitochondrial dysfunction in one form of 
another.   
Gaining credence is a new therapy of mitochondrial transplantation that 
has emerged as a possible treatment option to restore mitochondrial function 
after injury, consequently improving long term functional outcome (McCully et al 
2017). Transplanted mitochondria may exert beneficial effects by increasing ATP 
production and calcium buffering capacity, decreasing overall ROS production, 
providing more antioxidants, and providing a new pool of mtDNA-see Chapter 2. 
Though this therapy is relatively new, transplantation has been shown to be an 
important player in recovery after ischemic injury to cardiac tissue (Cowan et al 
2016, Masuzawa et al 2013, McCully et al 2009, Pacak et al 2015). It has also 
been shown recently that astrocytes inherently donate their mitochondria to 
nearby neurons after stroke injury in vivo, and that astrocytes can be induced to 
release mitochondria after injury resulting in neuroprotection (Hayakawa et al 
2016). Further, they showed that blocking astrocyte donation of mitochondria 
using CD38 siRNA inhibited mitochondrial transfer and resulted in neuronal cell 
death. This shows both the importance and possibility of mitochondrial transfer 
into damaged cells resulting in cell survival. Intravenous injections of isolated 
fluorescently-labeled mitochondria in a mouse model of Parkinson’s Disease 
resulted in increased ATP production, increased Complex I activity, decreased 
ROS, and increased behavioral rotarod scores compared to vehicle injected 
animals (Shi et al 2017). In a rat model of Parkinson’s Disease, injections of Pep-
1 conjugated isolated mitochondria into the medial forebrain bundle increased 
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locomotor scores and dopaminergic neuronal sparing (Chang et al 2016). We 
have previously shown that exogenous transgenically-labeled mitochondria can 
be taken into cells of the injured rat spinal cord and are visible at 24 and 48 hours 
post injury (Gollihue et al 2017).  
In the current studies, we investigated the therapeutic effects of immediate 
mitochondrial transplantation after traumatic SCI. We hypothesized that 
supplementing the injured spinal cord with a pool of healthy, well-coupled 
mitochondria could provide a new source of increased energy production, 
decreased oxidation, and dampened effects of glutamate excitotoxicity resulting 
in increased tissue bioenergetics. Further, we theorized that exogenous 
mitochondria would be successfully incorporated into a variety of cell types. 
Lastly, we posited that these beneficial effects in the short term would result in 
long term benefits, such as hindlimb functional recovery and tissue sparing.   
 
5.2 Methods 
5.2.1 Transgenic Labeling of PC-12 Cells 
PC-12 cells were transgenically labeled with a mitochondrial-targeting 
tGFP, as detailed in Chapter 4.2.1. Following transfection, cells were kept under 
constant selection using media containing 3 µg/mL puromycin in complete media.  
 
5.2.2 Mitochondrial Isolation from Cell Culture 
Purified mitochondria were isolated from transfected tGFP-PC-12 cells as 
described in detail in Chapter 4.2.2. Briefly, when cells were 95% confluent they 
were manually removed from culture plates using a cell scraper. Mitochondria 
were isolated using multiple centrifugation and resuspension steps to yield 
purified mitochondria. Importantly, after ficoll purification the non-mitochondrial 
layer was gently aspirated off the final pellet, ensuring the sample did not have 
contamination that would make it difficult to pull into the injection needle (see 
Chapter 3.7).  
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5.2.3 Mitochondrial Isolation from Soleus Muscle 
Immediately following CO2 asphyxiation and decapitation, the soleus 
muscle was dissected from naïve Sprague Dawley rats (n=6, see Table 5.1). The 
animal was placed on its stomach, with the hindlimb stretched backwards. 70% 
EtOH was sprayed on the hindlimb, and scissors were used to blunt dissect the 
skin away from the underlying calf muscle. The skin was then cut away from the 
muscle on the lateral sides, followed by cutting the Achille’s tendon. The muscle 
was pulled up and away from the leg, exposing the underlying soleus muscle. 
The tendons were cut at both insertion sites, and the soleus muscle was 
removed and placed in 2mL of isolation buffer (215 mM mannitol, 
75 mM sucrose, 0.1% BSA, 20 mM HEPES, and pH adjusted to 7.2 with KOH) 
containing 1 mM EGTA and trypsin. The muscle was chopped into smaller pieces 
using scissors to increase surface area exposed to the isolation buffer and 
trypsin. The sample was then mechanically homogenized taking care not to 
introduce air bubbles. Protease inhibitor was added to halt trypsin activity, 
followed by centrifugation at 1500 rcf, 4°C, 5min. The supernatant was removed 
and spun at 13,000 rcf for 10min, 4°C after which the pellet was resuspended in 
isolation buffer and purified using ficoll gradient (7.5%/10%) centrifugation at 
32,000 rpm for 30 min, 4°C.The pellet was removed and resuspended in 0.6 mL 
isolation buffer without EGTA, and spun at 10,000 rcf for 10min, 4°C.The 
resulting pellet contain purified mitochondria, which was resuspended in isolation 
buffer without EGTA for Pierce BCA protein assay and microinjection into spinal 
cord.  
 
5.2.4 Spinal Cord Injury and Microinjection Surgical Procedures 
Adult (12 weeks old, 225-250g) female naïve Sprague Dawley rats 
(Harlan) underwent intraperitoneal injections of anesthesia (80mg/kg ketamine 
and 10mg/kg xylazine, Butler Animal Health Supply) followed by lacrilube 
opthalmic ointment applied to both eyes before surgery to prevent drying. The 
surgical site along the dorsal spine is shaven with an electric hair trimmer and 
cleaned with both 70% ethanol and betadine solutions. Animals then had a T12 
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laminectomy to expose the L1/L2 spinal level (Patel et al 2012). Sham animals 
received a laminectomy only, whereas injured animals received a severe 250 
kDyn contusion injury using a force controlled Infinite Horizon impactor 
computerized injury device (Precision Systems and Instrumentation, LLL, 
Lexington KY (Scheff et al 2003)). Injured animals were split into three cohorts- 
the first cohort received vehicle injection, the second received cell-derived tGFP 
mitochondria, and the third received muscle-derived mitochondria. Injections 
were made immediately after injury into the mediolateral gray matter at 4 
circumferential sites of the injured cord separated by 2mM in the rostral caudal 
direction (see Figure 3.1) using a glass micropipette needle (World Precision 
Instruments, Sarasota, FL cat no. 4878) pulled and beveled to a 20-30 µm inner 
diameter pore opening. Each injection consisted of 750 nL of either vehicle 
(isolation buffer with 5mM pyruvate, 2.5 mM malate and 10mM succinate) or 
mitochondria suspended in vehicle (for a total of 50, 100 or 150 µg); hence a total 
of 3µL volume was injected per spinal cord. Muscle incisions were closed using 
silk sutures and skin incisions were closed using wound clips, followed by 
application of hydrogen peroxide and betadine. Immediately following surgery, 
animals were single housed in a clean cage on top of a towel on a 37C heating 
pad, and monitored until recovery from anesthesia. Yohimbine 1−2 mg/kg s.c. 
(Lloyd Laboratories) was used to counteract the effects of xylazine. 
Buprenorphine HCl (0.02−0.05 mg/kg s.c, Butler Animal Health Supply) was 
administered subcutaneously immediately after surgery to alleviate pain, and 
then every 8 hours for 3 days following operation. The antibiotic cefazolin (33.3 
mg/kg, s.c, Butler Animal Health Supply) was given twice daily for 5 days 
post−operatively to decrease incidence of infection. The animals were housed 
individually until staple removal, with the addition of aspen chew sticks and 
plastic toys for environmental stimulation. Cages were lined with absorbent pads 
for the duration of buprenorphine use, as pica has been observed in these 
animals. After discontinuation of buprenorphine, pine bedding was used. 
Additional parenteral fluids (Lactated Ringer’s solution) were provided as needed 
for 24−72 h post-surgery to compensate for dehydration brought on by 
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anesthesia. Bladder expression was performed 2 times per day until adequate 
spontaneous voiding returned to avoid urinary tract infections. Skin wound clips 
were removed 10−14 days post−injury under isoflurane anesthesia. Animals 
survived either 1) 24 hours for mitochondrial respiration analyses (n=45), 2) 24h, 
48h, or 7 days for histological analyses (n=15), or 3) 6 weeks for long term 
behavioral and tissue sparing analyses (n=36)- see Table 5.1 for division of 
animal cohorts.   
 
Table 5.1. Separation of animal cohorts by outcome measure. Animals were 
separated into cohorts for different timepoints and different outcome measures.  
Depending on the outcome measure, cell derived tGFP or muscle derived 
mitochondria were transplanted. It should be noted that in addition to these 
animals, 6 rats were used as donors for leg muscle-derived mitochondria, and 7 
animals from long term studies were removed from the study for various reasons 
(see Section 5.3.3).  
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5.2.5 Behavioral Analyses 
 5.2.5.1 Overground Locomotor Rating Scale (BBB) 
The BBB locomotor rating scale was used to analyze the hindlimb 
functional recovery of animals after contusion SCI. Assessments were performed 
according to published protocol (Basso et al 1995). Animals underwent contusion 
injury, followed by BBB assessment at 2, 7, 14, 21, 28, 35, and 42 days post 
injury. Testing was performed at the same time in the same room on each testing 
day to reduce variation. The scores for the right and left leg were averaged for 
each time point.  
 5.2.5.2 von Frey Filament 
 Mechanical tactile sensitivity and allodynia was measured using von Frey 
filament (Stoelting, Inc, Wood Dale, IL). Briefly, eight monofilaments increasing in 
logarithmic stiffness were used to incrementally stimulate the plantar hindpaw.  
As described previously, a modified up-down method was used to determine the 
50% withdrawal threshold (Chaplan et al 1994). An intermediate force von Frey 
filament (#4.31, 2.0g force) was first applied to the glabrous skin until the filament 
was slightly bent. If the animal immediately withdrew the hindpaw in response, 
this was designated a positive response and the next filament tested was of a 
lesser force. When there was not an immediate withdrawal of the hindpaw, the 
next filament applied was of a greater force. The thresholds for both hindpaws 
were averaged and reported.  
 
5.2.6 Mitochondrial Isolation from Spinal Cords 
For bioenergetics assays, animals were CO2 asphyxiated and decapitated 
24 hours after injury and injections. A 1cm segment of spinal cord surrounding 
the injury site and including all of the injection sites was quickly dissected and 
total mitochondria were isolated as described previously (Patel et al 2012, 
Sullivan et al 2007). Briefly, the spinal cord was placed in a homogenization tube 
with 2mL isolation buffer containing EGTA ((215 mM mannitol, 75 mM sucrose, 
0.1% BSA, 20 mM HEPES, and pH adjusted to 7.2 with KOH) containing 1 mM 
EGTA), and physically homogenized with 6 quick rotations of the pestle, without 
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introducing bubbles into the solution. The sample was poured into a 2mL 
Eppendorf tube and centrifuged at 1400 rcf for 3 min, 4°C. The supernatants 
containing mitochondria were poured into a separate Eppendorf tube which was 
filled up to 2mL with isolation buffer containing EGTA. To increase yield, the 
pellet was resuspended in 500uL isolation buffer containing EGTA and again 
centrifuged at 1400 rcf for 3 min 4°C. The supernatants containing mitochondria 
were again poured into separate tubes and filled to 2mL with isolation buffer 
containing EGTA. The supernatant tubes were centrifuged at 13000 rcf for 10 
min at 4°C. The resulting supernatant was discarded, and 350 uL isolation buffer 
containing EGTA was used to resuspend each pellet containing mitochondria. 
The samples underwent nitrogen bombing at 1200 PSI for 10 min at 4°C. The 
samples were placed on top of a ficoll gradient (7.5%/10%) and centrifuged at 
32000 rpm for 30 min 4°C. The supernatant was removed leaving a purified 
mitochondrial pellet. The pellet was resuspended in 450 uL isolation buffer 
without EGTA and centrifuged 10,000 rcf for 10 min 4°C to remove remaining 
EGTA from the sample. The pellet was resuspended in isolation buffer without 
EGTA. BCA protein assay was performed to determine protein content.  
 
5.2.7 Assaying Respiration of Isolated Mitochondria 
Mitochondria were assayed for OCR immediately after isolation using the 
Seahorse Bioscience XFe Flux Analyzer as described previously (Patel et al 
2014, Sauerbeck et al 2011) and described in detail in Chapter 4.2.5. Briefly, 
mitochondrial respiration was assessed using Seahorse Bioscience eXF24 Flux 
Analyzer at 37°C using respiration buffer: 215 mM mannitol, 75 mM sucrose, 2 
mM MgCl2, 2.5 mM inorganic phosphates, 0.1% BSA, 20 mM HEPES, pH 7.2. 
After isolation, purified mitochondria were added to the respiration buffer and 
centrifuged in cell plate cartridges to concentrate mitochondria to the bottom of 
each well. Then, 5mM pyruvate/ 2.5 mM malate/ 1mM ADP, 1µg/uL oligomycin, 3 
µM FCCP, and 100nM rotenone/10mM succinate were sequentially added to 
each well. Oxygen levels were measured after each substrate/inhibitor addition to 
calculate each state of mitochondrial respiration.  
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5.2.8 Mitochondrial Complex I Assay 
Function of the ETC complex I was assayed as we have previously 
described (Patel et al 2009b). Immediately after mitochondria were isolated, 20 
µL was stored at -80C. At the time of the assay, the samples were thawed at 
room temperature, then diluted to 1 µg/µL using 10 mM phosphate buffer (pH 
7.4) and vortexed to mix. The samples then underwent three cycles of 
freeze/thawing. This was followed by 3 cycles of sonication consisting of 0.5 
seconds sonication/0.5 seconds of rest for 10 seconds total/cycle. The samples 
were placed on ice between cycles to prevent overheating. 6 µg protein was 
added to buffer containing 45.45mM phosphate buffer, 1mM KCN, and 150uM 
NADH so that the total amount/well was 100uL. Each sample was run in wells 
both with and without 10uM Rotenone. 50uM CoQ10 was added using the 
BioTek Synergy HT plate reader (Vinooski, VT) and changes in NADH 
fluorescence (excitation 360nm/emission 460nm) were measured at 1 min 
intervals and reported as nmol/min/mg protein. The reduced form of NADH emits 
light at these wavelengths, while the oxidized form does not.   
 
5.2.9 Spinal Cord Processing for Histological Analyses 
Rats survived to their terminal time point after injection (24 hours, 48 
hours, 7 days, or 6 weeks). They were overdosed with 0.2 mL Fatal-Plus 
containing sodium pentobarbital (Vortech Pharma Ltd., Dearborn, MI) followed by 
transcardial perfusion with150 mL of 0.1M PBS, then with 250mL 4% 
paraformaldehyde (PFA) in phosphate buffered saline. A 3cm segment of spinal 
cord centered on the L1/L2 injury site was dissected, and post-fixed up to 4 hours 
with 4% PFA followed by washing overnight in 2M phosphate buffer. The cords 
were cryoprotected in 20% sucrose/PBS at 4°C until the cords sank in the 
solution, then embedded in tragacanth blocks and serially cryosectioned 
coronally at 20µM (Rabchevsky et al 2001). For the 24 hour, 48 hour, and 7 day 
cohorts in which more sections were necessary for planned histological analyses, 
every other section was mounted. Ten slide series were collected so that 
adjacent spinal cord sections on any given slide were spaced equally 400 µM 
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apart. For long term studies with a 6 week time point in which lesion volume 
analysis was performed, every 5th section was mounted onto a slide. Ten slide 
series were collected with adjacent sections on a slide separated by 1000 µM.  
 
5.2.10 Immunohistochemistry and Fluorescent Imaging 
Antibodies used for fluorescent imaging and co-localization studies 
included rabbit anti-tGFP (0.13µg/mL, Evrogen # Ab513), mouse anti-RECA1 
(5µg/mL, abcam # ab9774), mouse anti-GFAP (2µg/mL, abcam # ab10062), 
mouse anti-CC1 (0.5µg/mL, Cal Biochem #OP80), mouse anti-NeuN (5µg/mL, 
Millipore # MAB377), mouse anti-Ox42 (5µg/mL, abcam # ab78457), phosphor-
PDGF Receptor β (5uL/mL Cell Signaling mAb #3166), goat anti-rabbit 488 
(4µg/mL, Invitrogen # A11008), goat anti-mouse Biotin (7.5µg/mL, Vector # BA-
9200), and Streptavidin Texas red (3.3µg/mL, Vector # SA-5006). Images were 
obtained using Nikon Eclipse Ti Confocal microscope and NIS elements software 
(Nikon Instruments). 
 
5.2.11 Quantification of tGFP Volume and Spread Over Time 
 A set of tissue section slides for each time point were used to analyze the 
tGFP mitochondria volume and spread over time after injection. Anti-tGFP 
antibody was used to label injected mitochondria, as described above. Each 
spinal tissue section was then analyzed under the Nikon confocal microscope for 
the presence of distinct tGFP labeling. When a discreet tGFP injection bolus was 
present, ND2 software was used to measure the area of the bolus. Each of the 
four injection epicenters per spinal cord was verified by finding the largest area of 
discreet bolus. Every section both rostral and caudal of the injection epicenter 
that contained a discreet tGFP bolus was measured for bolus area. After defining 
the boundaries of the injection bolus, the tissue thickness and periodicity of the 
sectioning paradigm was used to calculate the total bolus volume of each cord 
that included all four injections. The rostral-caudal length through the cord that 
punctate tGFP labeling was evident, regardless of an apparent discreet injection 
bolus, was also calculated. 
83 
 
5.2.12 Quantification of Brain Macrophage Response 
 For the 24 hour, 48 hour, and 7 day animal cohorts, we analyzed the 
macrophage density at each injection epicenter. Once the injection site was 
located, a score of 0-3 was assigned for each injection epicenter. 0 indicates no 
abnormal density in macrophages, similar to staining evident in naïve tissues. A 
score of 1 indicated there was some increased infiltration/activation of brain 
macrophages.  This included a change in morphology of the macrophages from 
the inactivated state with long cellular processes to an activated state in which 
processes were withdrawn and the shape of the macrophage was larger and 
more spherical.  A score of 2 represented an increase in activated brain 
macrophages within the confines of the injection site, usually within a dense 
bolus. 3 was the highest score, and represented an injection site in which there 
was a brain macrophage response with a high density that exceeded the original 
injection bolus size.  
 
5.2.13 Cell-type Co-localization Over Time 
Cell-type co-localization of tGFP mitochondria was quantified for different 
cell types in the 24 and 48 hours and 7 day cords. Separate sets of slides were 
labeled for either microglia, endothelial cells, oligodendrocytes, astrocytes, 
pericytes or neurons, and co-labeled with antibodies against tGFP as described 
above in 5.2.11. Eight sections total per spinal cord were quantified using the left 
side injections of each spinal cord including the injection epicenter, one section 
(400um) from the injection epicenter towards the injury, one section (400um) 
from the injection epicenter away from the injury site, and the first section away 
from the injection epicenter that no longer contained a visible bolus (see Figure 
5.8A for counting schematic). The region of interest counted for each section was 
the left dorsal quadrant of the cord, drawing a vertical line from the central canal 
to the dorsal surface, and a horizontal line from the central canal to the lateral 
surface (see Figure 5.8B for depiction of ROI). Slides were visualized under an 
Olympus BX51 microscope at 100X magnification (10x eye piece) using a 
FITC/TRITC combination filter to simultaneously visualize the green and red 
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channels. Positive co-localization was defined by the yellow overlap of signal, or 
the green punctate signal contained within the cell membrane of the cell-type 
marker. Cells were verified using the DAPI filter to ensure that the nucleus was 
within the focal plane. Counts were performed within the ROI of a total of 8 spinal 
cord sections of each animal for 1) each time a specific cell was co-localized with 
the tGFP signal and 2) total cell counts for the specific cell type. Quantification of 
co-localization was reported as a percentage of the total number of a specific cell 
type within the ROI divided by the number of that specific cell type within the ROI 
that also stained positive for tGFP. 
 
5.2.14 Tissue Sparing Analyses 
Tissue sections were stained for eriochrome cyanine-cresyl violet (ECCV) 
to differentiate white matter and gray matter as previously described 
(Rabchevsky et al 2002, Rabchevsky et al 2001). Sections were imaged using a 
Nikon microscope (Nikon Corporation, Tokyo,Japan) and Scion Imaging analysis 
software (Scion Corporation, Frederick,MD, USA) was used to delineate injured 
versus spared tissue in each section. ROIs were manually drawn around the 
entire cord, spared gray matter, and injured tissue which allowed extrapolation of 
the spared white matter area. Eleven sections equally spaced apart by 1000 µm 
and centered on the injury epicenter were analyzed to get the volume of 
damaged versus spared tissue using the Cavalieri method (Michel & Cruz-Orive 
1988).  
 
5.2.15 Stereology 
Analysis was performed to determine sparing of the neurons in the medial 
portion of lamina VII and lamina X of the L1/L2 spinal cord in the 6 week injured 
cohorts. Stereological counts of neurons were performed using a method 
previously published (Patel et al 2012). We used an Olympus BX51 microscope 
to image sections and the Bioquant image analysis program to analyze our 
tissues (Nova Prime, V6.70.10, Bioquant Image Analysis Corp., Nashville, TN). 
Briefly, a region of interest was drawn over lamina VII and X, containing putative 
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CPG interneurons. A counting grid was placed over this region, with each 
counting frame measuring 125 X 125 µm. Disectors were set to 50 X 50 µm, and 
section thickness was set at 10µm, with a 2µm guard zone on both the top and 
bottom of the tissue to keep from double-counting cells across sections. NeuN 
positive cells were then counted under 40X magnification (10x eyepiece). The 
criteria for being counted required the neuron cell body to be contained within the 
disector and the nucleus was in focus within the set 10µm counting thickness, as 
verified by Hoechst staining (Hou et al 2008). The coefficient of error (CE) was 
calculated for each group (vehicle- 0.116, tGFP mitochondria- 0.1126, and 
muscle mitochondria – 0.1456) to determine intra-animal variation. The inter-
animal variation, or coefficient of variance (CV), was also calculated (vehicle- 
0.7007, tGFP mitochondria- 0.6506, and muscle mitochondria- 0.5145). The 
number of neurons in each section was extrapolated using a previously 
published equation (McCullers et al 2002).  
 
5.2.16 Statistical Analyses 
Changes in OCR and RCR for acute bioenergetic studies were analyzed 
using a one-way ANOVA for each respiration state or RCR, with Tukey’s multiple 
comparisons post hoc test. Complex I functional assays, injected tGFP bolus 
volume and rostral-caudal length, and tissue sparing analyses were analyzed 
using one-way ANOVA with Tukey’s multiple comparisons test when appropriate. 
Cell type incorporation was analyzed using a one-way ANOVA for each cell type, 
number of co-localization instances, and for percentage co-localization within 
each time point, with Tukey’s multiple comparison test. Brain macrophage 
density analyses were performed using Mann-Whitney U test for each time point 
analyzed. Rostral-caudal location of cell-type colocalization, von Frey tests, BBB 
scoring and neuronal stereology counts were analyzed using a repeated 
measures two-way ANOVA with Tukey’s multiple comparisons when warranted. 
All analyses were carried out using Graphpad Prism 6 (Graphpad Software, Inc., 
La Jolla, CA). Significance was set to p < 0.05. 
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5.3 Results 
5.3.1 Acute Mitochondrial Bioenergetics 
We transplanted mitochondria into the injured spinal cord in a dose-
dependent manner. Vehicle or one of three dosages of transgenically-labeled 
tGFP-mitochondria were microinjected into the injured spinal cord at 50, 100, or 
150 µg and 24 hours later the spinal cord was dissected and assessed for 
mitochondrial bioenergetics. Mitochondria isolated from this portion of spinal cord 
includes both endogenous mitochondria and exogenous transplanted 
mitochondria. When assayed for mitochondrial bioenergetics in terms of OCR, 
there were significant differences in state III [F (4, 27) = 6.269, P= .0011] and 
state V.1 [F (4, 27) = 11.80, P= <0.0001] respiration. Post hoc analyses indicated 
significantly maintained state III (89% of sham) and state V.I (73% of sham) OCR 
in the 100µg tGFP-injected group compared to significantly impaired rates in 
vehicle injected groups (Figure 5.1). There were no significant differences in 
RCR among tGFP mitochondria injected, vehicle injected, or sham laminectomy 
animals indicating that mitochondria in each group are well-coupled. 
 
Figure 5.1. Culture-derived tGFP mitochondrial transplantation after SCI 
maintains OCR. SCI caused significant decreases in mitochondrial respiration at 
state III, IV, and V.1, which was partially maintained with mitochondrial 
transplantation. State III and V.1 OCR were maintained near sham levels after 
100µg tGFP mitochondrial transplantation. Bars are means ± SEM. *p<0.05 vs 
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Sham; #p<0.05 vs Vehicle. (One-way ANOVA for each state, Tukey’s multiple 
comparison) n=6-7/group.   
 
The use of tGFP-labeled mitochondria allows for visualization and tracking 
of transplanted mitochondria in situ, which is important for determining cell-type 
incorporation and temporal uptake of exogenous mitochondria. However, 
cultured cells can have a lower energy demand, resulting in mitochondria that are 
well coupled but respire at lower rates (see Chapter 4.3.4). We were concerned 
that these lower respiring mitochondria may not have enough energy producing 
capability to be optimally beneficial to the injured cord, so we also tested the 
injection of muscle-derived mitochondria. We chose to inject muscle 
mitochondria at the 100 µg dosage to compare to the optimal dosage found in 
our tGFP mitochondrial transplant study (see Figure 5.1). Further, we 
hypothesized that because muscle mitochondria respire at higher rates than 
tGFP mitochondria, a lower dosage of 50 µg muscle mitochondria could possibly 
give the same OCR increases as tGFP mitochondria.  
  Muscle mitochondria were isolated from the soleus muscle of a separate 
naïve rat and injected into the injured spinal cord. Following transplantation, we 
found significant differences in state III OCR [F (3, 8) = 12.23, P= 0.0023] and 
post hoc analyses revealed significant increases with either 50 µg (83% of sham 
levels) or 100 µg (88% sham levels) mitochondria injection compared to vehicle 
injected groups (Figure 5.2). There were also significant differences in state IV [F 
(3, 8) = 8.940, P= 0.0062] and state V.1 respiration [F (3, 8) = 12.64, P= 0.0021]. 
Post hoc analyses showed significantly increased state IV OCR with 100 µg 
muscle mitochondria compared to vehicle and significant decreases in state V.1 
respiration after injury compared to sham levels which was not rescued through 
mitochondrial transplantation. There were no significant differences in RCR 
among muscle injected, vehicle injected, or sham laminectomy animals indicating 
that the mitochondria in each group are well coupled. 
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Figure 5.2. Muscle-derived mitochondrial transplantation after SCI 
maintains OCR. State III and IV OCR were maintained with 100 µg muscle-
derived mitochondrial transplantation. State V.1 OCR deficits after injury were not 
rescued with transplantation. Bars are means ± SEM. *p<0.05 vs Sham; #p<0.05 
vs Vehicle. (one-way ANOVA for each state, Tukey’s multiple comparison). n=2-
4/group in triplicate.  
 
 Using isolated mitochondrial samples obtained from the same animal 
cohorts used in acute OCR studies we assessed the function of complex I, the 
NADH Coenzyme Q oxidoreductase enzyme of the ETS (Figure 5.3).  
 
Figure 5.3. Complex I function following SCI and mitochondrial 
transplantation. Using the same mitochondrial samples used in OCR studies, 
we analyzed the function of mitochondrial ETC complex I. A. Complex I function 
was maintained near sham levels with 100 µg and 150 µg tGFP mitochondria 
compared to vehicle injection. n= 6-7/group. B. Complex I function significantly 
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increases after 100 µg muscle mitochondria transplantation compared to vehicle 
injections. n= 2-4/group. Bars are means ± SEM. #p<0.05 vs Sham 
Laminectomy; *p<0.05 vs Vehicle. (One-way ANOVA, Tukey’s multiple 
comparison). 
 
Mitochondrial transplantation maintained complex I function near sham 
levels. Similar to our OCR outcome measures, there were significant differences 
in complex I function in tGFP mitochondria injected experiments [F (4, 26) = 
5.432, P= 0.0026] and muscle mitochondria injected experiments [F (3, 9) = 
21.51, P= 0.0002]. Post hoc analyses showed that transplantation of 100 µg 
tGFP or muscle mitochondrial significantly maintains complex I function 
compared to vehicle. Interestingly, 150 µg tGFP mitochondria also significantly 
increased complex I function, though it did not significantly increase state III OCR 
compared to vehicle.  
Our results show the state III OCR of the 100 µg mitochondria injected 
animals of either mitochondrial origin was comparable to sham indicating rescue 
of oxidative phosphorylation function in the injured spinal cord to almost 90% of 
sham levels. We have shown historically that maintaining state III respiration 
towards sham levels corresponds to maintained long term behavioral recovery 
(Patel et al 2012). Thus, we chose to use the 100 µg dosage to investigate the 
effects of mitochondrial transplantation on both cell-type incorporation and long 
term recovery.   
 
5.3.2 Characterization of Transplanted tGFP Mitochondria in situ 
We characterized the uptake of exogenous tGFP mitochondria into 
resident cells of the injured spinal cord. Analysis of multiple time points after 
injury gave a time course picture of exogenous mitochondrial incorporation within 
tissues after 24 hours, 48 hours, and 7 days post injection. Injection sites 
contained a bolus at the injection epicenter, with scattered punctate labeling 
further from the injection site (Figure 5.4A). Earlier time points had a very 
discreet injection bolus (Figure 5.4B,C) in addition to scattered punctate tGFP 
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mitochondria (Figure 5.4D) within the cord. By the 7 day time point, these 
discreet injection boluses had almost completely disappeared, save for a few 
instances, and only dispersed tGFP mitochondrial stippling was present. We 
analyzed the spread of 100 µg dosage injected tGFP mitochondria in two ways. 
The first was a measure of the rostral-caudal distribution of all 4 injection 
boluses. There were significant differences in bolus length among time points [F 
(2, 9) = 22.46, P= 0.0003] (Figure 5.4E); post hoc analyses revealed a significant 
decrease in bolus length of the 7 day group compared to 24 and 48 hour time 
points. The measured length of the bolus had insignificantly increased length in 
the 48 hour group compared to 24 hour group. We further measured the rostral-
caudal length that instances of punctate mitochondria were visible, and found 
that there were no significant differences among groups [F (2, 9) = 2.996, 
P=0.1006] (Figure 5.4F). Interestingly, this may indicate that tGFP mitochondrial 
dispersal is quite uniform across time points, and the bolus disappears at a 
different rate than the punctate instances of tGFP mitochondria. The second 
analysis was a measure of total volume of the injection boluses throughout the 
spinal cord (Figure 5.4G). The tGFP mitochondria injection bolus volume was 
significantly different among time points [F (2, 9) = 15.61, P= 0.0012]; post hoc 
analysis indicated the volume was similar for 24 hour and 48 hour time points but 
was significantly different at the 7 day time point.  
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Figure 5.4. Quantification of transplanted tGFP mitochondria volume and 
spread. A. Injection schematics depicting bilateral injections into the spinal cord. 
Cross section shows a portion of the injection bolus is boxed in red, and 
representation of the punctate area analyzed is boxed in yellow. Longitudinal 
section indicates four peri-contusion injection sites (black stars) with injection 
bolus as solid green oval. Punctate tGFP labeling is represented by the shaded 
green oval. B. Representative image of bilateral tGFP injections. For volumetric 
measurements, the discreet bolus was circled (yellow) to give an area for each 
section which was used to calculate the subvolume of each section measured. C. 
High magnification image of tGFP located within the bolus of (B) as delineated in 
red box in (A). D. High magnification image of punctate tGFP-labeled 
mitochondria in (B) that were not part of the discreet bolus, as delineated in 
yellow box in (A). E. Rostral-caudal length of tGFP bolus was significantly 
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decreased at 7 days compared to 24 hour and 48 hour groups. F. Length in the 
rostral-caudal direction that any visible evidence of punctate mitochondria was 
apparent. G. Analysis of bolus volume was achieved by measuring the area of 
each bolus (circled in yellow in image B) and multiplying the subvolume by the 
total thickness of all sections with a bolus present to get total volume of 
bolus/cord. tGFP injection bolus was similar at the 24 and 48 hour time points, 
and significantly decreased at 7 days post injection. Scale Bars- B= 200µm, C 
and D =10µm. Bars are means ± SEM. *p<0.05 vs 24 hrs; #p<0.05 vs 48 hrs. 
(One-way ANOVA, Tukey’s multiple comparison) n=4/group.    
 
All of the tGFP injection sites (4/animal) for the 24 and 48 hour groups 
were visible using fluorescent microscopy. By 7 days post injection, the injection 
sites had almost disappeared so that only 3 total injections across all four 
animals in the group could be visually verified. Some instances of a remaining 
injection bolus were still evident and the rostral-caudal spread of punctate tGFP 
stippling was similar to 24 and 48 hour time points.  
We set out to characterize the cell-type co-localization with tGFP 
mitochondria. We looked at multiple different resident spinal cord cell types when 
performing our analyses, including neurons, macrophages, endothelial cells, 
astrocytes, pericytes, and oligodendrocytes (Figure 5.5).  
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Figure 5.5. Resident cell types of the spinal cord within the tGFP 
mitochondria injection bolus. The top box shows an injection bolus into the 
dorsal horn of the spinal cord at 24 hours post injection. Adjacent slide series 
(separated by 40uM) were stained with specific cell type markers and images 
represent different cell types within the same injection site. Green lines delineate 
the margins of the injection bolus, the white dotted lines outline the dorsal horn 
gray matter. Within the injection bolus, there appeared to be a loss of neurons 
and oligodendrocytes. There was a noticeably increased density of brain 
macrophages in the area of the injection bolus. Additionally, there were 
endothelial cells and pericytes evident within the injection bolus. While there 
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were not astrocytes within the bolus, they were prevalent in the area surrounding 
the injection. NeuN= neurons, OX42 = macrophages, RECA = endothelial cells, 
GFAP = astrocytes, PDGFR-B= pericytes, CC1 = oligodendrocytes, tGFP = 
exogenous tGFP mitochondria, DAPI = cell nucleus. Scale bars= 100um.  
 
When examining the different cell types within the injection epicenter 
bolus, we noted an almost complete absence of neurons within the bolus, while 
there was an influx and high density of macrophages. The concentration of 
mitochondria or volume of the injections could be inherently damaging the spinal 
cord tissue. When comparing vehicle injected and tGFP mitochondria injected 
animals, we typically saw that there was increased density of brain macrophages 
at the mitochondria injection sites compared to vehicle (Figure 5.6A), indicating 
the tGFP mitochondria could be causing an inflammatory response more so than 
vehicle injection alone. Semi-quantitative analyses were performed to evaluate 
the brain macrophage densities within the injection epicenters at different time 
points (Figure 5.6B). Mann-Whitney U test showed a significant effect between 
vehicle injected and tGFP mitochondria injected groups at 24 hours [P= 0.0012], 
48 hours [P= 0.0002], and 7 days post injection [P= 0.0196].   
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Figure 5.6. Brain macrophage activation at the mitochondria injection sites.  
A. Brain macrophage infiltration was compared between naïve, injured/vehicle 
injected, and injured/tGFP mitochondria injected animals at 24 hours post 
injection. There is an obvious high density of brain macrophages within the tGFP 
injection site compared to a vehicle injection site. B. At each of the injection 
epicenters, the macrophage density was given a semi-quantitative score of 0-3.  
For 0, there was no abnormal response (similar to A naïve), while a score of 3 
indicated extensive activation of brain macrophages. There was a significant 
increase in the macrophage response when tGFP mitochondria were injected 
compared to vehicle injections at all time points. Bars are for visual 
representation of means ± SEM. *p<0.05 vs vehicle; (Mann-Whitney U test for 
each time point) n=4 vehicle injection sites per time point, n=16 tGFP injection 
sites per time point. OX42 = macrophages, DAPI = cell nucleus. Scale bars= 
200um. 
 
One of our goals was to discern which cell types of the spinal cord had 
higher propensities to incorporating exogenous mitochondria, so we first 
characterized positive co-localization. Representative images show positive co-
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localization of various cell types both away from and within the bolus of tGFP 
injection (Figure 5.7). The left column represents instances of co-localization 
within the dense tGFP bolus, while the right column represents instances of co-
localization that were seen away from the bolus where only stippling was 
present. For our purposes, co-localization was defined in two different ways. The 
first criterion of positive incorporation was when tGFP labeling was present within 
the cytoplasm of the cell, as evident by green tGFP labeling within the confines of 
the red cell membrane marker juxtapositioned to the nucleus (DAPI). This was 
most often the case when using OX42 staining for macrophages, which labels 
the cell membrane of macrophages. The second criterion of positive 
incorporation was when the tGFP labeling was present and overlapped with the 
cell specific marker. GFAP labels the cytoplasm of astrocytes, thus both the 
incorporated tGFP signal and GFAP signal overlapped. If either of these 
definitions was met, this was counted as a positive instance of co-localization.  
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Figure 5.7. Representative images of cell type-specific tGFP co-localization. 
Images show instances of positive co-localization with different cell types at 24 
hours post injury. Z-stack images were captured, with the bottom panel of each 
image representing the x plane and the right panel of each image representing 
the y plane. ‘Within Bolus’ (left column) indicates images that were taken in the 
area of dense tGFP mitochondria, while ‘Away from Bolus’ (right column) 
indicates images that were taken in areas of more sparse punctate tGFP 
mitochondria. Crosshairs in each picture are placed over an instance of tGFP 
colocalization with that specific cell type. OX42 = macrophages, RECA = 
endothelial cells, PDGFR-B= pericytes, GFAP = astrocytes, CC1 = 
oligodendrocytes, tGFP = exogenous tGFP mitochondria, DAPI = cell nucleus.  
Scale bars= 10um.  
 
We found instances of cell-type specific colocalization with tGFP 
mitochondria for various cell types including brain macrophages, endothelial 
cells, pericytes, astrocytes, and oligodendrocytes at 24 hours post 
transplantation. Colocalization was evident for all cell types both within the 
injection bolus site as well as more distal from the injection epicenter, where 
sparse punctate tGFP was present.  However, no colocalization of tGFP 
mitochondria within neurons was evident when we looked either within the bolus 
or distal to the bolus site. For better visualization purposes, representative high 
magnification images were taken to show instances of colocalization 24 hours 
after transplantation (Figure 5.8).  
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Figure 5.8. High magnification images showing positive colocalization. 
Images show instances of cell-type specific colocalization of tGFP mitochondria 
either macrophages (Ox42), endothelial cells (RECA), or pericytes (PDGFR-B).  
White arrows point to instances of tGFP mitochondria colocalization within the 
cell. Tissues were processed 24 hours post tGFP mitochondria transplantation. 
OX42 = macrophages, RECA = endothelial cells, PDGFR-B= pericytes, tGFP = 
exogenous tGFP mitochondria, DAPI = cell nucleus. Scale bar = 10um.  
 
We quantified the propensity of tGFP mitochondria to be incorporated into 
different cell types across time. Tissue sections were analyzed per hemi cord as 
depicted in the schematic (Figure 5.9A) including the 2 injection epicenters, one 
section both rostral and caudal of the injection epicenters, and the first section 
distal to the injection epicenter that did not have a bolus present, but had 
punctate tGFP signal present. From each of these sections we quantified the 
percentage of a specific labeled cell type within the dorsolateral cross section 
ROI (Figure 5.9B) that were co-localized with tGFP mitochondria to compare 
their affinities for exogenous mitochondrial uptake. 
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Figure 5.9. Counting schematic for cell-type co-localization with tGFP 
mitochondria.  A. 8 sections were analyzed for the left side of each injected 
cord. This includes both injection epicenters (red box), the next section 400 um 
rostral and 400 um caudal of the injection epicenters (blue box), and the first 
section distal from the injection epicenter that no longer has an injection bolus 
but punctate tGFP mitochondria were present (dashed black box). Injection 
epicenters are denoted by the black stars, injection boluses are depicted as solid 
green ovals, and punctate tGFP stippling is represented by faded light green 
shading. We found the caudal injection sites to be closer to the injury epicenter 
than the rostral injections sites. This is due to the location of the T12 
laminectomy, which reveals the L1/L2 spinal level at the caudal side of the 
laminectomy. The location of the injury epicenter is therefore at the caudal side of 
the laminectomy window, and closer to the subsequent caudal injection sites. B. 
For each section analyzed, the ROI for cell counts was defined by drawing a 
horizontal line from the central canal to the lateral side and a vertical line from the 
central canal to the dorsal surface (red). Both the total labeled specific cell types 
and instances of co-localization were counted within this left dorsolateral 
quadrant.  
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Comparisons were made to determine which cell type was overall more 
likely to incorporate mitochondria. The cell type counts for each of the 8 sections 
(analyzed as described in Figure 5.9) were summed to give a total number of 
that cell type per spinal cord (Figure 5.10A, red). Likewise, the co-localization 
instances from each of the 8 sections analyzed were totaled (Figure 5.10A, 
green). One-way ANOVAs were performed to evaluate differences among total 
cells counted of a specific type, and showed significant differences at 24 hours [F 
(4, 15) = 72.59, P<0.0001], 48 hours [F (4, 15) = 87.46, P<0.0001], and 7 days [F 
(4, 15) = 37.32, P<0.0001]. Post hoc analyses revealed that total macrophages 
counted were significantly higher than all other cell types at each time point. One-
way ANOVA showed significant differences among the number of co-localized 
cells among cell types at 24 hours [F (4, 15) = 10.62, P=0.0003], 48 hours [F (4, 
15) = 45.55, P<0.0001], and 7 days [F (4, 15) = 5.159, P=0.0081]. Post hoc 
analyses showed that co-localization numbers were significantly higher in 
macrophages than other cell types. It should be noted that brain macrophages 
infiltrate the injury site and therefore there is a higher number of total 
macrophages in the ROI compared to other cell types (Figure 5.10A). This 
potentially puts the macrophages at an optimal location for interactions with the 
tGFP mitochondria. Consequently, we additionally report the percentage of cells 
that are also co-localized with tGFP (Figure 5.10B). One-way ANOVA revealed 
significant differences among cell type co-localization percentages at 24 hours [F 
(4, 15) = 6.384, P=0.0033] and 48 hours [F (4, 15) = 5.854, P=0.0048]. Tukey’s 
multiple comparisons showed both macrophages and pericytes co-localized with 
tGFP at a significantly higher rate than oligodendrocytes at 24 and 48 hours post 
injection, which had the lowest colocalization percentages at any time point.  
There was also colocalization of tGFP mitochondria with endothelial cells and 
astrocytes at each time point.  
102 
 
 
Figure 5.10. Cell-type co-localization of tGFP mitochondria across three 
time points. A. Cell type incorporation was compared for each cell type at a 
given time point. Total numbers of a given cell type were counted (red), as well 
as the number of cells co-localized with tGFP (green) per ROI. B. Co-localization 
was calculated as a percentage of total cells. Macrophages and pericytes had 
significantly higher co-localization percentages compared to oligodendrocytes at 
24 and 48 hours. There were no differences in percentage of co-localization 
among the cell types at 7 days. OX42 = macrophages, RECA = endothelial cells, 
PDGFR-B= pericytes, GFAP = astrocytes, CC1 = oligodendrocytes, tGFP = 
exogenous tGFP mitochondria. *p<0.05 vs macrophages, # p<0.05 vs 
endothelial cells, @ p<0.05 vs pericytes, $ p<0.05 vs astrocytes; (One-way 
ANOVA, Tukey’s multiple comparison) n=4/group. Bars are means ± SEM.   
 
The differences in cell type incorporation may be due to the different 
endocytic and phagocytic properties of each cell type. Additionally, we did not 
see any evidence of incorporation in neurons, though there was evidence of 
uptake in all other cell types examined in the injury penumbra. In fact, there was 
a profound loss of neurons in the gray matter where the injection epicenter was 
located (Figure 5.5). This may be due to many factors, including the 
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mitochondrial concentration and volume of injection into this area. Disturbance of 
the tissue by the injection compounded by the activated brain macrophages may 
be responsible for neuronal death at the injection site. However, if other cell 
types in the injury penumbra can be rescued using mitochondrial transplantation, 
the injury environment may be more favorable for overall cell survival, including 
neurons. Macrophages can be either pro inflammatory or anti-inflammatory, and 
are responsible for phagocytosing debris and foreign substances as well as 
having a part in mediating immune response. Astrocytes are important support 
cells for neurons, help maintain the blood brain barrier, and carry out functions in 
ion homeostasis of the extracellular space. Oligodendrocytes play an imperative 
role in insulating axons to increase signal transmission efficiency. Endothelial 
cells supply blood and oxygen to tissues, and pericytes wrap around endothelial 
cells for contraction of vessels and regulation of blood flow. Each of these cell 
types have important functions in maintaining homeostasis within the spinal cord 
tissue, and salvaging these cells could be as beneficial for functional recovery as 
neuronal cell survival after SCI. 
The injection epicenter contained a dense bolus of tGFP mitochondria, 
and based on the high concentration in this area it may be difficult for 
mitochondria to have access to various cells for incorporation. Alternatively, 
sections that are further from the injection epicenter showed dispersed tGFP 
mitochondria and may have differential uptake as higher concentrations of 
mitochondria have been shown to aggregate with less extensive distribution into 
nearby tissues (Chang et al 2013a). We therefore mapped the propensity of co-
localization in relation to the injection epicenters where there is a higher 
possibility for aggregation. We quantified the cell-type incorporation, as described 
above, and analyzed this across the rostral-caudal distribution of the 8 sections 
analyzed for each spinal cord (Figure 5.11). Two-way ANOVAs were performed 
and showed differences in cell-type colocalization for macrophages [F (2, 9) = 
8.123, P = 0.0096], endothelial cells [F (2, 9) = 10.69, P = 0.0042], 
oligodendrocytes [F (2, 9) = 9.575, P = 0.0059], astrocytes [F (2, 9) = 22.54, P = 
0.0003], and pericytes [F (2, 9) = 928.3, P < 0.0001].  We found that there were 
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differences in colocalization percentages dependent upon the location in relation 
to the injection epicenter, especially at the 24 hour time point. At 24 hours, 
macrophages had higher incorporation percentages one section rostral of each 
injection site compared to the most caudal section analyzed. Endothelial cells 
had higher co-localization percentages closer to the injection epicenters 
compared to the distal sections. This indicates there could be spatial-dependent 
incorporation in addition to cell-type dependent incorporation.  
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Figure 5.11. Rostral-caudal cell-type incorporation of tGFP mitochondria 
over time. Co-localization was quantified within ROIs across 8 different sections 
(numbered 1-8) in relation to injection epicenters. Top panel schematic of 
counted sections corresponds to the rostral-caudal counts of co-localization 
percentages. There were differences in colocalization percentages among 
location sites when analyzed within cell types. *p<0.05 vs section 8, #p<0.05 vs 
section 1, @p<0.05 vs section 3, $ p<0.05 vs section 5; (Two-way repeated 
measures ANOVA, Tukey’s multiple comparison) n=4/group. Bars= mean ± 
SEM.   
 
5.3.3 Behavioral Recovery and Tissue Sparing after Mitochondrial 
Transplantation 
We tested the effects of mitochondrial transplantation after SCI on 
hindlimb functional recovery and tissue sparing. Anesthetized animals underwent 
a severe contusion injury at the L1/L2 spinal level, followed immediately by 4 
injections for a total of 100 µg tGFP-labeled or muscle-derived mitochondria into 
the injury penumbra (see Figure 3.1 for injection schematic).  
The starting numbers per experimental group was n=12 per group. 
Throughout the course of the 6 week long study, there was an attrition of animals 
due to various causes. As animals were randomly assigned to groups, and we 
were blinded to the groups throughout the study, this resulted in uneven numbers 
per group at the terminal timepoint. 3 animals died from anesthesia during 
surgical procedures, 3 animals were removed from the study and euthanized due 
to extensive autophagia of the hindlimbs, and one animal was removed from the 
study due to its high 2-day BBB score (more than 2 SD from the mean, indicating 
a bad contusion injury). This resulted in final groups of Vehicle injection n= 10, 
tGFP mitochondria injection n=11, muscle mitochondria injection n=8.   
Animals were tested for mechanical sensitivity of hindpaws using the von 
Frey hair test, and hindlimb motor recovery using the overground locomotor BBB 
scale. Results show that 3 weeks after injury, mechanical hypersensitivity was 
increased in each group, as filaments with less force elicited responses in the 
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hindpaws (Figure 5.12). At 6 weeks post injury, hindpaw sensitivity approached 
baseline levels in all groups, but was somewhat decreased in the mitochondria 
transplant groups. Two-way ANOVAs showed no differences among treatment 
groups [F (2, 26) = 1.370, P= P = 0.2718]. However, there were significant 
differences among time points [F (2, 52) = 17.64, P<0.0001]. Post hoc analyses 
showed each treatment group was significantly decreased at 3 weeks compared 
to their baseline levels. Vehicle injected animals scored closer to their baseline 
levels at 6 weeks, but both mitochondrial transplant groups were still more 
hypersensitive at 6 weeks compared to their baseline levels. 
 
Figure 5.12. Mechanical hypersensitivity following SCI and mitochondrial 
transplantation.  At three weeks post injury, each group had significantly 
decreased mechanical thresholds compared to baseline levels, though there 
were no differences among groups. At 6 weeks post injury, the vehicle injected 
and tGFP mitochondria injected animals began to return towards baseline levels, 
while the muscle mitochondria transplanted group remained significantly lower 
than baseline. Two-way ANOVA showed no significant treatment effect 
differences between groups at any given time point, though there were significant 
time-dependent differences across groups. Bars are means ± SEM. $ p<0.05 
vehicle vs baseline vehicle; *p<0.05 tGFP mito vs baseline tGFP mito; #p<0.05 
muscle mito vs baseline muscle mito (Two-way repeated measures ANOVA, 
Tukey’s multiple comparison) n=8-11/group.   
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Two-way ANOVAs revealed that there were no significant differences in 
the BBB analysis among treatment groups [F (2, 26) = 0.01894, P = 0.9812] 
(Figure 5.13A). All animals recovered some functional recovery compared to 
scores at 2 day post injury, which is consistent with vehicle recovery scores we 
have reported with this injury type (Patel et al 2012). The BBB scale can be 
separated into three categories- the first third of the scale (score 0-7) evaluates 
movements of the three joints of the hindlimbs, the next part of the scale (score 
8-13) evaluates stepping and coordination, and the highest part of the scale (14-
21) evaluates fine movements of the paw during coordinated stepping. A score of 
7 indicates extensive movements of all joints in the hindlimb, 8 indicates plantar 
placement of the hindpaw, and a score of 9 indicates the animal is beginning to 
make weight supported plantar placements of the paw or is stepping on the 
dorsal face of the hindpaw. A score of 10 indicates the animal is making weight 
supported plantar steps. The animals in these studies plateaued at an average 
score of ~8, which is indicative of plantar placing of the hindlimb that is not weight 
bearing (Basso et al 1995). This level of recovery correlates to historical data 
using this injury severity and spinal level, indicating there was no overt damage/ 
effect of volumes of injections. We further performed a post hoc analyses on the 
BBB scores that transforms the scale to make it more ordinal and translational 
(Ferguson et al 2004) and again found no differences among groups [F (2, 26) = 
0.01319, P = 0.9869] (Figure 5.13B). It is important to note that while we did not 
see improvements in functional recovery with either type of mitochondrial 
transplantation, there was no loss of function.  
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Figure 5.13. Functional hindlimb recovery following SCI and mitochondrial 
transplantation. A. BBB scores for all animals was decreased after SCI, with 
gradual increases over time after injury. B. Transformed scores of original BBB 
scores. There were no significant differences among animal groups at any time 
point using either analysis. Bars are means ± SEM. (Two-way ANOVA, Tukey’s 
multiple comparison) n=8-11/group.   
 
Following terminal behavioral analyses, animals were euthanized and 
spinal cords were processed for tissue sparing analysis. Total lesion volume, 
percent sparing at the injury epicenter, and gray and white matter sparing were 
similar between both treatment groups, supporting our behavioral findings 
(Figure 5.14). There were no significant differences between groups of lesion 
volume [F (2, 26) = 1.913, P=0.1679] (Figure 5.14A) or percent sparing at injury 
epicenter [F (2, 26) = 0.8532, P=0.4376] (Figure 5.14B). Mitochondria injections 
were targeted to the medial lateral gray matter, allowing for possible 
mitochondrial integration into either gray matter or white matter. We therefore 
compared tissue sparing of either gray or white matter volume to determine if 
transplanted mitochondria differentially spare different tissue types (Figure 5.14C 
and D respectively). Again, we saw no treatment effects among groups in either 
gray matter tissue sparing [F (2, 26) = 1.586, P=0.2240] or white matter tissue 
sparing [F (2, 26) = 0.03762, P=0.9631]. 
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Figure 5.14. Tissue sparing analyses 6 weeks after injury and mitochondrial 
transplantation. Tissue sparing and lesion volumes were compared among 
vehicle, tGFP Mito injected, and Muscle Mito injected injured rats. At 6 weeks 
post injury and injection, total lesion volume and percentage sparing at the injury 
epicenter was assessed. Additionally, tissue sparing was analyzed for gray 
matter and for white matter to determine if there were tissue-type differences in 
sparing. There were no differences among groups in any of the measures 
assessed. Bars are means ± SEM. (One-way ANOVA, Tukey’s multiple 
comparison) n=8-11/group.  
 
There were no differences in tissue sparing among groups and this 
reflects what we might expect given the functional BBB scores after severe injury 
at L1/L2 (Magnuson et al 2005). We were also interested in determining if 
mitochondrial transplantation resulted in sparing of putative CPG interneurons, 
which represent only a portion of the gray matter sparing analyses. To more 
specifically investigate if mitochondrial transplantation salvaged these 
interneurons, we performed stereology of putative CPG neurons after injury and 
transplantation (Figure 5.15). We defined the ROI for neuronal counts to include 
lamina X and the central portion of lamina VII (Figure 5.15A).  
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Figure 5.15. Neuronal counts in the upper lumbar spinal cord after injury. A. 
ECCV stained section of the spinal cord representing the ROI analyzed including 
Lamina X and part of Lamina VII, which include putative CPG neurons. B. 
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Representative images showing neurons in the ROI (dashed box) at 4mm rostral 
and -1mm caudal of the injury epicenter. There appeared to be more NeuN 
staining within the ROI of the mitochondria injected animals at 1mm caudal to the 
injury compared to either vehicle or muscle mitochondria injected groups. C. 
Stereological counts were performed across 11 equally spaced spinal cord 
sections, centered on the injury epicenter (epi). Each point on the graph is then 
an extrapolated estimate of the number of NeuN positive cells per 1mm length of 
spinal cord section analyzed. NeuN positive cells were significantly higher in 
tGFP mitochondria injected groups compared to the other cohorts at 1mm caudal 
of injury epicenter, and significantly higher in tGFP mitochondria groups 
compared to muscle mitochondria groups at 2 mm caudal of the injury epicenter. 
Bars are means ± SEM. cc= central canal. * p<0.05 tGFP mito vs muscle mito; # 
p<0.05 tGFP mito vs vehicle, (2-way ANOVA, Tukey’s multiple comparison) n=8-
11/group.  
 
There were significant differences in neuronal sparing among groups [F 
(2, 286) = 3.658, P=0.0270]. Post hoc analyses showed that there were 
significantly more neurons in the ROI of tGFP mitochondria injected groups 
compared to vehicle or muscle mitochondria injected groups at 1 mm caudal of 
the injury epicenter. While there was more neuronal sparing at these regions, 
there was no corresponding functional recovery. This may be due to the fact that 
the putative CPG interneurons were not spared with mitochondrial treatment 
(Figure 5.15C, epicenter). Without these neurons there is a loss of rhythmic 
output to rhythmic elements which project on ventral motor neurons of the lumbar 
enlargement. If neuronal sparing of putative CPG interneurons had occurred 
rostral of the injury in the T13 spinal level, there may have been BBB 
improvements as was seen in previous publications (Magnuson et al 2005, Patel 
et al 2012). However, our studies showed neuronal sparing in levels caudal of 
the injury in the absence of putative CPG interneuron sparing. Our results are in 
agreement with Magnuson et al (2005) who showed that a kainic acid depletion 
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of putative CPGs in gray matter with concurrent caudal gray matter sparing did 
not result in improved BBB scores.  
 
5.4 Discussion and Future Directions 
We showed for the first time that mitochondrial transplantation into the 
injured spinal cord results in increased bioenergetics at 24 hours post 
transplantation using either cell culture-derived tGFP-labeled mitochondria or 
muscle-derived mitochondria. Cell culture derived mitochondria are optimal for 
post-transplant visualization; however, we have shown that these mitochondria 
respire at a lower rate than naïve spinal cord-derived mitochondria. To assess 
whether different sources of isolated mitochondria with inherent differences in 
respiration rates alter the effects of transplantation on acute bioenergetics, we 
compared culture derived to muscle derived mitochondria. When comparing the 
two sources of mitochondria on acute bioenergetics 24 hours after SCI, we found 
both to significantly maintain state III respiration at the 100 µg dosage compared 
to vehicle. As we have shown previously that maintaining state III respiration 
near sham levels corresponds to improved long term tissue sparing and 
functional recovery (Patel et al 2012), we used both sources of mitochondria at 
the 100 µg dosage to evaluate the effects of mitochondrial transplantation on 
long term histological and behavioral outcome measures.  
We evaluated the time course of exogenous tGFP mitochondrial 
incorporation into host cells and saw evidence as early as 24 hours post 
injection. Discreet tGFP mitochondria boluses were evident, though these 
decreased significantly in volume and rostral-caudal spread by 7 days post 
injection, and completely disappeared by 6 weeks. By 7 days post injury, the 
injection sites were barely evident as the exogenous tGFP mitochondria had 
dissipated within the tissues. A discreet bolus injection was not always visible in 
the 7 day cohort, but instances of small, punctate tGFP signal were visualized 
and calculated to have similar rostral-caudal distribution to earlier time points.   
We also evaluated the propensity of different cell types to incorporate 
exogenous mitochondria and found that brain macrophages and pericytes had 
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the highest propensity to colocalize with tGFP mitochondria, with lowest amount 
of incorporation into oligodendrocytes. We cannot at this time discern if the tGFP 
mitochondria were functionally incorporated within the macrophages or if they 
were phagocytosed.  While mitochondria were incorporated into a variety of cell 
types, it is important to note that they were conspicuously absent in neurons.  
When the same transplantation paradigm was used in long term studies, 
we did not see a restoration of functional recovery, tactile sensation, or tissue 
sparing. Von Frey testing showed a significantly decreased hindlimb mechanical 
sensitivity thresholds in each group after injury, with some recovery towards 
baseline at later stages. The vehicle injected group recovered closer to baseline 
(pre-injury) levels, which may indicate slight hypersensitivity in the transplantation 
groups. BBB hindlimb locomotor scores for each group showed functional loss 2 
days after contusion SCI, with some recovery that plateaued at day 35 post 
injury. This is consistent with spontaneous recovery with this injury severity at the 
L1/L2 spinal level that we have reported (Patel et al 2012). Lesion volume 
analyses were consistent with the behavioral outcome measures showing no 
group differences between lesion volume or percent tissue sparing at the injury 
epicenter. We further analyzed sparing of the spinal cord white matter or the gray 
matter and again found no differences. Stereological counts showed significantly 
higher numbers of NeuN positive cells when tGFP mitochondria were injected 
compared to vehicle or muscle derived mitochondria, though this was only 
evident 1 to 2mm caudal to the injury epicenter. While these differences were 
significant, they were not so different that they resulted in changes in behavioral 
recovery. The injury was performed at the L1/L2 spinal level, whereas the 
neuronal sparing differences were seen more caudal. This spinal level may not 
contain the putative CPG interneurons, so functional locomotor differences may 
be more dependent upon ventral horn motor neurons at these spinal levels, 
which were not targeted by our mitochondrial injections. This data is intriguing as 
it shows that neuronal sparing may be possible through mitochondrial 
transplantation, though there may be a threshold of neuronal sparing needed to 
achieve measurable functional recovery. Additionally, caudal injection sites that 
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target the ventral motor neurons, in addition to the CPGs may provide more 
potential locomotor recovery. Potential means for increasing the efficiency of 
mitochondrial transplant are discussed in Chapter 6. Importantly, these findings 
show that acute bioenergetic recovery may not be the best criteria for advancing 
experiments to long term functional recovery in mitochondrial transplant 
paradigms. Instead, exploration of other markers of recovery at the acute time 
points of 24 and 48 hours that do correlate into functional hindlimb recovery is 
necessary. One such outcome measure could be tissue sparing analyses at 
more acute time points such as 48 hours and 7 days post injury.  These would be 
expected to correlate to long term tissue sparing analyses.  
Our findings indicate the feasibility of mitochondrial transplantation into 
injured tissue with restored acute bioenergetics. There are multiple caveats to 
consider when trying to interpret why our short term outcome measures did not 
correspond to long term functional outcome measures. First, we noted an 
increased density of brain macrophages in the injection and injury sites. The 
volume of vehicle or mitochondria injected may disturb the intact spinal cord 
tissue causing injury and subsequent infiltration of brain macrophages. Further, 
mitochondria are a source of DAMPS (see Chapter 1.2.1.3) that may elicit a 
stronger immune response compared to vehicle alone. Thus, mitochondria 
injection could cause an influx of macrophages, increasing the overall number of 
healthy cells in that area. The mitochondria assayed for bioenergetic analyses 
includes both endogenous host mitochondria as well as injected mitochondria. If 
macrophage infiltration resulted in a higher density of healthy cells, then 
mitochondria from these macrophages would also be included in our OCR 
assays. However, if there truly was an overt immune response, we would expect 
this to be reflected in our long term studies. There was no decrease in functional 
recovery when mitochondria were injected, which means if there was an immune 
response it did not exacerbate long term functional deficits.  
There was evidence for more mitochondrial integration at shorter time 
points of 24 or 48 hours compared to 7 days post injury. If mitochondria are being 
taken into cells but not successfully incorporated as part of the endogenous 
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mitochondrial network, they may only exert beneficial effects at acute time points 
correlating to our OCR assays. As the exogenous mitochondria undergo 
mitophagy, a mitochondrial-specific form of autophagy, the OCR increases and 
benefits may disappear. This can be evaluated in future studies by measuring 
mitochondrial respiration at different time points after injury to determine exactly 
how long the improved bioenergetics effects are present.  
There may be a possibility that mitochondria are exerting their effects 
extracellularly. The McCully  lab noted functional benefits of cardiac tissue 
mechanics after ischemia/reperfusion injury was followed by direct mitochondrial 
injection (Masuzawa et al 2013, McCully et al 2009). Similar to our studies, they 
noted a low incorporation rate and theorized that the benefits seen could possibly 
be contributed by extracellular functions of the transplanted mitochondria. If 
mitochondria can function extracellularly, it can be hypothesized that this would 
be short lived before the immune response and debris-clearing mechanisms are 
enacted to remove the mitochondria. This may explain short-term effects in the 
absence of long term effects.  
There are probably various reasons for the scarcity of tGFP label at 7 
days and 6 weeks after injection- 1) It is likely that a certain amount of the 
injected mitochondria that are not taken into cells will be phagocytosed, 
especially at the injection site bolus as the density of mitochondria may be too 
high to be incorporated into the surrounding host cells; 2) tGFP mitochondria 
within the extracellular spaces will diffuse through the tissue away from the 
injection site with time, especially in the white matter where there is greater 
longitudinal diffusion; 3) When tGFP mitochondria are successfully incorporated 
within cells, they may fuse and divide with host cell mitochondria leading to a 
wider dispersal of fluorescent tGFP indicator within the cell. However, others 
reported evidence of fluorescently-labeled mitochondria at chronic time points. 
Using direct injection technique of mitochondria transplantation, one group 
showed the presence of exogenous mitochondria using fluorescent microscopy 
as late as 4 weeks after injection of human mitochondria into a porcine model of 
cardiac ischemia using an antibody against human mitochondria (Kaza et al 
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2016). Another group directly injected GFP-labeled mitochondria conjugated with 
the peptide carrier protein Pep-1 into the rat brain of a Parkinson’s Disease 
model, and found instances of GFP as long as 12 weeks after injection (Chang et 
al 2013a). 
While advances have been made in mitochondrial transplantation 
therapies, many caveats need to be addressed to make this therapeutic 
technique beneficial in models of SCI. Similar to previously published studies, we 
show that mitochondrial transplantation has beneficial short term effects.  
Increasing incorporation efficiency is the first step we can take to make our 
transplantation approach more successful in achieving our recovery goals after 
SCI. Alternative transplantation techniques for increasing incorporation rates or 
functionality of exogenous mitochondria are discussed in detail in Chapter 6.  
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CHAPTER 6 
Overall Conclusions, Discussions, and Future Directions  
 
6.1 Conclusions  
We have learned much in our studies to aid in the progression of 
mitochondrial transplantation as a therapy after a rat model of SCI. We 
characterized transgenic labeling of mitochondria in culture to serve as a donor 
of exogenous mitochondria both in vitro and in vivo for easy visualization. We 
saw similar acute bioenergetic results in vivo when performing either allogeneic 
transplantation of transgenically-labeled mitochondria or syngeneic muscle-
derived mitochondrial transplantation (Figure 5.1 and 5.2). This opens the 
possibility to transplant from either source depending on the needs of the study.  
Transgenic mitochondria may serve an important purpose for tracking 
studies, while muscle mitochondria transplantation may have importance in dose 
response studies as higher mitochondrial yields can be obtained from muscle 
tissue and higher concentrations can be successfully injected after SCI. Tracking 
tGFP-labeled mitochondria incorporation into host tissues of the injured spinal 
cord showed integration into specific cell types occurred at different percentages. 
Discreet injection boluses were evident at 24 and 48 hours post injection, though 
they significantly decreased by 7 days and were completely gone by 6 weeks. 
There was a cell-type dependent incorporation efficiency. At 24 and 48 
hours post injection, macrophages and pericytes had the highest percentage of 
tGFP mitochondria incorporation (Figure 5.10). Macrophages may be taking 
mitochondria into their cytoplasm, but it is also possible that these tGFP 
mitochondria are in the process of being phagocytosed. Different measures can 
be taken to determine whether this is a functional incorporation, which are 
discussed in section 6.3.5. Pericytes are found within the vascular basement 
membrane and are closely associated with endothelial cells. They have many 
similarities to macrophages, including originating from the mesoderm, 
possessing lysosomes, similar cell surface markers, and prostaglandin secretion- 
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for review on CNS tissue pericytes (see (McCully et al 2017). Perhaps 
unsurprisingly then is that pericytes are also known to be inherently phagocytic 
which may explain their higher tendency to pick up exogenous mitochondria. 
Other cell types incorporated tGFP mitochondria, though at lower rates. 
Oligodendrocytes took in the least amount of mitochondria, though this could 
possibly be due to the location of the injection sites which were more targeted to 
the gray matter. Injections targeted to the white matter may give 
oligodendrocytes more opportunities for interacting with tGFP mitochondria, and 
thus possibly more incorporation. There was no evidence of tGFP incorporation 
within neurons at any time point.  
There were no differences among treatment groups in lesion volume at 
the 6 week time point, and both gray matter and white matter tissue sparing were 
similar across the groups. Long term behavioral recovery was not apparent using 
our transplantation paradigm, though possible explanations and counteractive 
measures are presented later in this chapter. Some differences in neuron sparing 
in the CPGs were apparent, though this occurred caudal of the injury site and did 
not result in hindlimb recovery. Similar to our findings, changes in tissue 
bioenergetics, cell survival, and cellular mechanics have been reported in other 
studies, though it should be noted that few behavioral outcome measures have 
been either tested or reported after mitochondrial transplantation in vivo 
(Hayakawa et al 2016, Kaza et al 2016, Pacak et al 2015). However, one group 
has examined mitochondrial transplantation in a rat model of Parkinson’s disease 
and saw significantly improved locomotion behavior (Chang et al 2013a, Chang 
et al 2016) see Chapter 2.1.2 for details. Alternative approaches that may 
increase mitochondrial incorporation to promote further behavioral and functional 
recovery are discussed in detail later in this chapter. 
 
6.2 Discussion 
Great strides have been made in the field of mitochondrial replacement 
and transplantation therapies, and many techniques have proven to be 
beneficial, although there are still very important questions that must be 
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addressed before such therapies can be used widely and safely. There is 
discordance among labs as to the mechanisms of mitochondrial incorporation 
into host cells. While some argue that it may be endocytosis, others indicate the 
mechanism is much more complicated. Is the formation of nanotubes between 
cells necessary or is it the connection supplied by gap junctions or connexin 
pores? Are the connections seen in vitro formed in vivo? Some reported 
mitochondrial uptake upon co-incubation with cells in vitro (Clark & Shay 1982, 
Katrangi et al 2007) or into host cells after direct injection in vivo (Kaza et al 
2016, McCully et al 2009), while others found no such incorporation after co-
incubation in vitro (Spees et al 2006). One group showed conjugation of 
mitochondria with Pep-1, a cell penetrating peptide that increases incorporation, 
was necessary to incite mitochondrial uptake (Chang et al 2013a, Chang et al 
2013b, Chang et al 2016). Still others found connexins or gap junctions 
necessary for cells to take in extracellular mitochondria (Islam et al 2012, 
Koyanagi et al 2005, Wang & Gerdes 2015). One group proposed an actin-
dependent cellular incorporation of injected mitochondria (Pacak et al 2015). One 
possible incorporation method for these organelles could be massive endocytosis 
(MEND) (Lariccia et al 2011), which is a rapid internalization of large amounts of 
the plasma membrane. We found that coincubation alone in vitro was sufficient 
for mitochondria uptake into cultured cells. Similarly, we found direct injection of 
isolated mitochondria into spinal cord tissue in vivo results in uptake, though 
there is a relatively low incorporation rate (around 6% or lower of any specific cell 
type within the ROI analyzed, Figure 5.10). If the incorporation mechanism were 
revealed, then development of targeted techniques that take advantage of this 
mechanism could increase uptake efficiency into host cells. Further, it may be 
possible to exploit the uptake mechanism to specifically target certain cell types 
such as neurons so that they take in mitochondria at higher rates, which would 
be desirable in neuroprotection studies.  
Whether there are major technical differences among the studies that 
contributed to conflicting results or if there are other confounding factors remains 
unclear. Contradictory findings may be due to various cell types having different 
120 
 
metabolic needs or capacities for endocytosis. Additionally, the type of damage 
to the host cells may be a crucial factor. Whether the cell undergoes stress, 
depleted mtDNA, or damage to the ETC may dictate whether the cell can 
endocytose mitochondria as multiple studies have reported that only 
compromised cells can take in exogenous mitochondria (Cho et al 2012, Katrangi 
et al 2007); still others have noted the incorporation in healthy cells (Clark & 
Shay 1982). We found that healthy cells in culture are capable of taking in 
mitochondria upon co-culture, and injured tissues in vivo can take in exogenous 
mitochondria resulting in maintained bioenergetics. Importantly, a seminal finding 
is that mitochondrial transplantation from healthy cells to injured neurons in vivo 
occurs naturally, which can be further enhanced by direct injection of exogenous 
mitochondrial particles into injured tissues (Hayakawa et al 2016). This innate 
ability of damaged neurons to incorporate extracellular mitochondria after 
traumatic injury may open a new avenue for neuroprotective strategies.  
The origin of donated mitochondria may also be essential to uncovering 
optimal transplantation benefits. We delivered mitochondria from two different 
sources- cultured cells or muscle tissue, though isolating mitochondria from cell 
types commonly found in the spinal cord should also be compared. When 
targeting neuronal delivery, it may be better to use mitochondria from neurons, in 
the case that there are different inherent properties of mitochondria to be taken 
into like cell types. Astrocytes release mitochondrial particles into the 
extracellular matrix and are proven to be taken into neurons (Hayakawa et al 
2016), as such we may also choose to utilize mitochondria from this source.  
Future studies may compare mitochondria isolated from neurons and astrocyte- 
derived mitochondrial particles in an effort to increase incorporation efficiency 
into spinal cord tissue with an emphasis on neuronal uptake. However, the 
McCully group noted that using different sources of mitochondria does not alter 
cardioprotection after transplantation (Kaza et al 2016, McCully et al 2009). 
Additionally, we observed maintained bioenergetics at 24 hours post 
transplantation of either cell culture- or leg muscle-derived mitochondria, so we 
may not see differences with neuronal mitochondria transplantation. 
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Furthermore, while neurons may be spared directly through targeted 
mitochondrial transplantation, it may be possible to protect neurons more 
indirectly by increasing the overall health of the injury environment. Sparing other 
resident cell types of the spinal cord could provide a more hospitable 
environment and decrease overall necrosis and apoptotic factors, thereby 
decreasing extracellular-induced damage to neurons.  
 
6.3 Alternative Approaches and Future Directions 
6.3.1 Mitochondrial Delivery Methods  
We used direct injection techniques for mitochondrial delivery as others 
have shown it to be a feasible option (Chang et al 2013a, Masuzawa et al 2013, 
McCully et al 2009). Initial proposals considered cell-mediated delivery and 
liposome delivery methods as well. One pitfall of direct injection is that 
mitochondria are relatively unprotected from the extracellular matrix environment 
prior to cellular uptake compared to cell- or liposome- mediated delivery. As our 
early experiments showed increased OCR at 24 hours when using the direct 
injection method, this delivery method was used for the immunohistological and 
long term studies. However, we saw a higher density of macrophages with a 
concurrent loss of visible neurons in the injection epicenters that may be due to 
aggregation of the injected mitochondria. To counteract this possible damage, 
changing injection parameters to include more injections of lower volumes and 
concentrations may increase total numbers of mitochondrial incorporation into 
host cells. The same amount of mitochondria can be injected per spinal cord, 
though more spread out with potentially less aggregation. Increasing the number 
of injection sites could also allow for differentially targeted injections such as the 
CPGs at L1/L/2, and the ventral gray matter in more caudal regions.  Additionally, 
based on our relatively low incorporation numbers and lack of behavioral 
recovery, other delivery methods should be investigated.  
There are multiple methods that may be refined to increase incorporation 
after transplantation. Some have used cell-mediated delivery methods to donate 
mitochondria from transplanted cells into injured cells both in vitro (Cselenyak et 
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al 2010, Plotnikov et al 2008, Spees et al 2006) and  in vivo (Islam et al 2012). 
Using cell-delivery systems would protect mitochondria from extracellular matrix 
molecules. However, the mechanism of transfer, whether it be nanotube 
formation, connexin pore mediated, or gap junctions needs to be better 
understood (Chapter 2.4). For instance, donor cells need to be chosen that are 
compatible with targeted cells to successfully make these types of functional 
connections. This may allow for targeted delivery to specific cell types, 
depending on the docking and delivery mechanisms of the donor and host cells.   
Another delivery method to be considered is the encapsulation of 
mitochondria within liposomes. Liposomes have been used for targeted delivery 
to cells, though they have been used to carry small molecules such as RNA and 
not usually something as large as a mitochondrion organelle. Liposome delivery 
systems have been investigated to target macromolecules to the mitochondria 
(Weissig et al 2006, Yamada et al 2008, Yamada et al 2007). Modified liposomes 
with surface-linked polyethylene glycol and transactivating-transduction protein 
were delivered through caudal tail vein injections and found to cross the blood-
spinal cord barrier to accumulate within cells at the injury site in a rat model of 
contusion SCI (Gollihue & Rabchevsky 2017). Though delivering intact 
mitochondria themselves to a cell is not widely published, liposomal delivery 
methods of mitochondria are being investigated (Brzezinska 2012). One 
consideration to make before pursuing this avenue of delivery is that liposomes 
may be digested by macrophages before they can fuse with targeted cells to 
deliver the mitochondria (see Ahsan et al 2002).  
Vascular perfusion delivery methods of isolated mitochondria showed 
beneficial effects similar to using direct mitochondrial injections into injured heart 
tissue (Cowan et al 2016). This study used the coronary arteries to deliver 
mitochondria to ischemic heart tissue in vivo, eliminating the need for surgical 
implantation of isolated mitochondria. Cowan et al (2016) also noted that the 
mitochondrial incorporation efficiency was less when using perfusion delivery 
methods compared to direct injection into the heart tissue. To use a similar 
approach after SCI, one could perform intrathecal injections circumventing the 
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blood-spinal cord barrier to perfuse mitochondria over the pia of the injured spinal 
cord. However, this would not likely target mitochondrial delivery to neurons in 
the gray matter, but instead to resident cell types of the spinal white matter.  
Concentrating isolated mitochondria for injections can result in 
aggregation, making cellular incorporation more difficult. If delivery efficiency can 
be increased, then lower concentrations may be injected with the same endpoint 
number of mitochondria being taken into cells. Pep-1 is a cell penetrating peptide 
that allows for fast translocation of peptides across lipid bilayers with a 
hydrophobic core (Henriques et al 2010). This fast transfer could mean that 
mitochondria will be exposed to the extracellular matrix for a shorter amount of 
time. In a dose response study of Pep-1 conjugated mitochondrial transplant, 
lower dosage groups were found to have more mitochondrial dispersion within 
tissues compared to higher concentrations, which had the tendency to aggregate 
(Chang et al 2013a). Future studies could use Pep-1 conjugation with different 
dosages of mitochondria to evaluate changes in incorporation compared to our 
data for non-conjugated mitochondria.  
 
6.3.2 Inflammatory Response 
Previously published studies investigating mitochondrial transplantation 
tested for inflammatory markers and did not find increases. Masuzawa et al 
(2013) did not report inflammation after direct autologous mitochondria injection, 
instead they found that mitochondria transplantation resulted in significantly 
decreased tumor necrosis factor alpha (TNFa), interleukin 6 (IL-6), and high-
sensitivity C-reactive protein (hsCRP) (Masuzawa et al 2013). Further, they 
showed anti-mitochondrial antibodies were not present in blood serum samples 
28 days after injections. However, there could be differences when allogeneic 
mitochondria are transplanted, as was used in our studies (Chapters 4 and 5), 
compared to a syngeneic or autologous mitochondrial transplant. 
Mitochondrial transplantation after injury resulted in increased OCR 
acutely, which is thought to be due to exogenous mitochondria supplementing or 
replacing those damaged after the injury. However, this did not correspond to 
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increased functional recovery. One theory to explain increased OCR at the 24 
hour time point that does not correspond to long term outcome measures is that 
activation and recruitment of brain macrophages to the injection site may 
increase the density of healthy cells in otherwise damaged tissue. To determine if 
macrophage influx is responsible for increased OCR at the acute time point, we 
could assay different mitochondrial populations. After injury and transplantation, 
mitochondria will be isolated from the spinal cord. Unlike our experiments 
performed in Chapter 5 we will separate out the different populations of synaptic 
and non-synaptic mitochondria. The non-synaptic mitochondrial population 
contains mitochondria from all different cell types, including neurons, 
oligodendrocytes, astrocytes, endothelial cells, resident microglia, and infiltrating 
macrophages. The synaptic population, however, contains mitochondria only 
from neuronal cells. This allows distinction between increases in OCR that may 
be attributed to infiltrating brain macrophages (within the non-synaptic 
population), and what may be attributed to increased health due to 
transplantation (synaptic population). One major caveat, however, is that we did 
not see any mitochondrial incorporation into neuronal cells, and thus we may not 
see increases in synaptic OCR. Further, we have previously shown that synaptic 
mitochondria respire at lower rates than non-synaptic mitochondria when isolated 
from naïve spinal cord tissue (Patel et al 2014). Another way to test if 
macrophage infiltration may be the cause of increased respiration is to use 
different drugs such as a CCR2 antibody to block infiltration (see Ren & Young 
2013). This will result in the same resident spinal cord cells to be assayed across 
treatment groups with the aim of revealing whether increased respiration was 
peripheral macrophage-dependent. 
Another potential approach is to separate out the macrophages from our 
spinal cord homogenate before isolation of mitochondria. For instance,  
macrophage markers can be applied to the homogenate followed by 
fluorescence-activated cell sorting (FACS) to remove the macrophages, leaving 
behind homogenate containing the other resident cell types of the spinal cord. 
Mitochondria is isolated from the remaining homogenate, and increases in OCR 
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will reflect that of the resident spinal cord tissue. One caveat to this approach is 
that this will also remove endogenous macrophages that were already in our 
injury/injection sites, which were shown to have the highest mitochondrial 
incorporation efficiency.  
 
6.3.3 Mechanisms of Action 
It was recently shown that daily intraperitoneal injections of ATP after 
contusion SCI in rats significantly increased BBB scores above injury only groups 
(Sun et al 2013). However, prolonged high amounts of extracellular ATP after 
SCI activates P2X7 purine receptors on neurons, resulting in increased 
intracellular calcium and neuronal cell death (Wang et al 2004); antagonistic 
drugs that inhibit this receptor following SCI significantly improve BBB locomotor 
scores (Peng et al 2009). These studies indicate that there may be functional 
recovery following ATP supplementation, though extended or excessive amounts 
appears to be detrimental. Mitochondria transplantation may provide an 
additional source of ATP, though the benefits of transplantation seem to be 
dependent upon more than just energy alone. McCully at al found that injections 
of ATP or ADP did not give the same cardioprotection as mitochondria injections 
(McCully et al 2009). Similarly, delivery of ATP in liposomes to damaged neurons 
did not result in the same increase in cell survival when astrocyte-derived 
mitochondrial particles were delivered in a mouse model of stroke (Hayakawa et 
al 2016), concluding that benefits afforded by mitochondrial transplantation are 
multifaceted and not just as an extra energy source. Future studies that 
determine the exact mechanisms by which mitochondrial transplantation may 
benefit damaged cells can immensely extend our knowledge in this novel 
treatment field.  
 
6.3.4 Time Points of Injections 
The environment of the injured spinal cord may be too harsh at the acute 
timepoint for transplantation. Our mitochondria injections occurred within 30 
minutes of SCI. Hayakawa et al (2016) transplanted mitochondria into the mouse 
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brain 3 days after stroke; given the complex inflammatory response acutely after 
SCI this delayed time point may be more agreeable to mitochondrial survival and 
incorporation. Confounding this further, our tGFP mitochondria may be 
experiencing “donor rejection” as was seen in other transplantation paradigms 
involving bone marrow stromal cells injected into the naïve brain (Coyne et al 
2006). Others have shown that transplantation of fetal spinal cord tissue and 
neurotrophic factors into the transected adult rat spinal cord showed axonal 
regeneration and motor function recovery; this was only evident when 
transplantation occurred two or four weeks after transection, but was not 
apparent with acute transplantation (Coumans et al 2001). Neural precursor cell 
transplantation in a rat model of compression SCI was successful in improving 
hindlimb BBB scores when transplants occurred 2 weeks but not 8 weeks after 
injury, indicating there may be an optimal time window for transplantation 
paradigms (Gollihue & Rabchevsky 2017). Similar to (Okano et al 2003), who 
found that neural stem cell transplantation at the acute time point after SCI may 
not be optimal as the inflammatory response is in full swing, we propose 
transplanting at later time points. For transplantation to be clinically relevant, 
therapies administered 3.2 hours after injury should be investigated, as this is the 
average time after SCI a patient is admitted and diagnosed (Bracken et al 1997).  
Future transplantation studies may attempt this clinically relevant time point, as 
well as a later time point of 3 days post SCI to correspond to published studies 
using stroke injury models (Hayakawa et al 2016).  
 
6.3.5 Quantifying Incorporation 
One major hurdle in these studies is quantifying the amount of tGFP 
mitochondria that are successfully taken into host cells. First, we must define 
what is considered successful incorporation- are the mitochondria simply taken 
into the cytoplasm, do they need to maintain their membrane potential, and do 
they have to incorporate into the endogenous mitochondrial network? For our 
tracking purposes, we define successful incorporation as co-localizing with the 
labeled cell which was verified using confocal fluorescent microscopy. However, 
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as the tGFP tag is coded for by nuclear DNA and not the mitochondrial DNA, the 
tag will not be propagated after transplantation. This means that the tag will most 
likely dissipate over time, making the exogenous mitochondria hard to track as 
time progresses. Further, the tag will be progressively degraded as different 
portions of the mitochondrial network are mitophagocytosed, a natural 
occurrence that works to maintain an overall healthy membrane potential (Twig 
et al 2008b). Together, these make fluorescent tracking of mitochondria difficult 
at later time points.   
We attempted to measure the tGFP mitochondrial presence in injured 
spinal cords after 6 weeks, but only one instance of dispersed punctate tGFP 
mitochondria was evident and could only be visualized at high magnification. 
These studies attempt to discern the tGFP label for identification of exogenous 
mitochondria, though the presence of exogenous mitochondria could be 
established by utilizing a xenogenic transplantation model. Not only could we use 
species-specific mitochondrial antibodies that will not dissipate over time (Kaza 
et al 2016), but we could also perform quantitative real-time PCR (qRTPCR) on 
the mtDNA to quantify exogenous mitochondria.  
Others have measured mtDNA to demonstrate transfer in vitro. We used 
PC-12-Adh cells originating from the rat Rattus norvegicus as our source of 
donor mitochondria and transplanted into the Sprague Dawley strain of Rattus 
norvegicus rats. We transplanted mitochondria between like-species based on 
previous published studies suggesting mitochondrial uptake occurs more 
prevalently when like-species are used (Clark & Shay 1982, Yang & Koob 2012). 
However, the differences in the mtDNA may not be enough to discern between 
host and exogenous mitochondria. Alternatively, other studies have performed 
xenogenic transfer with successful incorporation. Future studies may employ 
xenogenic transplant after SCI so that the host and donor mtDNA can be 
differentiated and quantified using real time qRTPCR. This will allow 
quantification at chronic time points that is more dependable than tGFP 
immunolabeling, possibly giving more insight into the time-dependent uptake and 
maintenance of transplanted mitochondria.  
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Additional metrics of successful incorporation need to be investigated. 
Evaluating the health of exogenous mitochondria after they have been 
incorporated into cells is an important measure, such as maintenance of 
membrane potential. One possible way of testing this immunohistologically is by 
co-labeling the tGFP mitochondria before transplantation with MitoTrackerRed 
CMXRos, a membrane-potential mitochondrial marker. Utilizing fluorescent 
microscopy, the proportion of mitochondria in situ that have both the tGFP tag 
and MitoTracker Red fluorescence, indicating transplanted mitochondria that 
maintained membrane potential, can be evaluated. Additionally, we can define 
successful incorporation as exogenous mitochondrial integration into the host cell 
mitochondrial network. in vitro studies can utilize transgenic labeling of host cell 
mitochondria with DsRed, then co-incubation with isolated tGFP mitochondria.  
Live time-lapse imaging allows tracking of tGFP mitochondria movement within 
the cell, and fusion events that result in co-localization with DsRed host 
mitochondria. To test this in vivo, a transgenic rat line that has DsRed-labeled 
mitochondria could be created. Upon transplantation of tGFP mitochondria after 
SCI, we will be able to track the fusion, or co-localization, of tGFP mitochondria 
with the endogenous DsRed-labeled mitochondrial network. Alternatively, there is 
a mouse line currently available that has a yellow fluorescent protein that targets 
mitochondria of neuronal cells that can be used in the same manner (JAX Labs, 
Bar Harbor, ME). Using a mouse line as the recipient of PC-12 tGFP 
mitochondria would further allow for qRTPCR (see previous paragraph) to 
corroborate our findings of exogenous mtDNA with fluorescent microscopy 
indicating the presence of exogenous tGFP mitochondria.  
One method that could be extremely helpful in our characterization studies 
is FACS flow cytometry. At a timepoint after transplantation, the spinal cord will 
be dissected and homogenized as the first step of mitochondrial isolation. This 
homogenate includes all different cell types of the spinal cord. Fluorescently 
labeling one cell type at a time will allow measurement of the proportion of that 
cell with and without tGFP mitochondria, thus quantifying uptake propensity. 
When homogenate samples undergo mitochondrial isolation procedures, the final 
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sample includes both endogenous mitochondria and tGFP mitochondria. These 
mitochondria can be sorted based on whether or not they have the fluorescent 
tag, and their OCR values can be compared. Comparisons can be made 
between the bioenergetics within the endogenous mitochondria population of 
vehicle-injected animals to mitochondria-injected animals. This allows evaluation 
of whether mitochondrial transplantation benefits the health and survival of host 
mitochondria. The two mitochondrial populations can be further assayed for 
membrane potential, calcium buffering capacity, and fusion and fission proteins.   
Once methods have been further refined to quantify incorporation of 
exogenous mitochondria both in vitro and in vivo, studies can be performed to 
discern possible mechanisms of isolated mitochondrial uptake. Multiple 
mechanisms of incorporation have been proposed, though there is currently not a 
consensus on the matter (see Chapter 2.4). It is widely accepted that 
mitochondria are of bacterial origin. Moreover, there are many types of bacteria 
up to 5um in size that can successfully enter into a cell where they can reside 
and replicate. Therefore, we theorize that it may be possible that the mechanism 
used by bacteria for host cellular infiltration is similar to that used by isolated 
mitochondria for incorporation. Like bacteria, mitochondria may have proteins on 
their surface that bind to receptors on host cell surfaces, initiating a zipper-like 
actin-mediated phagocytosis. This zipper-like mechanism of incorporation can 
utilize different receptors such as integrin for binding and signaling  (for review of 
bacterial invasion methods see Cossart & Sansonetti 2004). Interestingly, it was 
found that neuronal internalization of mitochondria-containing particles in vivo is 
dependent upon integrin-mediated Src/Syk signaling pathways (Hayakawa et al 
2016). Further comparisons must be made between bacteria and mitochondria to 
determine if they share a conserved cell surface protein that interacts with host 
cell receptors.  
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6.4 Summary of Thesis 
The data and conclusions derived from the studies of this dissertation 
investigate different facets of mitochondrial transplantation after traumatic SCI. 
We have described the importance of healthy mitochondrial function, as well as 
the involvement of dysfunctional mitochondria in the pathophysiology of SCI. This 
was followed by a thorough discussion of the current state of the mitochondrial 
transplantation field. Importantly, we are the first to transplant exogenous 
mitochondria in a model of spinal cord injury. Different experimental techniques 
were explored to best test the effects of mitochondrial transplant. Transgenically-
labeled cell culture-derived mitochondria were characterized for their use as the 
exogenous mitochondrial source and were found to possess an indelible 
fluorescent marker that could be tracked both in vitro and in situ. In vivo studies 
showed that transplanting either culture or leg muscle-derived mitochondria 
acutely maintained bioenergetics of the injured spinal cord. tGFP mitochondria 
co-localized within a multitude of cell types, though at various percentages 
indicating that incorporation is cell-type dependent. Co-localization was also 
time-dependent, as evidence of tGFP mitochondria significantly declined at 7 
days, and was all but absent at 6 weeks post injection. Hindlimb functional 
recovery and tissue sparing were not improved with mitochondrial 
transplantation, though multiple alternative approaches are addressed that may 
increase the efficiency of incorporation and thus benefits of mitochondrial 
transplantation.  
While optimization of therapeutic techniques can be further refined, we 
have shown feasibility for transplantation after SCI. Further systematic 
characterization is necessary to fully understand the intricacies of transplantation 
paradigms, but I believe that mitochondrial transplantation can be developed into 
a viable option for treatment after SCI as well as other injury and disease states 
in which dysfunctional mitochondria are implicated.  
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Appendix 1.  Abbreviations 
ADP   Adenosine diphosphate 
AIF   Apoptosis inducing factor 
ALC   Acetyl-L-carnitine  
AMPA   α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
ANOVA  Analysis of variance  
ATP   Adenosine triphosphate 
BBB   Basso, Beattie, Bresnahan overground locomotor scale 
CAP   Chloramphenicol 
CNS   Central nervous system  
CPG   Central pattern generator  
CTVT   Canine transmissible venereal tumor  
DAMPs  Damage-associated molecular patterns 
DMSO  Dimethyl sulfoxide  
ECCV   Eriochrome Cyanine-Cresyl Violet  
EGTA   Ethylene glycol tetraacetic acid  
ETC   Electron transport chain 
EtOH   Ethyl alcohol  
ETS   Electron transport system  
FACS   Fluorescence-activated cell sorter  
FADH   Flavin adenine dinucleotide 
FCCP   Carbonilcyanide p-trifluoromethoxyphenylhydrazone 
hsCRP   High-sensitivity C-reactive protein  
IL-6    Interleukin 6 
IMM   Inner mitochondrial membrane 
MEND  Massive endocytosis 
MERFF  Myoclonic epilepsy with ragged-red fibers  
mBMSC   Mouse bone marrow derived stromal cells  
MnSOD  Manganese superoxide dismutase 
MPTP   Mitochondrial membrane permeability transition pore 
mtDNA  Mitochondrial DNA 
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MTG    MitoTracker Green FM  
NACA   N-acetylcysteine amide  
NADH   Reduced nicotinamide adenine dinucleotide 
NMDA  N-methyl-D-aspartate 
NSAIDs  Non-steroidal anti-inflammatory drugs 
OCR   Oxygen consumption rate  
OGD   Oxygen glucose deprivation 
OH-    Hydroxyl radicals 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PD   Parkinson’s Disease 
PFA   Paraformaldehyde 
PPARγ                     Peroxisome proliferator-activated receptor gamma 
qRTPCR   Quantitative real-time PCR  
RCR   Respiratory control ratio 
RNS   Reactive nitrogen species 
ROI   Region of interest  
ROS   Reactive oxygen species 
RT   Room temperature 
SCI   Spinal cord injury 
TBARS  Thiobarbituric acid-reactive substances 
TEM   Transmission electron microscopy  
tGFP   Turbo green fluorescent protein 
TMRE   Tetramethylrhodamine Ethyl Ester  
TNF-α   Tumor necrosis factor alpha  
TUNEL  TdT-mediated dUTP nick-end labeling  
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